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Dengue virus and Zika virus are both emerging flaviviruses and pose growing risks to the 
global human population. Despite numerous links being drawn on the similarities of both viruses, 
there have been no direct, large-scale comparisons of the interactomes of these two viruses. With 
NS5 playing such an important central role with virus-host interactions, the similarities between this 
protein’s interactors could advance our understanding of the evolutionary closeness between the 
species and inform future studies about the potential for dengue-developed therapeutic host 
targets to be utilised for Zika fever. It would also provide a side-by-side comparison to show the 
differences in interactome that may explain the biological differences between dengue and Zika 
virus. Using transfected HEK-293-Flp cells as a viral gene expression system and pulldown LC-
MS/MS proteomics, the similarities and differences between ZNS5 and DENV-NS5 interactors are 
explored, revealing that differences lie largely at the individual protein level with mostly similar 
pathways being targeted by both viruses. The comparability of different proteomic programmes 
and pulldown techniques was also investigated with a comparison between MaxQuant and 
Proteome Discoverer revealing large differences in the data generated from the sample spectra at 
both the protein identification level and in large scale pathways analysis with STRING and DAVID. 
BioID-labelling and FLAG-tag pulldowns were also compared with the intention to investigate the 
differences in interactomes generated by these two methods which once again highlighted the 
potential for differences in LC-MS/MS proteomics to arise. Cdk1 and UBR5, two ZNS5-specific 
interactors detected robustly by LC-MS/MS proteomics, were then validated as interactors in 
reverse-pulldowns and western blots to test the reliability of LC-MS/MS proteomics but called into 
question the quantitative aspects of the technique by also pulling down DENV-NS5 which further 





The Flavivirus genus is a taxonomic collection of >50 arthropod-borne viruses that lies within 
the family Flaviviridae alongside Pestiviruses, Pegiviruses, and Hepaciviruses. Of the known 
flaviviruses, roughly half of them cause significant clinical disease in humans (1) including diseases 
of high global importance such as dengue fever (DF), West Nile fever, yellow fever, Japanese 
encephalitis, tick-borne encephalitis, and Zika fever (ZF). However flavivirus infection is not 
exclusively limited to human infection with other flaviviruses capable of causing disease in cattle, 
pigs, birds, primates, and rodents. Most viruses within the Flavivirus genus are transmitted via an 
arthropod vector, generally mosquitoes or ticks, although there are some viruses where no current 
vector transmission is known between animals (direct transmission of the virus) and some that 
solely transmit through the arthropod population. There are also those who can transmit via 
multiple routes like Zika virus with mosquitoes acting as the major route for transmission but with 
the additional capability to be sexually transmitted (2). All flaviviruses share the characteristics of 
being morphologically-similar, enveloped viruses that contain a single-stranded, positive sense 
RNA genome which contains the same general gene organisation across all viruses (3). While it 
was previously believed that the bulk of the mosquito-borne flaviviruses could be further 
categorised into two main groups; the haemorrhagic, Aedes-borne viruses and the neurologic, 
Culex-borne viruses (4), the recent emergence of neurological side effects from infection with the 
Aedes-borne Zika virus has cast doubt on the accuracy of this categorisation. 
 
1.2: The global impact of dengue virus 
Dengue virus (DENV) is the causative agent for dengue disease; a febrile illness known for 
having both exanthematic and haemorrhagic manifestations that is now classified as either dengue 
without, or with, warning signs or severe dengue based upon the symptoms present and their 
severity (described further in 1.4.1). Before the clinical outcomes of dengue disease were 
reclassified in 2009, dengue disease severity was classified instead as either DF, dengue 
haemorrhagic fever (DHF), or dengue shock syndrome (DSS). Prior to 1939, DF was seen as a 
relatively mild disease; mortality was very low, DHF was very uncommon, and epidemics were rare 
due to the small size of densely populated urban areas in affected countries (5). During World War 
II, infected troops moving through South East Asia and the Pacific spread new serotypes of DENV 
leading to the first hyperendemic DENV-regions. Increased rural-to-urban migration within 
developing countries around the tropics post-World War II led to high population numbers and 
densities within urban environments which permitted greater levels of transmission and more 
regular epidemics. The increased use of air travel and the rapid globalisation in the coming 
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decades led to previously-unseen serotypes of DENV to be introduced into naïve populations 
which had a greater effect than could be predicted; while a single circulating serotype of DENV 
caused a low level of DHF and mortality, multiple strains circulating had a much higher level of 
DHF and subsequent mortality. This effect has been well documented in a number of case studies 
such as the 1981 Cuban DENV-2 epidemic which caused an unprecedented level of mortality in a 
population that had only previously been exposed to DENV-1 (6). The severity of the epidemic also 
put an incredible financial strain on the country, costing ~$103 million in healthcare, aid, mosquito 
control, and public outreach (7). Figure 1 shows the growth of dengue disease over time based 
solely on reported figures (8), however due to inadequate reporting and asymptomatic infections, 
these numbers are not believed to truly reflect the impact of dengue disease during this time. 
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The current global infection rate is predicted to be ~390 million infections per year (95% - 294-
528 million), 96 million of which are symptomatic (95% - 67-136 million) (9) and it is estimated that 
up to 3.97 billion people across 128 countries are at risk (10). Another study, which used a 
prediction of only 58.4 million symptomatic infections per year predicted a worldwide economic 
burden of $8.9 billion (95% - $3.7-$19.7 billion) (11) and, while recent advancements such as the 
licenced Dengvaxia vaccine suggest that those numbers could fall (12, 13), recent studies 
questioning the efficacy of the vaccine across young populations and in low-risk areas (14, 15) put 
into question whether those numbers will rise instead. 
DF and DHF place a heavy strain on the healthcare systems of endemic countries with the 
World Health Organisation reporting ~500,000 hospitalisations and ~25,000 deaths per year due to 
the disease, most of these due to hypovolemic shock caused by high levels of haemorrhaging 
(DSS). Even for those who do not become hospitalised, the disease still has very important social 
and economic costs. The Disability Adjusted Life Scale (DALS) is a method for determining the 
impact of a disease not only on the emotional/physical level to the patient but also on a scale of 
loss of income and cost of medical care over the larger population. When analysed using this 
method, DF/DHF was ranked alongside serious, high-morbidity diseases such as tuberculosis and 
malaria (16). 
DENV consists of 4 serotypes spread via the Aedes aegypti and Aedes albopictus mosquitoes 
which live predominantly within regions between the Tropic of Capricorn and the Tropic of Cancer. 
This means that autochthonous DF cases are prominent in equatorial countries which mostly 
consist of countries defined as ‘developing’. These countries lack the level of healthcare, 
infrastructure, and social/economic support for its population that is seen in developed countries 
meaning that a highly prevalent, highly debilitating disease can have a greater impact on the 
population of these countries than might be seen in more developed nations. Low cost, local 
methods for vector control have already been highlighted as a main strategy for countries in Latin 
America due, in part, to reasons like this (17). 
 
1.3: The global impact of Zika virus 
Zika virus (ZIKV) is the causative agent of ZF; a relatively mild febrile illness known mostly for 
the recent 2007-2017 Asian lineage pandemic which gained attention due to the appearance of 
neurological and developmental complications that were previously unseen in both the Asian and 
African lineages. First isolated in 1947 from a rhesus macaque from the Zika forest in Uganda (18), 
scientists quickly determined that ZIKV was also capable of human infection (19). However, it was 
established that ZF was a very mild disease; it had a roughly 80% asymptomatic rate, it had very 
mild symptoms even when symptomatic, and compared with other prevalent diseases in West 
Africa such as malaria, it appeared far less serious. For this reason, ZIKV research did not 
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advance very far in the next few decades however some miniscule surveillance did continue. In 
1969 ZIKV was detected for the first time outside of Africa; in Malaysia (20), and then a few years 
later in 1977 it was detected in Indonesia (21). Although ZIKV exposure was found to be fairly 
common (around 40% of Nigerians tested in one 1970’s study had signs of previous infection with 
ZIKV (22)) between ZIKV’s isolation in 1947 and 2007 only 14 cases of natural ZIKV infection were 
ever confirmed (23). 
Figure 2 shows the epidemiology of the outbreak that began in 2007 from its origin in Asia, 
across the Pacific, and finally into Latin America by 2015. ZIKV, like DENV, is transmitted via the 
Aedes aegypti and Aedes albopictus mosquitoes and while there were initial reports that Culex spp 
might be capable of transmission of the virus (24, 25), most studies so far have shown otherwise, 
at least in European/North American Culex species (26-28). However, unlike DENV, the virus is 
also capable of transmitting sexually (even after a vasectomy) (29), can form reservoirs in sexual 
organs (30), and has already shown it is a risk for contaminating the blood supply (31) and sperm 
banks (32) so the potential to spread to a wider geographic population than DENV is present. 
 
Currently, it is very difficult to predict the global burden of ZIKV both economically and 
medically due to the high asymptomatic rate of ZIKV infection, a lack of global monitoring, and an 
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ongoing pandemic. However there are currently 59 countries reporting active transmission to the 
World Health Organisation and there have been predictions that ~2.17 billion people live in areas 
that potentially put them at risk of ZF (33). The U.S also made available $1.1 billion for ZIKV 
research/healthcare though a recent study has suggested that, depending on the successful 
transmission rates of ZIKV via mosquito bites, the cost could be far higher (34). 
ZIKV has recently had a very large social impact across the globe with extensive media 
coverage (35) following the pandemic from as early as 2014-2015 when reports of microcephaly in 
congenital Zika syndrome (CZS) began to emerge (36). Since then, it has also been linked to 
Guillain-Barré syndrome (GBS) (37, 38) and acute disseminated encephalomyelitis (ADEM) (39) in 
adults as well as numerous further neurologic conditions in infants in cases of CZS (40). These 
have also been broadcast globally (41-43) causing travel fears (44) and loss of income via tourism 
(45) for affected developing countries. 
 
1.4: Presentation of disease: 
1.4.1: Dengue: 
Dengue, as previously mentioned, is a febrile illness that has a wide spectrum of symptoms 
that can occur. These symptoms usually manifest between day 4 and day 9 post-infection but have 
been known to extend up until day 12. Rarely do they all manifest together but usually the common 
symptoms of fever and malaise are added to depending on severity of the infection with some 
symptoms appearing more commonly than others. Figure 3 shows the general spectrum of disease 




As shown in Figure 3, there are a number of general classifications for where certain symptoms 
would classify a patient on the scale of DENV disease. Further details are: 
Asymptomatic – Asymptomatic infections are difficult to track and so the exact asymptomatic 
rate is difficult to estimate; current predictions though tend to range between 14-~50%. It used to 
be believed that the level of viremia in people with asymptomatic infections was not high enough to 
generate symptoms or spread the disease but recent research shows that asymptomatic carriers 
can pass the virus onto feeding mosquitoes (46). 
Non-specific febrile symptoms – These symptoms tend to solely be malaise and fever making 
diagnosis of DENV infection extremely difficult as it is indistinguishable from many viral infections 
here. This level of disease is common in children who are experiencing their first DENV infection in 
an endemic country and due to the mildness of the fever, recovery often occurs naturally and 
without need for medical care within a week of the first symptoms appearing. 
Dengue (without warning signs) – Dengue without warning signs consists of ‘probable’ cases of 
dengue which covers cases of fever in patients in dengue endemic areas that also have two other 
symptoms out of: nausea, macropapular rash, aching, leukopenia, or a positive tourniquet test. 
Although far less likely to progress into severe dengue, patients without warning signs can still 
develop severe dengue. 
Dengue (with warning signs) – Dengue with warning signs is so named due to the increased 
severity of the symptoms outlining a great probability of progressing to severe dengue. 
Haemorrhagic manifestations of dengue are often small such as petechiae on the lower 
extremities, gingival bleeding, increased bruising, and even cases of thrombocytopenia but can 
extend to gastrointestinal haemorrhaging and systemic internal bleeding. The current list of 
‘warning sign’ symptoms however is: mucosal bleeding, abdominal pain, persistent vomiting, fluid 
accumulation, lethargy, liver enlargement by >2cm, or a decrease in platelet count that causes an 
increase in hematocrit levels. 
Severe dengue – Severe dengue patients develop more serious haemorrhagic symptoms 
along with severe vascular leakage into the pleural and abdominal cavities in what is known as ‘the 
critical phase’. During this stage, the severe plasma leakage can lead to respiratory distress due to 
fluid accumulation around the lungs as well as other organ dysfunction like increased cardiac 
stress and liver damage. If the haemoconcentration is managed appropriately with IV fluid 
replacement then the chance of entering shock is greatly reduced. Shock usually occurs when a 
patient’s fluid levels are not monitored or managed properly causing them to fall into 
hypovolemic/hypotensive shock. This causes further respiratory distress, cardiac arrhythmia, and 
organ failure. Roughly 25% of dengue-related shock patients die, rising to almost 100% if vascular 
collapse occurs. Once past the critical phase, patients then enter the ‘convalescent phase’ during 
recovery where they reabsorb the lost fluids from the abdominal and pleural cavity. Newer fluid 
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dosage guidelines have begun to reduce the problems of overcompensating for fluid loss, 
especially in children, which can cause hypervolemia, respiratory distress and death during the 
convalescent phase (47). 
 
1.4.2: Zika 
ZF has a much milder set of symptoms than dengue. Although the symptoms may be wide 
ranging, they rarely pose any risk to the patient. Approximately 80% of ZF is asymptomatic and 
although death can occur, it is incredibly rare and only usually occurs in those who are already 
severely immunocompromised. The common symptoms during symptomatic ZIKV infection consist 
of; fever, arthralgia, descending maculopapular rash, malaise, and occasionally abdominal pain 
and diarrhoea. The symptoms are very similar to other viral infections and other more common 
arboviruses in endemic areas such as chikungunya virus and DENV. Conjunctivitis tends to be 
more common with ZF than with dengue or chikungunya infection as well as limb oedema. Also 
hepatomegaly, leukopenia, and thrombocytopenia are far less common in ZF than in dengue. 
ZF can have serious complications though with GBS being one of the most documented of 
ZIKV-caused maladies. GBS is an autoimmune condition targeting the myelin sheath of the 
peripheral nervous system causing the myelin to be degraded and removed from the axon of the 
nerve. Myelin, when produced and wrapped around the nerve axon by Schwann cells, allows for 
action potentials to pass more quickly along the nerve by increasing the maximum effective 
distance between each set of ion channels to efficiently polarise the axon (48). Exposed nerves 
lose efficacy and speed in transmitting action potentials leading to a tingling sensation in the limbs 
and muscle weakness and, if left untreated, nerve degeneration, atrophy, and therefore permanent 
paralysis (49). As this condition affects any peripheral nerves, breathing problems are relatively 
common and, depending on the speed of treatment, permanent nerve damage can occur. ZIKV is 
thought to cause GBS by a cell-mediated response to molecular mimicry (38) due to the speed of 
onset post-infection. 
ADEM is also now associated with ZIKV infection and, unlike GBS, it is a demyelinating 
autoimmune condition that affects the central nervous system (CNS) rather than the peripheral 
nervous system (PNS). Symptoms have been described as similar to an acute attack of multiple 
sclerosis (seizures, headaches, ataxia, optic neuritis) however ADEM is a curable, single-attack 
disease driven by class switched IgG and triggered by trauma/infection whereas MS is an 
incurable condition driven predominantly by serum IgM but where individual attacks are stimulated 
through the same triggers. Like GBS, the demyelination can cause permanent damage if the 
autoimmunity is left untreated. ADEM and GBS have already been linked as a complication in 
numerous other viral infections (39, 50-53).  
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ZIKV presents its greatest and most specific risk when pregnant women become infected, 
especially if they are within the first trimester of pregnancy. This is because ZIKV is capable of 
infecting neurosphere cells and neural progenitors and then promoting apoptosis in them (54) and 
during the first trimester is when the brain is developing these key tissues. Retarded growth during 
this stage leads to a much smaller brain size which then presents as microcephaly when the infant 
is born. CZS at later stages can still affect other areas of the foetus’ brain development due to the 
virus’ ability to infect a wide variety of cell types, leading to other brain malformations such as 
calcifications, hypoplasia, ocular abnormalities, ventriculomegaly, enlarged extra-axial spaces, 
hypodensity of the white matter, and even reports of encephalomalacia in rare cases (40). It should 
also be noted that ZF has been linked recently to heart conditions like pre-eclampsia, palpitations, 
and arrhythmia though is not the only flavivirus to do so (55). 
 
1.5: Flavivirus physiology, life cycle, and pathogenesis 
1.5.1: Flavivirus genome organisation and physiology 
The mature flavivirus virion consists of three structural proteins and a plasma membrane 
enveloping the genomic RNA. As shown in Figure 4, the RNA is encased within capsid (C) proteins 
which are in turn surrounded by a plasma membrane taken from the endoplasmic reticulum (ER) of 
infected cells. Embedded in the membrane is the membrane (M) protein - cleaved from the pre-
membrane (prM) protein by a host furin or furin-like protease, and the envelope (E) protein which 
covers the M protein if it has been properly cleaved. The prM protein is not always cleaved during 
egress of the virus particle from infected cells, leading to totally-uncleaved and partially cleaved 
virion particles that have a ‘rough’ appearance to their surface as the prM proteins block the E 
proteins from forming their usual structure. These are known as immature/partially mature 
particles. There are minor differences in the macro structure of DENV and ZIKV as identified by 




Along with structural similarities, flaviviruses also share the same general genome organisation 
and mechanism of polyprotein processing. The flavivirus genome is a non-segmented, positive-
sense, single stranded RNA of ~11kb with a type 1 cap and a single open reading frame (ORF) 
which is translated into a polyprotein of ~3400 amino acids (aa). The polyprotein is both co- and 
post-translationally cleaved by both viral and host proteases into 10 proteins; C, prM, E, NS1, 





The ORF is bordered by two untranslated regions (UTRs); the 5 UTR and the 3 UTR. These 
play important roles in the virus lifecycle with both the 3 and 5 UTR forming secondary RNA 
structures called stem loops that help in RNA-protein interactions with both viral proteins and host 
ribosomes and RNA-RNA interactions (58). The 5 end of the genome is protected with a 
m7GpppN-cap and, unlike some viruses, the 3 UTR of flaviviruses is not poly-adenylated. 
 
1.5.2: Transmission of dengue virus and Zika virus 
Both DENV and ZIKV have a sylvatic and anthroponotic cycle as shown in Figures 6 and 7. It is 
likely that DENV originated from non-human primates as it is known to infect primates without the 
occurrence of DHF in either laboratory or natural infections (59). Humans would therefore be the 
‘spillover’ hosts which would explain the severity of symptoms shown compared to non-human 
primates. ZIKV’s species of origin is still currently unknown, however rhesus monkeys have been 
shown to be permissive for ZIKV replication and ZIKV was first isolated from a rhesus macaque. 
Upon ZIKV infection, rhesus monkeys do however show symptoms like human ZF and so are 
potentially another ‘spillover’ host. Antibodies against ZIKV infection have been found in a wide 
range of species as well such as: horses, cows, ducks, sheep, bats, and orangutans (60). 
Both viruses cause viremia in a naïve host (as detected by PCR) for ~5-7 days during which 
they are infectious to feeding mosquitoes. Although little is known about the associations with 
ZIKV, faster passage from the midgut to the salivary glands of the mosquito has been linked with 
more severe dengue disease (61). For both viruses though, the average time it takes is ~12 days. 
Once in the salivary glands, the virus can be passed down the proboscis of the mosquito when it 
feeds and into the subcutaneous layers of the host skin. 
ZIKV can also be transmitted sexually with detectable levels of ZIKV RNA being present in 
semen up to 125 days post-infection (62) and also in urine for ~40 days. ZIKV has been noted to 
pass from male to female (63) as well as through men who have sex with men (MSM) (64) but due 
to the virus’ presence in cervical/vaginal fluid it has also been discovered to be capable of female 
to male transmission (65). The R0 of sexual transmission in ZIKV infection is lower than 1 (66) and 







1.5.3: Dengue lifecycle 
Once DENV is introduced to the subcutaneous layer of the skin, its initial target is local 
immature Langerhans cells (67) but it can also infect macrophages and monocytes (68). These 
skin-specific dendritic cells are rich in receptors that are believed to be involved in DENV entry; 
dendritic cell-specific intracellular adhesion molecule-3-grabbing non-integrin (DC-SIGN), T-cell 
immunoglobulin mucin domain (TIM) receptors, and Tyro3, Axl, and Mer (TAM) receptors (69). As 
shown in Figure 8, DENV is taken up by clathrin-mediated endocytosis and proceeds through the 
normal endocytosis pathway. 
 
The endocytic particle then fuses with endosomal vesicles and progresses to an early and then 
late endosome where the pH drops to ~5.0-5.5. At this point, the DENV E protein undergoes a 
conformational change from its neutral pH conformation of a dimer to a low pH conformation of a 
trimer. In this conformation, the fusion loops are exposed and inserted into the endosome 
membrane to bring the membrane of the virus close enough to allow for membrane fusion (70). 





As the genome is positive sense RNA, it can be translated by ribosomes without the need for 
the production of coding RNA. The cap structure helps load the RNA into the ribosome but the 3’ 
UTR also plays a role in enhancing translation (71). The produced polyprotein is capable of 
autocleavage to release the non-structural proteins that then promote replication and modulate 
host responses. This processing is done within unstructured convoluted membranes induced by 
the virus. 
Replication takes place within ‘replication pockets’ that are induced in the ER membrane (72) 
to produce a high concentration of viral RNA and viral replication proteins to increase the efficiency 
of replication and also to ‘hide’ triggers like dsRNA replication intermediates and uncapped ssRNA 
from the intracellular antiviral proteins such as retinoic acid-inducible gene I (RIG-I) (73). Inside the 
replication pockets, the genome must cyclize for the production of the negative sense antigenome 
to be created (74) which is necessary to produce positive sense genomes which can then be used 
to increase viral protein production and as genomes to be packaged into new virions. 
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Viral genomes then become packaged within invaginations in the ER membrane that are 
caused by the build-up of viral structural proteins on the internal side of the ER membrane. These 
bud off into the ER and then are transported in vesicles to the golgi to be matured by furin before 
being exocytosed. Figure 10 shows the steps of the virus lifecycle at the ER. 
 
As the infection of DENV will have triggered the immature Langerhans cell to migrate to the 
local lymph node to mature, the virus will emerge from the eclipse phase and be capable of 
infecting surrounding dendritic cells, monocytes, and macrophages as well as escape into the 
blood from the lymphatic system and disseminate into other organs like the liver. There, DENV is 
capable of infecting not only hepatocytes but also Kupffer cells (75), using the abundant 
37kDa/67kDa high affinity laminin receptor to enter hepatocytes (76). The immune response 
surrounding the liver is always fairly strong and damage to the liver during DENV infection is often 
associated with DENV-mediated apoptosis and immune response-mediated cell death. Cytotoxic 
CD8+ T-cells are implicated as playing a role in dengue-associate liver damage due to their 
prevalence in viral infection (77). Elevated aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT) levels are seen in the majority of dengue with warning signs and severe 
dengue cases and while some patients show no liver symptoms, those that do can have symptoms 
that range all the way up to acute liver failure. However, myeloid cells are believed to be the 
primary target of DENV and upon infection they secrete high levels of cytokines and leukotrienes 
which have been shown to induce increased permeability in endothelial cell monolayers (78). 
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These are also believed to be the main source of vascular permeability as the appearance of 
DENV-specific CD8+ T-cells almost exclusively after haemoconcentration means CD8+ T-cell-
mediated damage to the endothelium does not play an integral role in vascular leakage (79). 
So far, no clear biochemical markers have been identified for distinguishing between dengue 
and severe dengue in the early stages of the disease and no markers have been found for 
determining whether particular genotypes of dengue virus cause a higher level of cytokine 
production. The cytokine storm generated predominantly by infected monocytes/macrophages is 
associated with the vascular leakage in dengue disease due to cytokines such as TNF-α and IL-1β 
increasing vascular permeability and errant platelet coagulation damaging the vasculature. 
However, NS1 protein binding and subsequent interference with the glycocalyx layer that provides 
barrier function in microvessels as well as the induction of complement by NS1 leading to the 
formation of terminal complement complex C5b-C9 have been shown to induce higher levels of 
vascular leakage. In gram negative bacteria, lipopolysaccharide (LPS) is well documented to bind 
toll-like receptor 4 (TLR4) to trigger a large cytokine response. DENV NS1 has recently been 
discovered to bind TLR4 and cause in vitro cytokine release and endothelial monolayer disruption 
(80) though its role in vivo is not yet known. It does however present a potential for further 
explanation as to the similarities between LPS-mediated endotoxic shock and severe dengue-
associated shock. The similarities go further with greater numbers of circulating endothelial cells in 
a mouse model of dengue being shown to lead to higher levels of inducible nitric oxide synthase 
(iNOS) and peroxinitrate which caused greater apoptosis of cells and subsequent haemorrhage. In 
sepsis patients, higher numbers of circulating endothelial cells is linked with more severe septic 
manifestations and a worse prognosis as well (81). 
 
1.5.4: Pathogenesis of Zika virus 
The route that ZIKV takes through the human body is not well understood due to the only 
recent emphasis on ZIKV research. However, it is already known that ZIKV’s main route of entry is 
the same as DENV; subcutaneous introduction via Aedes aegypti or Aedes albopictus mosquitoes, 
however ZIKV is also capable of sexual transmission. Currently, the primary target cell/organ of 
ZIKV is not known but ZIKV has been shown to be capable of infecting a large number of cell types 
(82, 83) including DCs (84) and macrophages (85) similar to DENV. Due to the high number of 
permissible cell lines, the cell entry receptor for ZIKV has been predicted to be either a very 
common cell surface receptor or, potentially, multiple receptors that can all be utilised as primary 
receptors by ZIKV. Tyrosine-protein kinase receptor UFO (AXL) was a prime suspect due to the 
previous evidence suggesting it was involved in the entry of a number of enveloped viruses and it’s 
present on the surface of a wide range of cell types however knock-out (KO) studies in mice 
showed that removing AXL did not stop viral entry (86). AXL is however still thought to be heavily 
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involved alongside DC-SIGN, tyrosine-protein kinase receptor TYRO3 (Tyro3), and TIM-1 (87) 
much like in DENV infection. 
Mouse models of ZIKV are not particularly reliable as, much the same as in DENV mouse 
models, the pathogenesis and disease progression is not comparable to human infection. ZIKV 
mouse models see no degradation of signal transducer and activator of transcription 2 (STAT2) 
which is a very well-known feature of human ZIKV infection (88, 89). As such, ZIKV mouse models 
must be IFN -/- (90, 91) with immunocompetent mice being highly resistant to infection. ZIKV 
mouse models also showed severe testicular atrophy to the point of infertility (92) which has so far 
not been reported within human infection.  
Rhesus and cynomolgus macaques appear to be higher quality animal models for ZIKV 
infection however come with greater ethical restrictions and greater costs than mouse models. 
They do however provide more reliable descriptions of pathogenesis. A study performed by Osuna 
et al (30) showed the levels of viremia in 10 different macaques as well as the presence/absence 
of virus particles and RNA within saliva, blood, urine, semen, vaginal secretions, and cerebrospinal 
fluid (CSF) at specified timepoints over 21 days. The study used a virus similar to the Asian strain 
currently circulating in South America and as well as studying the presence/absence of the virus 
and its RNA, the study also kept track of the immune response generated by the infection as it 
progressed and during a re-infection 45 days after the initial infection. ZIKV was found in the urine 
of the macaques as early as day 2 post-infection and disappeared at roughly the same time as the 
viremia was resolved although a few sporadic reappearances suggest the possibility of reservoir 
sites within the urinary system. Even at 28 days, ~50% of the animals still had detectable ZIKV 
within the saliva and those that showed the presence of ZIKV within semen also showed signs that 
it had formed a reservoir there that was shedding detectable levels beyond the 28 day mark, which 
matches human reports of ZIKV being detected in semen months after infection (93). ZIKV was 
also detected within 50% of the macaques inside the CSF at various timepoints however it was 
only the macaques that had higher than mean viremia levels suggesting that neuroinvasion may 
simply be a ‘spillover’ effect of high viremia levels rather than a targeted route. This also seemed to 
be the case with all other bodily fluids except saliva. The three animals with the highest levels of 
viremia had detectable ZIKV in their CSF, urine, saliva, blood, and semen (all three were males) 
whereas the lowest peak viremia (female) only showed ZIKV RNA within her blood and saliva. The 
six animals in between showed a mix of results – all had ZIKV detectable in blood and saliva but its 
presence/absence in their urine, semen, cervicovaginal lavage, and CSF varied. The detection 
within the semen was also similar to what was seen in human males as the virus was detected in 
higher numbers in the prostate and seminal vesicles where it is predicted to reservoir in humans 
(29). 
The spillover theory of ZIKV infection is a convincing one due to the large number of cell types 
currently found to be permissive to ZIKV infection; immune cells (84, 85), placental cells (82, 83), 
30 
 
neuroprogenitor cells (94), ocular nerve cells (95), fibroblasts and keratinocytes (87) are but a few. 
Likely ZIKV has a main target organ/cell type but its use of a widely expressed entry receptor or 
multiple receptors means that high levels of viremia expose greater numbers of permissive cells to 
the virus leading to invasion of other tissues. During infection of a pregnant mother though, the 
very high permissibility of placental cells and in particular placental macrophages and Hofbauer 
cells makes vertical transmission very likely. Hofbauer cells have been seen to migrate into the 
brain tissue of infected foetuses and so introduce the virus to permissive neural progenitor cells. 
Due to the apoptotic nature of ZIKV infection, the loss of neural progenitor cells leads to a 
diminished brain size as well as malformations and incomplete development (96, 97). Congenital 
infections are also linked with spinal cord deformities too suggesting that the infection of the 
undeveloped CNS extends into the spine or at least affects the development of the spinal nerves 
(98). 
 
1.5.5: Antibody-dependent Enhancement 
Antibody-dependent enhancement (ADE) is the term used to describe a well-documented side 
effect of DENV infection that raises the chance of severe dengue 15-80 times if the patient has 
been exposed to another serotype of DENV. As mentioned in 1.2, DENV infection was historically 
not considered a particularly dangerous infection but the globalisation that occurred brought new 
serotypes into populations that had developed immunity to a different serotype, leading to 
widespread cases of DHF/DSS like in Cuba in 1981 (6) so that now hyperendemic countries face a 
huge problem with multiple endemic serotypes circulating at once. 
During primary infection, an effective antibody repertoire is developed that, if faced with the 
same serotype again, would provide a protective immune response that would neutralize the virus 
by stopping the conformational change of E protein so that even when the pH drops in the 
phagolysosome, the virus cannot escape into the cytosol of the phagocytic cell. Figure 11 shows a 
representation of a DENV particle in a phagolysosome. 
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Occasionally during the initial phase of the secondary infection (with a different serotype), the 
antibody response to the primary infection is stimulated due to similarities in protein structure. 
DENV serotypes are ~70% similar to each other in amino acid sequence, giving a chance that an 
antibody epitope could partially recognise a resembling peptide on another serotype. However 
there are likely to be differences within that peptide as well, which would reduce the binding affinity 
of the antibody. The antibody response that was effective to the first serotype binds weakly to the 
second serotype and so fails to fully neutralize the virus. The virus is taken up by the Fc receptor 
as in a primary infection but unlike in a primary infection, when the phagolysosome pH drops, 
some of the E proteins can still undergo their trimerization and conformational change to induce 
membrane fusion and viral release (Figure 12). Even if there were antibody epitopes that are high-
affinity binders to the second serotype present within the generated antibody repertoire, they would 
be unlikely to have been high-affinity binders of the initial serotype and so would not be produced 
at a high enough concentration to be considered neutralising (59). As the Fc receptor is faster at 
uptake than DENV’s usual cell entry receptors, partially neutralised virus particles can infect at a 
faster rate than non-neutralised virus particles, meaning that an ineffective antibody response is 
more detrimental than no prior immunity at all as it leads to greater infection and higher viral load in 
early infection. As macrophages and monocytes are the primary target for DENV (as described in 
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1.5.3), this enhanced infection then leads to greater cytokine production, increased vascular 
permeability, and more severe symptoms. 
 
Cells in hypoxic conditions have been shown to require a higher titre of neutralising antibodies 
to neutralise viral particles as well as having a greater rate of uptake via the Fc receptor meaning 
that immune cells in hypoxic tissues have a far greater risk of ADE (99). Although this study was 
done in vitro, it reveals that the in vivo implications could be much more severe than previous in 
vitro ADE experiments have shown. 
The two lineages of ZIKV have shown no signs of ADE between each other. In fact, antibodies 
raised against one serotype have been shown to be protective to the other serotype (100, 101). 
However, there have been reported cases of ADE between ZIKV and DENV (102). One study in 
particular presented evidence that all of its DENV-immune serum samples showed ADE for 
subsequent ZIKV infection that was not seen in DENV-naïve serum (103). Sharing the same 
vectors, the emerging ZIKV epidemic is passing through populations in DENV-endemic and –
hyperendemic countries which is quite possible amplifying the ZIKV infection. There are currently 
no studies reporting whether ZIKV antibodies would increase the chances of ADE during DENV 
infection but there is potential for the current ZIKV epidemic to have another lasting effect by 
putting people at greater risk of ADE and subsequently more severe disease. Due to this risk, 




1.6: Flavivirus Proteins 
1.6.1: Capsid 
The flavivirus C protein is responsible for forming a protective capsule structure around the 
genomic RNA inside virus particles. Each immature monomer is ~114 aa in length and is cleaved 
by the NS2B-NS3 protease on the cytoplasmic side of the anchor peptide which creates the 
mature form of C protein (~100aa (~12kDa)) which then stabilizes in solution as a dimer. The host 
signal peptidase cleaves from within the ER lumen at the other end of the anchor peptide to 
release prM from the anchor peptide however this first requires the C protein-anchor cleavage by 
NS2B-NS3 protease so that C protein cleavage is a prerequisite for prM cleavage. The C protein 
dimers bind together in the presence of RNA to create an amorphic, physical protective barrier 
around the genome that is then enveloped in host membrane during viral particle assembly. Upon 
membrane fusion inside the lysosome of an infected cell, the capsid structure is released into the 
cytoplasm where the multimeric structure is believed to break apart to release the genome to be 
transported to the ER. Currently the process of encapsulation and capsid assembly, as well as 
capsid deconstruction upon virus entry are not well understood. However, what is known is that the 
C protein is not just a structural protein. A deletion study performed by Sansa et al (105) has 
shown that the DENV C protein can perform its structural role despite rather large deletions as long 
as two basic residue sequences at the N-terminus are intact but the infectivity of the deletion 
mutants which retained the ability to form a nucleocapsid was reduced, suggesting that there are 
other mechanisms performed by the C protein that affects the pathogenicity of the virus which was 
interrupted by the deletions (106, 107). The research into these other mechanisms is not yet 
extensive but there have been some breakthroughs. For DENV it was shown that the C protein 
interacts with lipid droplets early in infection which allowed for greater replication than if this action 




Flavivirus prM protein is a ~166aa protein that is embedded in the virus lipid membrane by its 
C-terminal end, with the N-terminal end outside of the virus particle (109). prM is important for 
correct folding of the E protein during virus assembly, initially forming a heterodimer with the E 
protein. The N-terminal end of the protein prevents the E protein from structural rearrangements 
due to premature fusion during the process of virus assembly and secretion. Once the prM protein 
is cleaved by the host protease furin at the golgi body, the E protein rearranges on the virus 
surface to form a E protein homodimer, resulting in the mature virus particle. The prM protein is 
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considered matured and is then referred to as the membrane (M) protein. In the mature virus 
particle, the E protein dimers cover the M protein fully. Partially-mature and immature virus 
particles are produced when the prM proteins that coat the virus are either or only partially cleaved 
or not at all. Immature virus particles are not infectious but may be taken into cells by the route of 
ADE by antibodies recognising the prM protein (110). There has also been evidence to suggest 
that immature particles can be infectious in immature DCs via interaction with DC-SIGN (111). 
 
1.6.3: Envelope 
E protein is a ~495 aa surface glycoprotein anchored to the viral envelope membrane by two 
transmembrane helices. It is fairly well conserved across flaviviruses with a ~40% similarity at the 
aa level (112). There are 180 E proteins per virion consisting of 90 pairs of E protein homodimers 
that interact with 2 M proteins each and are arranged on the virus surface in a herringbone pattern 
(113). The E/prM interaction occurs within minutes of translation and processing of the polyprotein 
and involves two conserved helices located towards the C-terminal end of the protein (114); in 
DENV-2 these equate to aa 398-420 and aa 426-448. Each E protein is made up of three domains; 
domain I which is the central structural domain, domain II which is the dimerisation domain, and 
domain III which is the Ig-like receptor binding domain. 
The E protein’s role is to act as a cell surface binding and fusion protein. It interacts with cell 
surface receptors using the glycosylated domain III. The glycosylation patterns vary even from 
strain to strain which can affect the affinity of different receptors to be utilised for cell entry and this 
can play a role in the virulence of the virus. For example, the YFV-17D vaccine strain is largely 
attenuated by mutations within E protein domain III so that it has a very high affinity for 
glycosaminoglycans (GAGs) which are expressed on the surface of many cells as well as being 
very prevalent within the extracellular matrix (ECM). This means that YFV-17D does not remain in 
the blood for long once it has been introduced and often becomes harmlessly bound to the ECM. 
Even cells that are infected are believed to be re-infected by progeny virus that attach immediately 
after being secreted from the cell, leading to an ineffective infection that is easily overcome by the 
immune system (115). After the uptake of the virus, the phagolysosome acidifies and this 
acidification causes the E protein dimers to dissociate and then reform irreversibly as a trimer. The 
trimer inserts itself into the membrane of the phagolysosome and the E protein bend at the domain 
I/domain II hinge, fusing the envelope membrane with the phagolysosome membrane to release 
the capsid and its contents into the cytoplasm (112). 
The E protein is also responsible, alongside prM protein, for the budding of the membrane that 
occurs in the creation of viral particles. The expression of prM and E alone causes the release of 
virus-like particles that are structurally and functionally like the flavivirus membrane (116). The E 
protein is the primary target of the host antibody response. Antibodies raised within mice to domain 
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III of E protein are often neutralising as they can obstruct the receptor binding region. As previously 
mentioned, glycosylation on the E protein varies between flaviviruses and even strains within those 
species, which means that those antibody responses towards E protein domain III are fairly 
specific. This fact has garnered some therapeutic interest because most flavivirus ELISA tests run 
with high levels of cross-reaction (117) that means clear identification is not possible without RT-
PCR tests or viral plaque assays which are more costly and take more time. ELISAs based on 
domain III of E protein have been shown to identify the correct infection using a patient’s serum 
with higher sensitivity than with larger viral antigens (118). Vaccination with WNV E domain III 
generated an antibody response that was protective in vitro and in vivo to WNV challenge but also 
partially protective to DENV (119). When JEV was incubated with the same serum and then 
introduced into mice, the development of brain injuries was prevented compared to untreated virus 
(120). This gives E protein domain III an enticing prospect of being used in vaccines. Other 
therapeutic uses for E protein domain III have included the generation of mAbs that could be 
infused as a treatment which was shown, as well as the use of domain III as a competitive binder 
of cell entry receptors, to reduce virus infection of cells (118). 
 
1.6.4: NS1 
NS1 is a highly conserved protein across flaviviruses. It is 352 aa long and has a molecular 
weight of 46-55 kDa depending on its glycosylation status. It is found commonly in one of three 
native states: a secreted hexameric lipoparticle form (121), a cell surface-bound dimeric form, or a 
virus-induced intracellular vesicle-bound form (122). NS1 forms a hydrophobic dimer without the 
assistance of other proteins (123) and associates with lipids via a glycosyl-phosphatidylinositol 
(GPI) linkage (124).  
The secreted form is an early marker of disease, especially in primary infection, and it is also 
known for being highly immunogenic and potentially plays a role in flavivirus virulence. The 
hexamer is held together by weak hydrophobic bonds that are easily disrupted although this has no 
effect on secretion levels of NS1. When secreted, NS1 has a number of targets such as; the 
complement system (125, 126) and coagulative regulators (127), and has also been reported to 
accumulate within the late endosomes of hepatocytes in vitro (128) resulting in increased DENV 
virulence upon infection. The antibody response to NS1 also plays an important role in secondary 
infection though it is not yet clear what defines a protective response and what defines a 
detrimental one. Although the antibody responses are not neutralising, antibodies capable of fixing 
complement allow cell surface-bound NS1 to be targeted and infected cells to be destroyed via the 
membrane attack-complex (MAC). There has however been recent evidence to show that non-
complement-binding antibodies can also provide protection by binding cell-surface NS1 and 
directing the immune response towards the infected cells via the Fc receptor (129). The antibody 
36 
 
response has been known to cause problems too. NS1/antibody immune complexes have been 
shown to cause vascular damage and antibodies raised against NS1 can be cross-reactive against 
the ECM and epithelial cells resulting in apoptosis of uninfected cells (130). 
Non-secreted NS1 is required for flaviviral replication though its role is still speculative. It has 
been shown to co-localise with dsRNA and other flaviviral replication proteins but given its 
placement on the internal lumen of the ER (while the replication complex is external), it likely 
performs a scaffolding/recruitment function for the replication complex (131). WNV NS1 has also 
been shown to inhibit the TLR3 response in WNV replicon-expressing cells (132). 
 
1.6.5: NS2A 
NS2A is a hydrophobic protein of ~231 aa in length that is membrane-associated and, like 
many flaviviral proteins, has multiple roles in vivo. It is not highly conserved between different 
flaviviruses with the NS2A proteins of DENV and ZIKV only having a ~24.8% similarity at the aa 
level. This explains the differences in some of NS2A’s function in different flavivirus. For example, 
the presence of ZIKV NS2A in radial glial cells was shown to disrupt adherens junctions and lead 
to premature differentiation into neurons both in vitro and in vivo as show by in utero 
electroporation transfecting the cortex of embryonic Crl:CD1 (ICR) mice with the ZIKV NS2A gene 
(133). This phenotype is seen in native infection of foetuses and so NS2A is believed to the main 
contributing factor behind this aspect of the neuropathogenesis seen in CZS. The same study 
tested DENV NS2A in the same manner and did not see the junction disruption or the premature 
differentiation. Many, if not all, flavivirus NS2A proteins play a role in modulating the IFN pathway, 
however they do so in different ways. NS2A from DENV-1, -2, and -4 inhibit the IFN-β induction 
pathway by interfering with tank binding kinase 1 (TBK1) phosphorylation of interferon regulatory 
transcription factor 3 (IRF3) in conjunction with NS4A (134). For WNV, NS2A is also essential for 
the inhibition of IFN-α/β induction (135, 136) providing evidence that NS2A interference with the 
IFN-signalling pathway could be a common interaction within flaviviruses. 
NS2A does however retain a set of functions common to all flaviviruses. Its localisation within 
the replication complex is well-documented with its role predicted to be mostly structural in keeping 
the replication complex close to the membrane (137) likely via its strong interactions with RNA. It 
also plays a role in virus particle assembly. Mutagenesis of the YFV and WNV NS2A proteins 
resulted in the production of non-infectious prM/E particles but no C protein or RNA was loaded 
into them, leading to the prediction that NS2A may be involved in transporting and/or packaging 






The NS2B protein is a ~96 aa (~14 kDa) transmembrane protein consisting of two 
transmembrane domains (TMD) at the N- and C-termini of the protein with one central domain. The 
NS2B protein functions as an essential cofactor for the NS3 protease. The central region of NS2B 
expressed without the two TMDs has the capability to solubilize (though not activate) the NS3 
protein (139). When interacting with the NS3 protease, the C-terminal end of the central region (aa 
68-96) inserts itself within the substrate binding pocket using a hydrophobic β-hairpin structure and 
plays a direct role in protein-protein interactions with the substrate. Therefore, the NS3 protease 
cannot function without the NS2B cofactor (140). The TMDs of NS2B also play an important role by 
localising NS3 to the membrane via the NS2B/NS3 protease binding – a localisation that is 
important in efficient viral replication. 
 
1.6.7: NS3 
The NS3 protein is a ~619 aa (~69 kDa) multifunctional protein with the N-terminal domain 
containing a chymotrypsin-like serine protease, modulated by NS2B, which cleaves both in trans 
and in cis and the C-terminal domain containing a helicase domain which bears some structural 
similarity to the conserved RecA fold responsible for nucleotide binding and ATP hydrolysis. The 
protease domain (~167 aa) and its structural relationship with NS2B was discussed in 1.6.6. Its 
individual structure was described by Luo et al (139). The helicase domain (~446 aa) consists of 
three subdomains; subdomain 1 and 2 form a RecA-like structure that contains 8 highly conserved 
motifs that control RNA binding, ATP hydrolysis, and the mediation of the binding and activation of 
both sites, while subdomain 3 forms the RNA binding tunnel that feeds RNA into the RNA binding 
site (140). The ATPase site within NS3 helicase subdomains 1 and 2 is also responsible for 
RTPase activity. NS3 helicase subdomain 3 is also responsible for the interaction with NS5. 
NS3 plays numerous highly important roles within the flavivirus lifecycle. The NS3 protease 
cleaves in cis and in trans to proteolytically process the flavivirus polyprotein; cleaving the C 
protein (with host signalase) from prM protein and also cleaving between NS2A/NS2B, NS2B/NS3, 
NS3/NS4A, and NS4B/NS5 (141). NS3 has also been shown to undergo autoproteolysis within 
mammalian cells though the biological relevance of this action is not yet understood (142). The 
NS3/NS5 heterodimer is a key flaviviral feature, acting as the core component of the replication 
complex. The helicase action of NS3 releases ssRNA from dsRNA to be used as either a template 
for replication in the case of antigenomes, or to be processed and packaged into viral particles in 
the case of newly formed genomes. The NS3 protein also processes the newly formed genomes 
using the RTPase activity of the helicase domain to trigger the first step in viral capping that is then 
completed by the NS5 protein. 
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NS3 also plays a role in the modulation of the host response to infection. A study analysing the 
human cellular interactome of the NS3 protein from multiple flaviviruses including; DENV, the WNV 
strain Kunjin (WNVKun), Japanese encephalitis virus (JEV), tick-borne encephalitis virus (TBEV), 
and Alkhurma virus (ALKV) revealed a tendency for NS3 to interact with ‘hub’ proteins allowing it to 
have a much more prominent effect on the regulation of host cell pathways (143). In human cells, 
though not in mouse cells, the DENV NS3 protease was observed to cleave stimulator of interferon 
genes (STING) (144), a regulator of both IFNα/IFNβ induction as well as cleaving protein arginine 
methyltransferase 5 (PRMT5) (143), a member of the mitogen-activated protein kinase (MAPK) 
signalling cascade, whilst the JEV NS3 protein cleaved AP-1 (145), a transcription factor important 
in the transcription of genes relating to inflammation and apoptosis. The DENV NS3 protein has 
been reported to co-localise and bind to fatty acid synthase (FASN) during infection (146). FASN is 




NS4A is a membrane-bound ~127 aa (~16 kDa) protein containing TMDs that induces 
curvature of the membrane that it is situated in. Within the viral polyprotein, it is located alongside a 
conserved 23 aa linker protein known as the 2K fragment. When the polyprotein is cleaved, the 
NS4A/2K boundary is cleaved by NS2B/NS3 protease which then triggers the cleavage of 
2K/NS4B by a host signalase. Despite being cleaved off, the 2K fragment plays an important role 
in NS4A’s function. In DENV infection, the 2K fragment prevents NS4A activity and must be 
cleaved free before it can function and, as shown by studies on WNV, the 2K fragment must be 
present and attached to NS4A before proteolytic processing or NS4A accumulates in the golgi and 
cannot have its native effect (147). When expressed and cleaved, mature NS4A can naturally form 
a heterodimer with NS4B as well as NS4A oligomers via TMD1 as well, though the role of NS4A 
oligomers is not yet known (148). 
NS4A has been observed to co-localise with dsRNA and within flavivirus infection, it is known 
to form a key part of the replication complex. Its interaction with host vimentin and viral NS1/NS4B 
allows it to regulate and initiate the construction of the replication complex. The interaction with 
NS4B can only be performed by monomers of NS4A. The WNV NS4A protein has also been 
shown to regulate the ATPase activity of the NS3 helicase (147). Its capability to induce curvature 
within the membrane also contribute to the induction of the replication pockets that are seen within 
the ER and virally-induced membrane structures in flaviviral infection. NS4A is also responsible for 
triggering the formation of these virally-induced membrane structures (149, 150). 
Outside of the replication of the virus and interaction with viral proteins, NS4A also interacts 
with host factors to assist in flaviviral infection. Autophagy is well documented to be used by 
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numerous flaviviruses either to protect from apoptosis or as a site of replication in the case of 
DENV-2. NS4A from DENV-2 and Modoc virus (MODV) induced an increase in cellular autophagy 
via the PI3K pathway (151). This response is thought to be important during infections such as 
DENV when post-acute-phase infection of hepatocytes and epithelial cells occurs, however the 
role of PI3K in preventing apoptosis has only been shown in vitro so far (152). Its presence can 
trigger the unfolded protein response (UPR) within the ER and can play a role in IFN suppression 
though that remains species and serotype specific. During DENV-1 infection, for example, NS4A 
strongly inhibits RIG-I/TBK –mediated IFNβ production, but that inhibition has not seen observed in 
studies using DENV-2 or DENV4 infected cells (153). 
 
1.6.9: NS4B 
NS4B is a highly hydrophobic protein of ~249 aa (~28 kDa) in size that is fairly well conserved 
at the aa level - ~35% across mosquito-borne flaviviruses and ~78% between all DENV serotypes. 
The high hydrophobicity of the protein has prevented structural characterisation of the protein at 
atomic level resolution so far, however there is a generally accepted topology model from 
biochemical studies of 3 TMDs and 2 membrane-associated domains (MADs) (154). The 
hydrophobicity is also one of the reasons the protein readily forms homodimers and heterodimers 
with NS4A without needing any additional proteins present (147, 155). 
The formation of NS4A/NS4B heterodimers is clearly important for flavivirus replication as 
prevention of this interaction or a reduction in the affinity of this binding by mutation of the binding 
site leads to a greatly diminished capability to replicate. The interaction is also important for 
improving NS4A’s ability to rearrange the ER. The dimerisation with NS4A isn’t the only role NS4B 
plays within the replication complex with the 30 aa cytoplasmic loop of NS4B known to bind 
subdomains 2+3 of the NS3 helicase to increase the dissociation of the helicase with ssRNA and 
so improve replication efficiency (156). A single point mutation at aa 52 within a non-lethal strain of 
DENV increased lethality to 80% within mice (157) through changes in replication efficiency only. 
The reverse was also shown with a naturally lethal strain within mice showing how integral NS4B is 
to DENV replication.  
When expressed alone, NS4B inhibits protein synthesis, reduces ER vesicle production, and – 
in DENV – stimulates the UPR. This reduces the production and release of IFN upon infection as 
well as providing more ER membrane for use in replication. NS4B’s role in impeding the IFN 
pathways extends further though. For example, DENV NS4B inhibits the phosphorylation of STAT1 
and while it hasn’t been shown for other flaviviruses, both YFV and WNV NS4B proteins co-
localise with STAT1 indicating they may also have a role in STAT1 signal transduction. Both DENV 
and WNV NS4B also inhibit RIG-I/mitochondrial antiviral-signalling protein (MAVS) signalling by 
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blocking TBK1/IRF3 phosphorylation and so prevent the induction of IFN. YFV NS4B also blocks 
RIG-I/IFN signalling but instead binds and sequesters STING (158). 
 
1.6.10: NS5 
NS5 is the largest flaviviral protein at ~899 aa (~103 kDa) and has been well conserved across 
Flavivirus species. It consists of two main enzymatic domains; an N-terminal methytransferase 
(MTase) domain and a C-terminal RNA-dependent RNA-polymerase (RdRp) domain. The two 
domains are critical for capping and replication of the flaviviral genome respectively. NS5 localises 
differently for different flaviviruses and occasionally for different serotypes within those species. 
DENV NS5 is well characterized to localise both in the nucleus and the cytoplasm but DENV-1 and 
DENV-4 have a predominantly cytoplasmic localisation whereas DENV-2 and DENV-3 have a 
much more prominent nuclear localisation (159). There are multiple sites found to be responsible 
for this variation in localisation between the serotypes; the βNLS, αβNLS, and a C-terminal 18aa 
region (160, 161). YFV , WNV, and JEV all have NS5 proteins that predominantly localise to the 
cytoplasm but a significant minority is also found within the nucleus (162). The localisation of NS5 
within DENV serotypes shows that replication and IFN inhibition is not significantly altered when 
the localisation of the NS5 protein is changed (160). Therefore the role of NS5 within the nucleus 
must pertain to another function. 
As the viral RdRp, NS5 is responsible for the production of genomes and anti-genomes from 
viral RNA. Recruitment of the NS5 protein to the 5 end of the viral RNA is dictated by structural 
elements within the RNA that also control the cyclization of the genome for antigenome production 
(74). NS3 and NS5 make up the core of the replication complex with NS5 shown to be essential for 
NS3 NTPase activity (163). Although the polymerase has retained a high level of conservation 
across the flaviviruses there are differences between them. ZIKV heavily favours Mg2+ as a 
cofactor, requiring 5 times as much Mn2+ as DENV to function comparably (164). 
N7-methylation is key in the processing and protection of the viral genome as one of the final 
steps in RNA capping. Methylating the guanine cap at the N7 position, and then subsequent 2’-O-
methylation of the base attached to the m7Gppp cap, gives rise to the classical cap-1 structure 
which is essential for the translation of the viral genome (165). The MTase activity of NS5 covers 
both N7-methylation and 2’-O-methylation with both using S-adenyl-L-methionine (SAM) as their 
methyl donor. 2’-O-methylation protects the virus from detection by the immune system by 
mimicking cellular mRNA and loss of this kind of protection, although not lethal, is highly 
attenuating to the virus (166). m6A-methylation is also important in the lifecycle of some flaviviruses 
but this is only performed by host MTases (167). 
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Like the other non-structural proteins of flaviviruses, NS5 interacts with host proteins as well as 
with viral proteins/RNA. All NS5 proteins intervene in the IFN pathway by preventing transduction 
of the IFN-receptor signalling at various stages. DENV is well documented to degrade human 
STAT2 using the E3 ubiquitin-ligase UBR4 to target STAT2 to the proteasome (168). The inhibition 
of type-1 and type-3 IFN responses seen in ZIKV infection is indicative of a loss in STAT2 function 
(89). ZIKV binds STAT2 before phosphorylation and, like DENV, leads to proteasomal degradation 
but in a UBR4-independent manner (88). The expression of ZIKV NS5 (ZNS5) also leads to a 
~70% reduction in interferon induced protein with tetratricopeptide repeats 1 (IFIT1) expression. 
These responses are specific to human hosts as wild-type (WT) mice are resistant to ZIKV 
infection and have to be IFN-deficient for mouse studies to take place. WNV NS5 inhibits the 
surface expression of IFNAR1, YFV NS5 binds phosphorylated STAT2 to stop it binding to 
interferon-stimulated response element (ISRE) promoters, LGTV NS5 interrupts interferon alpha 
and beta receptor subunit 1/2 (IFNAR1/2) signal transduction, and JEV NS5 blocks STAT1/Tyk2 
phosphorylation (169). 
Outside of IFN inhibition, NS5 still has important host interactions. In a Y2H study involving 
flavivirus NS5, common gene ontology (GO) groups that were enriched included RNA binding, 
cytoskeleton proteins, and intracellular transport with numerous examples published in the same 
study (143). A DENV-specific interaction study saw an enrichment of UPR proteins interacting with 
NS5 (170) as well as another study showing that DENV NS5 interacts with U5 snRNP spliceosome 
proteins to alter splicing patterns (171). It even utilises host factors to assist in replication with host 
cyclophilin A (CyPA) being shown to localise with NS5 and the replication complex and its 
enzymatic activity shown to be important in the replication of WNV, YFV, and DENV (172). 
 
1.6.11: Similarities between ZIKV and DENV NS5 
Outside of the basic roles of NS5 as an RdRp and MTase and despite some minor differences 
as discussed in 1.6.10, the ZIKV and DENV NS5 proteins have been shown to possess decent 
functional and structural similarities in a few studies which directly compared them. The structural 
similarities of the two NS5 proteins was compared by Baez et al (173) to examine whether, from a 
structural point of view, known inhibitors of DENV NS5 would be likely to have efficacy on ZIKV 
NS5. These comparisons showed a fairly high similarity in shape and structure within inhibitor 
binding pockets as well as conservation of numerous important residues within those sites. The 
similarity between the MTase region of ZIKV and DENV NS5 is ~65-70% at aa level and combined 
with the prediction of similarity presented in the previous study, it has formed the basis of 
developing ZIKV MTase inhibitors based from the knowledge of DENV-developed inhibitors (174). 
It has also led to the re-examination of DENV NS5 inhibitors for their efficacy on ZIKV which 
provided new leads that were more effective in ZIKV than they had been in DENV (175). Potisopon 
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et al (164) compared the specificity of the RdRp domains of DENV and ZIKV for different modified 
chain terminators for effective drug discovery. Both polymerases incorporated 2’-C-Me-CMP chain 
terminators more readily than any other tested modification. The similarities in their interference 
with the IFN pathway was discussed in 1.6.10. 
 
1.7: Flavivirus treatment and control methods 
1.7.1: Drugs 
As with many diseases, the symptoms caused by a single flaviviral infection can vary from 
asymptomatic/relatively mild up to severe symptoms that require hospitalisation. As discussed 
earlier, DENV infection can range from an entirely asymptomatic infection to a severe 
haemorrhagic fever with hypovolemic shock. ZIKV can range from asymptomatic infection in the 
majority of cases to neurological and autoimmune manifestations. Therefore each patient is treated 
on a case-by-case basis. This is also because there are no specific drugs currently available for 
flaviviral infections and so treatment of the disease is more a management of the symptoms rather 
than targeting of the infection itself. In the case of hospitalisation with DENV infection, extensive 
monitoring is required with fluid replacement with crystalloids or colloids, and potentially serum 
transfusions if thrombocytopenia occurs (176). The treatments of JEV, YFV, and WNV also involve 
purely supportive therapies upon hospitalisation. Even ribavirin, the classic wide-spectrum antiviral 
drug, has been shown to have little effect on flavivirus infections both in vitro and in vivo and so is 
not given to patients (177). 
There is, therefore, a high demand for flaviviral drugs and a number of potential specific 
inhibitors have begun to emerge. Non-structural proteins are highly favoured drug targets due to 
their wide range of activities intracellularly, with emphasis focussed towards those involved in RNA 
replication, viral capping, and the inhibition of the IFN response, due to their essential nature in the 
flavivirus lifecycle and previous successes with targeting these processes in other viruses. NS5 
and NS3 are particularly favourable targets as core components of the replication complex and so 
now there are a number of MTase inhibitors (175), polymerase inhibitors (164), chain terminators, 
and helicase inhibitors in testing (178). Repurposing existing drugs such as Geneticin (179) and 
Sofosbuvir (180) to treat flaviviral infection is also a possibility. CZS particularly needs specific 
inhibitors due to the need to treat the infection within a growing foetus. Ribavirin is known to be 
embryotoxic and teratogenic (181), azauradine is highly toxic to foetuses within model systems 
(182), and IFN treatments have been flagged as potentially abortifacient (183), meaning that wide-
spectrum antivirals cannot be used. The need to prove that the drug has no effects on the foetus’ 





With antivirals often being only effective within the first few days of infection, vaccines remain 
the best route for defence against viruses. There are human vaccines currently available for YFV, 
JEV, TBEV, and DENV as well as an equine vaccine for WNV (184). The YFV-17D vaccine is the 
most well-known flavivirus vaccine and was made through serial passage in chicken embryo cells 
in vitro until the virus was attenuated enough to no longer cause human disease. YF-17D produces 
a very good long-term protective response and has been in use for well over half a century with a 
very impressive safety record. The YF-17D virus itself is so safe and effective that it formed the 
basis for the chimeric tetravalent Dengvaxia vaccine virus which came into use in 2015. The threat 
of ADE has always hindered the development of a DENV vaccine as there needs to be a protective 
response raised to all four serotypes. The Dengvaxia vaccine, although generating only a mild 
protective response to DENV-2, was initially deemed to give a good enough response to provide 
meaningful protection to all four serotypes (12, 13). However, as mentioned in 1.2, since being 
introduced the vaccine has shown worrying signs of increasing the likelihood of severe disease via 
ADE in countries with low-endemicity as well as giving poor responses in children (14, 15) and has 
been halted in some countries now over safety concerns. Multiple active vaccines for JEV and 
TBEV are in clinical use and all require multiple challenges to generate a high seroconversion rate. 
They are however both effective despite the relatively short lifespan of TBEV protective immunity. 
WNV vaccines are possible, as shown by the introduction of the equine WNV vaccine, however 
there is currently no demand from governments to fund and distribute a WNV vaccine as the total 
numbers of infection and disease severity is considered to be too low. 
There are numerous contenders in development as well, including a promising replacement to 
the Dengvaxia vaccine which produces responses far close to natural infections as well as a 
stronger DENV-2 response (185). ZIKV has also been very heavily targeted for vaccine production 
with the recent outbreak (100, 104) revealing the morbidity of CZS and the lack of antiviral drugs 
available for use in pregnant women so that now many candidates are progressing through early 
stage trials (186). Despite the lack of government interest in a human WNV vaccine, a number of 
vaccine candidates have progressed through phase I and phase II trials as WNV cases are 
increasing and the vector’s population has increased in both population and spread in recent 
years. 
 
1.7.3: Vector control 
Flaviviruses are spread via vectors, infected blood, and, in the case of ZIKV, sexual contact. 
The sexual route of ZIKV infection has already been determined to contribute very little to the R0 
value (187) and, although ZIKV did infect the blood supply once during the recent pandemic (31), 
44 
 
there are now layers of protection to stop infected blood from flaviviruses from ever reaching a 
patient. Therefore the main transmission method for all flaviviruses, and the only one capable of 
supporting the virus, is vector-borne transmission. 
During the 1940’s, attempts were made to control mosquito populations in Latin America by 
using newly developed long-lasting chemical insecticides in focus areas. Whilst this was initially 
effective, mosquito populations quickly developed resistance to the insecticides and their 
populations recovered. Insecticides are therefore not a viable option for large scale vector control 
in modern society due to resistance within mosquito populations, environmental concerns around 
heavy insecticide use, and the increasing incidence of urban transmission where insecticide use 
would be heavily restricted (17). 
The most promising strategy currently for Aedes aegypti control is the introduction of the 
intracellular symbiont Wolbachia pipientis which reduces the lifespan of female mosquitoes by 
~50%. As the migration of DENV and ZIKV infection from the midgut of the mosquito to the salivary 
glands takes ~12 days, the reduction in life expectancy reduces the number of females reaching 
an age where they can transmit the infection without affecting the mosquito population by killing 
them before breeding age (188). There is also evidence to show that the presence of Wolbachia 
inhibits the infection of the mosquito and also the transmission of DENV from the salivary glands 
as well (189). The symbiont is passed maternally and can get into the population if the initial 
number of introduced infected mosquitoes is high enough by utilising cytoplasmic incompatibility to 
overcome the fitness cost reduction of being uninfected. This theory was tested and Wolbachia-
infected Aedes aegypti were successfully introduced into the local population within two small 
areas in Australia (190). Wolbachia is a symbiont found in roughly 60% of insect populations and 
so its use in other species has been questioned, however some research suggests that natural 
strains of Wolbachia are less aggressive than the wMel Wolbachia used for these experiments. 
Education is also an important factor, especially within urbanised areas where urban-adapted 
mosquitoes like Aedes aegypti breed and thrive. Public education campaigns have been produced 
to raise awareness of common containers/locations that gather stagnant water and act as a 
breeding site for these mosquitoes to encourage the public to remove them. Other vector-related 
theories involve focussing vaccinations on animal hosts to reduce the number of sylvatic-to-
anthroponotic infections seen as well as vaccinating those who live/work nearest these animal 
hosts to also reduce that chance (191). 
 
1.7.4: Host factor targets 
Drugs targeting viral proteins give a specific response to a particular infection, however they 
are expensive to bring to market, rarely work on more than one virus, and there are strong 
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selective pressures that encourage the development of resistance. Targeting host proteins 
massively reduces the chance of pathogens developing resistance and targeting host 
proteins/pathways used by multiple pathogens allows for one drug to inhibit multiple infections. For 
drugs against host factors to be of interest, the host target must be essential to the virus lifecycle 
and inhibition of the protein/pathway must not have severe detrimental effects on the patient. 
Preferably the proteins/pathways to be targeted already are known to be inhibited by modulatory 
drugs on the market, so the drugs will already be approved as safe for human use and licenced. 
The concept of host factor drugs has already been proven clinically in HIV patients using CCR5 
antagonists (192). 
Host factors are key to almost every step of the virus lifecycle and many of these are currently 
being examined in flaviviruses. DENV cell entry has been shown to be inhibited in vitro when 
exposed to a high level of GAGs, GAG mimics, heparin, or heavily sulphated heparin (193). 
Flavivirus replication has been shown to be inhibited by; stopping the enzymatic activity of CyPA 
(172), preventing the binding of elongation factor-1α (EF-1α), polypyrimidine tract-binding protein 
(PTB), or TIA1 cytotoxic granule associated RNA binding protein/-like 1 (TIA1/TIAR) to flavivirus 
genomes (178), and through the use of mycophenolic acid to inhibit inosine-5’-monophosphate. 
Nuclear import inhibition by way of inhibiting importin-α/β, has been shown to inhibit DENV 
infection (194). Autophagy and the proteasome are important in DENV survival and so inhibitors of 
these have been shown to severely limit DENV infection in vitro, however WNV can be degraded 
by autophagy and so autophagy inducers limit WNV infection in vitro (195). 
Host factor targets can also be used to limit specific symptoms from flavivirus infection such as 
with an in vitro experiment showing that the inhibition of metalloproteinases (MMPs) reduces the 
damage to cell-cell junctions usually seen at the blood brain barrier of patients with neuroinvasive 
WNV (196). Antagonists to the platelet-activating factor receptor (PAFR) showed in DENV mouse 
models to reduce thrombocytopenia, vascular permeability, and mortality (197). 
 
1.8: Methods for investigating host-virus protein-protein interactions 
The detection of novel protein-protein interactions is an important investigative tool in virus-host 
studies and there are numerous current methods to do so. All have different pros and cons but 
none so far are considered proof of interaction and all require further experimentation to prove any 
potential interactions. Yeast 2 hybrid (Y2H) and yeast 3 hybrid (Y3H) experiments were the original 
protein-protein interaction techniques which utilise a transactivation protein that has been split and 
attached to the bait and prey protein so that interaction of the two proteins allows the reformation of 
the transactivation protein and then transcription of the reporter gene. These techniques, however, 
are notorious for false positives and require an extensive cDNA library. As the read-out is reporter 
gene expression and therefore relies on both proteins being localised to the nucleus, false 
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positives arise from biologically irrelevant interactions between proteins that do not co-localise 
naturally and also through protein modifications made to localise the protein to the nucleus but that 
alter the protein’s behaviour (198). The split-ubiquitin assay and split-ubiquitin bridge assay was 
then developed to overcome this problem of forced nuclear localisation, using two fragments of 
ubiquitin and haemagglutinin (HA) degradation in place of gene transcription. Fluorescence 
resonance energy transfer (FRET) also uses modified bait and prey proteins to show protein 
interactions with the donor protein being capable of stimulating the acceptor protein into emitting a 
particular frequency wavelength if they are within close proximity. This does however require a 
detailed understanding of the absorbance and emission profiles of both the acceptor and donor 
and, as with all of these reporter-based bait-prey techniques, it only measures proximity and not 
direct interaction and so false positives can occur. 
Large scale detection techniques that allow for the detection of more than just single protein 
interactions in each assay are becoming more prevalent. Far western blotting uses a western blot 
procedure but involves re-naturing the proteins after they have been transferred to a membrane 
and then incubating the membrane with a bait protein to allow for any complexes between bait and 
prey to form (199). The bait protein is then probed for during the rest of the western blot procedure 
to reveal where the bait protein has bound. Mass spectrometry (MS) has become an invaluable 
tool for protein identification which has allowed for the development of high-throughput techniques 
though these techniques rely on the correct matching of the peptide fragments to their proteins of 
origin as well as a comprehensive list of ‘possible’ proteins in the sample provided by the user for 
the proteomic programme to compare the spectra to. There are also multiple techniques available 
for generating the pool of proteins to be used in MS such as co-immunoprecipitation (Co-IP) which 
uses antibodies against the bait protein bound to beads or within a column which are then used to 
remove the bait protein from a sample along with any interacting proteins bound to it. The washing 
steps can remove weak binding partners leading to incomplete interactor lists and at the same time 
fail to remove strong interactors of the prey proteins themselves or strong non-specific interactors 
to either protein leading to false positives. Biotin-label identification (BioID) with an APEX (200) or 
BirA (201) tag allows for permanent labelling of close proximity proteins with molecules of biotin 
and, as the streptavidin/biotin binding affinity is incredibly high, far stronger detergents can be used 
compared with standard Co-IP to remove most nonspecific binding to reduce the false positive rate 
dramatically. As the proteins are labelled permanently, even transient/weak interactors are labelled 
when they come into proximity with the BirA/APEX tag and will therefore be present in the pulldown 
sample. Finally, there are in silico methods of prediction, which utilise computer modelling 
techniques to determine likely interactors based on information such as; protein localisation, 
physicochemical properties, sequence data, structural data, and co-expression data. However 
these predictions can only be made on proteins that are included in the database used and are 
well characterised (202). 
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All except for the in silico method requires the experimental expression of the viral protein. 
Using WT virus for individual protein analysis is not always ideal or possible for some methods and 
so alternative expression systems of viral proteins are used instead. These expression systems, 
often of a single viral protein, require some considerations however. Using non-native species for 
expression can affect post- and co-translational modifications which can affect protein localisation 
and function. Codon optimisation may be necessary in these cases to account for particular tRNA 
expression levels but codon sequences can affect co-translational folding as well as translocation 
of membrane proteins (203). High expression promoters are often used in expression systems 
however overexpressed proteins will have high levels of nonspecific binding. Some proteins also 
require host chaperones, the presence of other viral proteins to fold properly, or even specific 
cleavage to become active. Care must also be taken with the inclusion of tags which can interfere 
with active regions and affect localisation signals. 
 
1.9: Project aims 
The overall aim of this project was to generate a list of human proteins interacting with ZIKV 
NS5 (ZNS5) and compare them to proteins interacting with the DENV-2 and -4 NS5 proteins to 
identify common proteins and cellular pathways interacting with flavivirus NS5 proteins.  
The specific aims were to: 
1) use ZNS5-FLAG and DENV NS5-FLAG expressing cell lines; both already available, for 
comparative pull-down and tandem mass tagging/mass spectrometry (TMT-MS) analyses.  
2) produce a ZNS5-BirA expressing cell line and devise and implement a method for whole 
cell streptavidin-bead pulldowns such that the recovered proteins can be analysed by TMT-
MS. 
3) undertake a comparative analyses of the proteomic datasets produced in Aims 1 and 2 
using commercially available proteomic programmes, and online bioinformatic resources, to 
identify proteins commonly and distinctly interacting with ZNS5 and DENV NS5 as well as 
those proteins interacting with ZNS5-FLAG and ZNS5-BirA. Over the course of this 
investigation, proteomic datasets generated using different bioinformatic analyses software 
(Proteome Discoverer (PD) and MaxQuant) will also be compared to identify the differences 
in MS proteomic programmes and highlight the inconsistencies and flaws within the current 




2: Methods and materials 
2.1: Cell culturing 
 2.1.1: Cell culture conditions 
Cells were incubated at 37⁰C and 5% CO2 in sterile T25/75/175/225 flasks that contained a 
growth media (GM) which consisted of: Dulbecco’s Modified Eagle’s Medium (DMEM) + Glutamax 
(Lonza, Basel, Switzerland), 10% foetal bovine serum (FBS) (Life Technologies, Paisley, UK), and 
0.1mM non-essential amino acids (Life Technologies). Cells were washed with phosphate-buffered 
saline (PBS) (Lonza) and then detached using 10% trypsin when they reached high confluency 
before being passaged to a new flask. Stably transfected cell lines also received 150µg/ml 
hygromycin/3.5µg/ml puromycin and 15µg/ml blasticidin (Sigma Aldrich, Gillingham, UK) added 
once every two passages and every four passages respectively for selection purposes. All work 
with live cells took place in a sterile laminar flow hood. 
2.1.2: Cell lines 
Table 1: Cell line details: 
Cell line name Cell line description Production credit 
293-Flp HEK 293 Flp-In™T-REx™ 
cells 
-Life Technologies 
D2NS5-FLAG HEK 293 Flp-In™T-REx™ 
cells expressing DENV2 
NS5-FLAG 
-Life Technologies 
-Dr Holga Hannemann (Dr 
Andrew Davidson’s lab) 
D4NS5-FLAG HEK 293 Flp-In™T-REx™ 
cells expressing DENV4 
NS5-FLAG 
-Life Technologies 
- Dr Holga Hannemann (Dr 
Andrew Davidson’s lab) 
ZNS5-FLAG HEK 293 Flp-In™T-REx™ 
cells expressing ZIKV NS5-
FLAG 
-Life Technologies 
-Mr Josh Lee (Dr Andrew 
Davidson’s lab) 
ZNS5-BirA HEK 293 Flp-In™T-REx™ 
cells expressing ZIKV NS5-
BirA*-containing HEK 293 
Flp-In™ 
-Life Technologies 
-Mr Jack Hales/Dr Lisa 






2.2: DNA/RNA techniques 
2.2.1: DNA gel electrophoresis 
1% agarose gels (w/v) (0.5μg/ml ethidium bromide) were made by dissolving 1g agarose 
powder (Promega, Wisconsin, USA) in 100ml 1xTBE buffer (Appendix A) under heat and then 
mixing in 50μg ethidium bromide (Invitrogen, California, USA) by gentle swirling. It was then 
poured into a gel mould and left to set. Once set, the gel was placed in a Sub Cell GT Cell 
horizontal electrophoresis tank (Bio-Rad, California, USA) and submerged in 1xTBE buffer 
(0.00005% 10mg/ml ethidium bromide (v/v)). DNA samples were mixed with 6xDNA loading dye 
(Thermo Fisher Scientific, Massachusetts, USA) at a 5:1 ratio and were then loaded into individual 
wells alongside GeneRuler 1kb Plus DNA ladder (Thermo Fisher Scientific) before being run at 
100V for ~30-60min. The final gel was then imaged using a UVP Biodoc-IT™ System Ultraviolet 
Transilluminator UV spectrometer (UVP, California, USA). 
2.2.2: DNA concentration determination 
The DNA concentration of samples was determined using a NanoDrop™ spectrophotometer 
(Thermo Fisher Scientific). Small aliquots of the samples were then run on an electrophoresis gel 
alongside 5μl GeneRuler 1kb Plus DNA ladder (Thermo Fisher Scientific) so that the purity of the 
sample could be assessed and an estimation of the DNA concentration of the desired band could 
be determined. It was then compared back to the NanoDrop™ results. 
2.2.3: Primer design and synthesis 
pcZNS5-BirA was sequenced using five forward oligonucleotide primers post-midi-prep to 
ensure that the cloning procedure had not led to mutation of the ZNS5-BirA sequence. Primers 
were designed every ~700 nucleotides to cover the entire sequence using the same gene 
sequence used to design the codon-optimised ZNS5 and BirA genes synthesised by Invitrogen. 
The primers were synthesised by Eurofins Genomics (Luxembourg City, Luxembourg). 
2.2.4: Primer sequences 
Table 2: Primer details: 
Primer name Primer sequence (5-3 direction) Target gene/gene 
fragment 
Forward/Reverse 
prStart CGACTCACTATAGGGCGAATTCGG ZNS5 Forward 
pr582 GATGGAAACCCTGGAACGGC ZNS5 Forward 
pr1260 GAAAGAGTGGAAAACCGCCG ZNS5 Forward 
prMid CAAGTACACCTACCAGAACAAGG ZNS5 Forward 
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pr1980 GAAGAGAATGGCCGTGTCCG ZNS5 Forward 
pr2647 GAGAAGTACATGGACTACC ZNS5 Forward 
prB621 CATGGCCATGAGAAGAGTGG BirA* Forward 
prEnd GTCACTTCTCTGCGCTTCTCAGGG ZNS5 Reverse 
prMidRev GCTGCACCACCAGGTTGGTGAAGG ZNS5 Reverse 
 
2.2.5: DNA sequencing 
DNA sequencing was done externally by Eurofins Sequencing. 15μl 10ng/μl sample DNA was 
sent off accompanied by 15μl 10pmol/μl primer DNA per primer per reaction. The results of the 
sequencing were BLAST searched against the original sequences which showed no mutations. 
The sequence of the primers are provided above in table 2 in 2.2.4 and the placement of all 
primers within the gene as well as the sequencing results are provided in appendix B. 
2.2.6: RT-PCR 
RNA used in the RT-PCR procedure was isolated from samples (see 2.3.1) using the SV Total 
RNA Isolation kit (Promega) following the protocol provided. The primers were designed as 
described in 2.2.3 and are shown in table 2 in 2.2.4.A one-step, two fragment RT-PCR was 
performed using the One Taq® RT-PCR kit (New England Biolabs, Massachusetts, USA) 
according to their protocol by creating a mastermix consisting of: ~1μg RNA, 2μl 25xOneTaq 
Enzyme Mix, 25μl 2xOneTaq Reaction Mix, 2μl 10μM forward primer, 2μl 10μM reverse primer and 
made up to 50μl with ddH2O. A GS1 thermocycler (G-Storm, Somerset, UK) was then used to 
perform the run cycle shown in Figure 10. After DNA electrophoresis confirmed that the two step 
RT-PCR was successful, the samples were purified using the reagents and protocol from the 




2.2.7: Transfection of 293-Flp cells (transient) 
The pGK-Helper plasmid (ThermoFisher Scientific), and pcZNS5-BirA were mixed at the ratios 
of 9:1 and 11.5:1 (μg/μg) and then added to an appropriate amount of TurboFect (ThermoFisher 
Scientific, following the standard recommended transfection procedure) and vortexed before being 
added dropwise onto a culture of ~70-80% confluent 293-Flp cells in a 24-well plate. After 
overnight incubation, doxycycline was then added to the media to a final concentration of 1µg/µl 
and the cells incubated for 4d for adequate expression of ZNS5-BirA. 
2.2.8: Transfection of 293-Flp cells (stable)  
The transfection was as described in 2.2.7 but after overnight incubation with the plasmids and 
Turbofect. The 293-Flp cells were then detached and plated into 10cm dishes. After overnight 
incubation, hygromycin was added to the media to a final concentration of 150ug/ml and 
hygromycin resistant cell colonies selected for over the course of 3-4 weeks. Hygromycin resistant 
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cell colonies were then removed from the 10cm dish and grown up sequentially in a 24-well plate, 
T25 flask, and then T75 flask for culturing and confirmatory tests. 
2.2.10: Bacterial transformation 
50μl α-Select Silver Efficiency E.coli (Bioline, Toronto, Canada) were incubated on ice for 
30min with 1-10ng of plasmid DNA. The bacteria were then heat shocked at 42⁰C for 30-45sec and 
then immediately placed on ice for 2min. 1ml of warm Luria broth (LB) (Appendix A) was added 
before being incubated for 1h at 37⁰C with shaking at 225rpm. The bacteria were then plated onto 
warmed LB agar (Appendix A) containing 50μg/ml zeocin (w/v) (Thermo Fisher Scientific) and then 
incubated overnight at 37⁰C. Resulting colonies were then picked and grown in LB. 
2.2.11: Growth/selection of bacteria 
Transformed E.coli were plated on LB agar (Appendix A) under the selection pressure of 
50μg/ml zeocin (w/v) (Thermo Fisher Scientific) and incubated overnight at 37⁰C. A colony was 
then picked and grown in LB (Appendix A) with 50μg/ml zeocin (w/v) (Thermo Fisher Scientific) at 
37⁰C with shaking at 225rpm. 
2.2.12: Restriction enzyme (RE) digest 
RE digests were performed using HindIII and BamHI kits (New England Biolabs) according to 
the protocols provided. 1μg of sample DNA was mixed with 1μl HindIII (~10 units), 1μl BamHI (~10 
units), and 5μl 10x NEbuffer 2.1 (New England Biolabs) and made up to 50μl with ddH2O. The 
sample was then incubated for 1h at 37⁰C. The REs were removed using a GeneJET PCR 
purification kit (Fermentas). 
2.2.13: Ligation 
The ligation was done in accordance with the T4 DNA Ligase protocol provided with the T4 
DNA Ligase kit (New England Biolabs). A reaction mix consisting of: 25μg of vector DNA, 75μg of 
insert DNA, 2μl 10xT4 DNA Ligase buffer (New England Biolabs), and 1μl T4 DNA Ligase was 
made with ddH2O to make the reaction volume to 20μl. The reaction mix was incubated at room 
temperature for 10min and then heat inactivated at 65⁰C for a further 10min. 
2.3: Protein techniques 
2.3.1: Cell lysis 
The cells were detached using 10% trypsin (in PBS), centrifuged at 150 x g for 5min at room 
temperature, washed with PBS, and then centrifuged at 150 x g for 5min a second time. The PBS 
was removed and 0.5ml of 2x sample buffer (Appendix A) was added to each pellet and mixed 
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using a pipette. A 21 gauge needle and a 1ml syringe were then used to passage the cell lysate 5 
times up and down. The resulting sample was heated at 95⁰C for 5min and then stored at -20⁰C. 
2.3.2: BCA assay 
The BCA assays were done using the Pierce Microplate BCA Protein Assay Kit (Reducing 
Agent Compatible) (ThermoFisher Scientific) according to the protocol provided in the kit and using 
the cell lysate attained using the method described in 2.3.1. 
2.3.3: Immunofluorescence assay (IFA) 
Sterile glass coverslips were placed in 24 well plates, washed with PBS (Lonza), incubated 
with poly-D-Lysine (0.1mg/ml in PBS) for 5min, and then washed twice with PBS. Cells were grown 
in GM + doxycycline (1μg/ml) for 3d before being seeded at roughly 5x104 cells per well. These 
were incubated in GM + doxycycline (1μg/ml) overnight before fixation in either ice cold methanol 
for 5min, or 4% paraformaldehyde for 5min followed by permeabilization with 1% (w/v) Triton-X 
100 for 5min. The fixed cells were blocked in 1% (v/v) FBS (in PBS) on a plate rocker for 1h at 
room temperature. The blocking solution was removed and the coverslips coated in 100μl of 
primary antibody solution at the recommended IFA concentration (in 1% FBS (in PBS), (antibody 
information in 2.10) for 1h at room temperature. The primary antibody was removed and the 
coverslips  were washed 4 times in PBS for 5min per wash before 100μl of secondary antibody 
solution was added at the recommended concentration (in 1% FBS (in PBS)). After removal of the 
secondary antibody the coverslips were washed 4 times in PBS for 5min per wash and then 
mounted onto glass slides using VectaShield® mounting media (Vector laboratories, California, 
USA) and nail varnish to seal the glass coverslips. Slides were then imaged under a DM IRB 
inverted epifluorescence microscope (Leica, Wetzlar, Germany) at 60x or 100x magnification using 
the Leica Application Suite Advanced Fluorescence programme to capture and analyse the 
images. 
2.3.4: Coomassie blue staining 
Samples were prepared by adding appropriate quantities of cell lysate (as determined by BCA 
assay) to 5% β-mercaptoethanol (B-MERC) (made up in 2x sample buffer containing bromophenol 
blue). The samples were then heated at 95⁰C for 5min before being loaded into a reducing and 
denaturing 10% SDS-Page gel with 5% stacking gel and run at 100V for ~1h. The gel was then 
transferred to a container containing Coomassie Brilliant Blue dye (ThermoFisher Scientific) 
(Appendix A) and placed on a plate rocker for 1h. It was then placed in Coomassie destain solution 




2.3.5: HRP-conjugated western blot 
The samples were set up and run as in 2.3.4 but instead of being placed in Coomassie brilliant 
blue (ThermoFisher Scientific) after running, the gel was placed in 1x transfer buffer (Appendix A) 
for 5min and then transferred to an Amersham™ Hybond™ P0.45 PVDF nitrocellulose blotting 
membrane (GE Healthcare, Buckinghamshire, UK) using a Trans-Blot® Semi-Dry Transfer Cell 
(Biorad, California, USA) at 15V for 1h between two pieces of blotting paper that had been 
dampened in 1x transfer buffer. This type of transfer was done when examining proteins that 
ranged ~25-150kDa in size. Those larger than 150kDa were transferred using a wet transfer blot 
technique as described in 2.3.7. Before transfer, the nitrocellulose membrane was washed in 100% 
methanol for 1min, distilled water (ddH2O) for 2min, and 1x transfer buffer for 5min. After transfer 
the membrane was placed in a 50ml Falcon tube containing 5ml of blocking solution (Appendix A) 
and rotated on a tube roller for 1h at room temperature. The membrane was then cut to detect 
proteins with different molecular weights as needed. Then each filter fragment was placed in a 
50ml falcon tube containing an appropriate concentration of primary antibody diluted in 3 ml of 
blocking solution and placed on a tube roller for 1h at room temperature. The membranes were 
washed in PBS containing 0.1% (v/v) Tween, 4 times for 5min each wash before being placed in 
50ml falcon tubes containing an appropriate concentration of HRP-conjugated secondary antibody 
diluted in 3 ml of blocking solution and placed on a tube roller for 1h at room temperature. The 
membranes were washed again in PBS containing 0.1% (v/v) Tween, 4 times for 5min each wash 
before being coated in ECL reagent (Insight Biotechnology, Wembley, UK) for 1min. The excess 
fluid was removed and the membranes were placed inside a developing cassette and exposed to 
Hyperfilm ECL (Amersham, GE Healthcare) once in a dark room. The films were then developed in 
a Konica SRx-101A film processor. 
2.3.6: Fluorescent western blot 
The fluorescent Western Blot was run in the same way as described in 2.3.5 except the 
Amersham™ Hybond™ P 0.45 PVDF nitrocellulose blotting membrane (GE Healthcare) was 
replaced with an Immobilon®-Fl Transfer Membrane (Li-Cor, Nebraska, USA). The secondary 
antibodies are attached to fluorescent molecules instead of being conjugated to HRP, causing 
them to fluoresce under particular wavelengths of light depending on the antibodies used. They 
should also be made up in blocking solution (Appendix A) containing 0.01% SDS. Alternatively, a 
fluorescently-labelled binding partner can be used in place of an antibody such as the Streptavidin 
Alexa Fluor™ 488 (Thermo Fisher Scientific) which is the binding partner for biotin. 
2.3.7: Wet transfer 
The protocol used for wet transfer allowed for the transfer of proteins up to ~500kDa within 1h. 
The samples were incubated at 95⁰C for 10min with 2x sample buffer (5% β-mercaptoethanol) and 
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then run on NuPAGE™ 3-8% Tris-Acetate gels (Thermo Fisher Scientific) with a high molecular 
weight marker; HiMark™ prestained protein standards (Thermo Fisher Scientific). The gel was run 
in a Mini Gel Tank (Thermo Fisher Scientific) in 400ml 1x NuPAGE™ Tris-Acetate SDS Running 
Buffer at 150V for 1h. The Amersham™ Hybond™ P0.45 PVDF nitrocellulose blotting membrane 
was equilibrated by soaking it in 100% methanol for 1min, ddH2O for 2min, and 1x NuPAGE™ 
Transfer Buffer (Thermo Fisher Scientific) for 5min. The gel was soaked in 1x NuPAGE™ Transfer 
Buffer (Thermo Fisher Scientific) for 15min which was made up from 20x NuPAGE™ Transfer 
Buffer (Thermo Fisher Scientific), ddH2O, and 10% methanol/ 20% methanol for one gel being 
transferred or two respectively. The transfer ‘sandwich’ was then made up according to Figure 14 
and placed in the Mini Trans-Blot® Electrophoretic Transfer Cell (Biorad) with 1x NuPAGE™ 
Transfer Buffer (Thermo Fisher Scientific) (+ an appropriate concentration of methanol) filling the 
transfer tank. A small magnetic stirrer at the bottom of the tank and an ice pack in the transfer 
buffer is essential to keep the ion concentration even and the temperature of the transfer 
components low. The transfer settings are described in table 3. Once the transfer was complete, 
the Western blot procedure continued post-transfer as described in 2.3.5. 
 
Table 3: Wet transfer settings: 
Number of gels Transfer time Voltage (V) MilliAmperes (mA) 
1 1h 100 350 
1 Overnight (~16h) 30 90 
2 1 100 375-450 
2 Overnight (~16h) 30 100 
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2.3.8: FLAG-bead pulldown 
Cells were grown to around 70% confluency in T225’s and doxycycline added to the media to a 
final concentration of 1ug/ml for 4d before cell harvesting. The cells were detached by gentle 
scraping and then harvested by centrifugation at 300 x g for 5min at 4⁰C. The cells were then 
washed twice with PBS with centrifugation at 300 x g for 5min at 4⁰C each time. The cell pellets 
were then resuspended in 1ml ice cold lysis buffer (Appendix A) per T225 used and left on ice for 
30min with mixing by pipetting every 10min. The samples were then sonicated 4x (pulse 5 secs on, 
10 sec pause, Amp 50%) with a Q125 Sonicator (QSonica, Connecticut, USA), centrifuged at 
14,000 x g for 15min at 4⁰C, and then added to equilibrated Pierce Control Agarose Resin (Thermo 
Fisher Scientific) to be mixed on an end-over-end rotor for 1h at room temperature. The samples 
were then centrifuged at 3000 x g for 1min and the supernatant of each was added to FLAG 
magnetic beads that had been equilibrated by washing twice in 10x resin volume equilibration 
buffer (Appendix A) with 50μl of FLAG beads per ml of lysate used. The samples were then placed 
on an end-over-end rotor overnight at 4⁰C. Using a magnetic Eppendorf tube holder, the 
supernatant was removed and washed 3 times in 5x bead volume Wash Buffer (Appendix A) 
before resuspending the FLAG beads in 20μl of Wash Buffer and storing in -70⁰C until being sent 
for TMT labelling. The samples and all reagents were kept on ice throughout except where 
specified. 
2.3.9: Biotin labelling 
To induce biotin labelling, cells expressing BirA or BirA fusion proteins were incubated at 37⁰C 
and 5% CO2 with 2μg/ml biotin for 14-18h. 
2.3.10: Streptavidin pulldown 
The protocol for the streptavidin bead pulldown was adapted from protocols used in previous 
BioID pulldown studies to suit large scale whole cell lysates (204, 205). The steps are similar to the 
FLAG pulldown protocol in 2.7 but, due to the strength of the streptavidin-biotin binding, the 
washing buffers were much more stringent than those used in the FLAG pulldown (the recipes of 
which can be found in the appendix). The cell lysates were prepared in the same way as for the 
FLAG protocol except the cell lysates (derived from 3x 80% confluent T225’s) were incubated with 
rotation overnight at 4⁰C with 50μl Streptavidin Sepharose High Performance beads (GE 
Healthcare). After overnight incubation with the sample, the beads were washed for 10min with 
1.5ml of Wash Buffer 1, 2, 3, then 4 (Appendix A) with 1min of centrifugation at 1000 x g between 
each wash to collect the beads and allow for the removal of the previous wash buffer. The final 




2.3.11: Protein G-bead pulldown 
The cell lysates were prepared using the same protocol as described for both the FLAG and 
Streptavidin pulldowns. The lysates were then incubated with rotation overnight at 4⁰C with the 
selected antibody at the concentration specified by the antibody manufacturer. After the overnight 
incubation, the samples were incubated with rotation for 1h at room temperature with equilibrated 
Pierce™ Protein G Magnetic Beads (Thermo Fisher Scientific) at 50μl per ml of cell lysate. Using a 
magnetic Eppendorf tube holder, the supernatant was removed and the beads were washed 3 
times in 5x bead volume Wash Buffer (Appendix A) before resuspending the beads in 20μl of 
Wash Buffer and storing in -70⁰C 
2.3.12: Antibody and binding partner information 










FLAG epitope Sigma Aldrich F1804 Mouse IFA, WB IFA: 1:500-
2000 
WB: 1:1000 
GAPDH Sigma Aldrich G9545 Rabbit WB WB: 1:5000 
ERC1 Abcam ab50312 Mouse WB WB: 1:2000 
Biotin (Streptavidin 
Alexa Fluor™ 488) 
Thermo Fisher 
Scientific 
S11223 - WB WB: 1:5000 
ZNS5 GeneTex GTX133312 Rabbit IFA, WB IFA: 1:500  
WB: 1:100-
10,000 
BirA Aviva Systems 
Biology 
OARA01977 Rabbit IFA, WB IFA: 1:1000 
WB: 1:5000 
UBR5 Abcam ab4376 Goat WB, IP WB: 1:500 
IP: I:200 
Cdk1 Call Signalling 
Technology 


















































Li-Cor 926-68021 Goat WB WB: 1:10,000 
 
2.4: Proteomics and bioinformatic techniques 
2.4.1: TMT-labelling and LC-MS/MS 
100μg of each sample was digested with 2.5μg of trypsin overnight at 37⁰C and labelled with 
TMT reagents. The samples were pooled and evaporated until dry before being resuspended in 
buffer A (Appendix A) and then fractionated in an Ultimate 3000 liquid chromatography system with 
an XBridge BEH C18 column (Waters, Herts, UK). Proteins were eluted with an increasing gradient 
of buffer B (Appendix A) from 0-95% for 60min. These collected fractions were then evaporated 
until dry again and resuspended in 1% formic acid before being analysed in an Orbitrap Fusion 
Tribrid mass spectrometer (Thermo Fisher Scientific) using the Xcalibur 2.0 software (Thermo 
Fisher Scientific). The peptides were detected in an FT-IT MS/MS manner with MS1 being 
performed at a resolution of 120,000, a max injection time of 50ms, an automatic gain control of 
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200,000, and a normalised collision energy of 55%. The monoisotopic precursor selection setting 
was used to select the peaks that proceeded to MS2 which were detected with a quadrupole mass 
filter ion trap at a width of 1.2m/z. The samples for MS2 were processed before detection with a 
collision-induced dissociation collision energy of 35%, a max injection time of 70ms, and an 
automatic gain control target of 5000. 
2.4.2: Bioinformatic analysis 
The TMT-LC-MS/MS data was initially processed through a quantitative proteomic software 
package, either PD or MaxQuant, to identify the proteins of origin for each peptide fragment and 
determine their relative quantities. This data was then further processed in Perseus, a modified 
SPSS programme designed for proteomic data. The statistically analysed data was then exported 
to Microsoft Office Excel where it could be processed by hand to create spreadsheets of high 
confidence hits based on an increase of at least 1.5 fold compared with control samples as shown 
by t-test previously performed in Perseus and those with statistical significance based on the p 
value of that t-test. Some consideration was taken for proteins slightly under this cut-off point if 
there were mitigating circumstances. High confidence lists for the potential protein interactors were 
compared in Microsoft Office Excel and were also analysed individually using the online 
bioinformatic resources STRING and DAVID that were highlighted in the literature (206) as being 
effective in pathway, Gene Ontology, and protein cluster analysis, to enable us to compare not only 





3.1 Experimental background to the study 
Prior to the commencement of this study, experiments had been done in the laboratory to 
examine the human cellular protein interactome of the DENV-2 and -4 NS5 proteins (D2NS5 and 
D4NS5 respectively). For these experiments 293-Flp cell lines had been constructed that stably 
expressed the D2/4NS5 genes under control of an inducible promoter (159). To regulate the 
expression of the NS5 genes, a TetO2 operator was used, which allowed inducible transcription in 
response to the addition of tetracycline/doxycycline to the cell culture media. Compared to 
transient expression systems, the use of the 293-Flp cells facilitated expression of the NS5 genes 
at more physiological levels in the entire cell population. The NS5 genes were expressed in 
isolation from the other viral genes in order to identify protein interactions that were mediated 
solely by the NS5 proteins and not other viral proteins that may interact with NS5. To allow efficient 
purification of the NS5 proteins and their cellular interaction partners, sequence encoding a FLAG 
epitope tag was fused to the 3 end of the NS5 gene sequences.  
It was decided to adopt a similar strategy for expression of the ZNS5 gene for interactome 
analysis. The production of a 293-Flp cell line that expressed the ZNS5 gene fused to a sequence 
encoding a FLAG tagged epitope would allow a direct comparison with the cellular interactomes of 
the DENV NS5 proteins which were also FLAG epitope tagged and expressed in 293-Flp cells. The 
FLAG epitope tag was used, once again, so that experiments could be done under the same 
conditions using the same reagents/antibodies for protein purification. A human-codon-optimized 
ZNS5 gene fused to a 3 terminal FLAG tag sequence (designed by Dr A. Davidson; sequence in 
Appendix B) was synthetically constructed from oligonucleotides and then ligated into the plasmid 
pMK-RQ(kanR) (Thermo Fisher Scientific). The DNA was sequenced and determined to be 
accurate before being delivered. In addition to the use of the FLAG tag for protein purification, a 
BirA* tag was also selected for its functionality as a proximity labelling tag, which would potentially 
allow the detection of proteins that interacted even transiently/weakly with ZNS5. These interaction 
partners could then be compared to those using the traditional FLAG epitope tag pulldowns. The 
plasmid pcDNA5FrtTolntr-S497, which contained a BirA*-tagged insert (the insert corresponded to 
the E gene of Middle East respiratory coronavirus (MERS-CoV) (Thermo Fisher Scientific) was 
also purchased. Using a HindIII/BamHI digest, the ZNS5 gene was then removed from pMK-
RQ(kanR) and ligated into the corresponding sites of pcDNA5FrtTolntr-S497, such that the ZNS5 
sequence was fused at the 3 end to a sequence encoding the BirA* tag rather than a FLAG tag. A 
vector map for both plasmids is shown in Figure 15B. The design of the plasmids, the generation of 
a ZNS5-FLAG stable cell line and the preparation of the ZNS5-BirA plasmid were all completed 




3.2: Introduction to the 293 Flp-In™ system 
The 293-Flp-in™ system is a commercially available system to allow for efficient production of 
cells stably expressing exogenous genes. As shown in Figure 15, the main constituents of the 293-
Flp-in™ system are the FRT (Flp recombination target) site and the zeocin resistance gene which 
allows for selection of cells with an intact Flp-in site. The FRT Flp-in plasmid inserts via the action 
of the Flp recombinase which is supplied in trans by a helper plasmid expressing the Flp 
recombinase enzyme. This cleanly inserts all of the plasmid DNA into the chromosomal DNA of the 
293-Flp cells as shown below. The FRT Flip-in plasmid can be designed to contain a particular 
gene of interest or one can be added using restriction enzyme digests after ordering the plasmid 
backbone. The gene of interest itself is expressed using a high expression promoter; PCMV, and this 
is under the control of the tetracycline/doxycycline operator TetO2. Once inserted into the 
chromosome of the 293-Flp cells, the DNA is stable as long as hygromycin selection occurs once 






3.3: Production and testing of a ZNS5-FLAG cell line 
Prior to the commencement of the project a stable ZNS5-FLAG expressing cell line was 
produced (by Mr Joshua Lee). Briefly, the ZNS5-FLAG FRT Flp-in plasmid described above was 
used to transfect 293-Flp cells according to the protocol in 2.2.8 using ratios (µg:µg) of 11.5:1 and 
9:1 of helper plasmid:ZNS5-FLAG FRT Flp-in plasmid. Approximately 2d after transfection, the 
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transfected 293-Flp cells were then cultured using media containing 150ug/ml hygromycin to select 
for stable recombinants. Colonies were then isolated and cultured and then tested for production of 
the ZNS5-FLAG protein prior to this project. 
In order to determine the timing of induction for optimal protein production, ZNS5-FLAG 
expressing cells were grown in media containing 1µg/ml doxycycline for various times and then 
examined by IFA and western blot analysis. Every 2 days for 8 days the cells were either fixed or 
harvested and used to make total cell lysates for IFA and Western blot analysis respectively. The 
IFA samples were kept in PBS at 4 ⁰C after 4% paraformaldehyde fixation and the cell lysates 
were stored at -20 ⁰C until all samples were collected. The IFA was performed (according to 2.3.3) 
using an anti-FLAG antibody and analysed by widefield fluorescence microscopy. Phase contrast 
images were also taken as it was observed that cell health declined after 4d of doxycycline 
exposure. The results (Figure 16) showed that very minimal induction of ZNS5-FLAG was detected 
after 2 days whereas day 4 to day 8 showed far more detectable levels of ZNS5-FLAG. There was 
however a noticeable decrease in cell health after day 4 with day 6 and day 8 showing a higher 




The amount of protein in the cell lysates were then quantitated using a BCA assay and then 
equal quantities of protein were analysed by western blot using an anti-FLAG antibody. A band 
was detected at ~105kDa, the predicted size of ZNS5-FLAG, in all cells incubated with doxycycline 
(Figure 17). The blot was also probed with an anti-GAPDH antibody. A band was detected at ~37 
kDa; the expected size of GAPDH. It appeared from the western blot that the peak time of ZNS5-




It was decided that ZNS5-FLAG was being expressed as desired and that 4d of doxycycline 
exposure (1μg/ml) were optimal for cell health and provided ample protein expression. The 
localisation of ZNS5 was percieved to be highly nuclear in Figure 18 which fit with previous 
descriptions of ZNS5 localisation. To ensure that the ZNS5-FLAG gene was being expressed 
solely under the induction of doxycycline and to test the specificity of the anti-FLAG antibodies, 
another IFA was performed comparing ZNS5-expressing cells with no doxycycline exposure and 
those exposed to doxycycline for 4d. 293-Flp cells were also treated in the same way as a control 
group for the experiment. As shown in Figure 18, the red fluorescence indicative of the presence of 









The ZNS5-FLAG cell line was therefore determined to be adequately under the control of 
doxycycline induction and of adequate expression levels to progress with. 
3.4: Production and testing of a ZNS5-BirA cell line 
 The same 293-Flp-in system was used to produce the ZNS5-BirA cell line. As described in 3.1, 
the ZNS5-BirA plasmid construct was created using the ZNS5-FLAG plasmid and a BirA-tag 
containing plasmid such that the ZNS5 gene was inserted upstream of the BirA-tag. The resultant 
plasmid DNA was propagated as a plasmid midi-prep and examined by restriction enzyme digest. 
The resulting DNA digest revealed two bands that have the predicted sizes of the ZNS5 gene 
insert and the BirA plasmid backbone (Figure 19). 
The sequence of the codon optimized ZNS5 gene and the BirA gene were then used to design 
primers for sequencing (shown in Table 2). DNA sequence analysis of the plasmid midipreps 
confirmed that the ZNS5 gene and BirA sequence had acquired no mutations during the cloning or 
midi-prep procedures. The BLAST nucleotide comparison of the results with the original gene 
sequence showed that there were no mutations (data not shown). 
The ZNS5-BirA plasmid was then used to produce a 293-Flp cell line stably expressing ZNS5-
BirA as described in Sections 2.2.8 and 3.3 and shown in Figure 20. Initially 293-Flp cells were 
transfected in parallel for transient and stable gene expression analysis. 293-Flp cells were 
transfected according to the protocol described in 2.2.7 and then were seeded on coverslips and 
either exposed to doxycycline for 4 days or not exposed at all before being fixed and treated with 
the corresponding antibodies. Cells transiently expressing ZNS5-BirA were used as a control for 
the purpose of testing the anti-BirA (Aviva Systems Biology OARA01977) (Figure 21) and anti-
ZNS5 antibodies (GeneTex GTX133312) (Figure 22) and confirming production of the ZNS5-BirA 
protein. 293-Flp cells exposed to the same conditions were used as a control for non-specific 
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binding of the antibodies. For stable cell line production, the initially transfected cells were 
detached and reseeded into petri dishes after 2 days followed by incubations with hygromycin to 
select for stably transformed cells. Three colonies were successfully isolated and cultured to test 











As shown in Figure 21, the anti-BirA antibody did not specifically detect ZNS5-BirA using IFA 
analysis, as similar levels of fluorescence were observed in 293-Flp cells which did not have the 
ZNS5-BirA construct present. An anti-ZNS5 antibody was then used for IFA analysis (Figure 22) 
which showed more potential, only binding to the ZNS5 expressing cells, but the fluorescence was 
very weak, so determining whether the antibody specifically recognised ZNS5-BirA was difficult to 
judge. There also appeared to be some non-specific binding of the antibody to cells even without 
doxycycline induction. 
To investigate further whether the anti-ZNS5 antibody specifically recognised the ZNS5 protein 
and whether the protein was produced, a western blot was performed using cell lysates prepared 
from C3/C4/C5 and cell lysates from the ‘day 4’ and ‘day 6’ timepoints from the ZNS5-FLAG 
doxycycline exposure validation experiment, which had already confirmed the presence of the 
ZNS5 protein. As shown in Figure 23, the anti-ZNS5 antibody failed to detect a band either at the 
size expected for the ZNS5-BirA protein or the ZNS5-FLAG protein, previously easily detected 
using the anti-FLAG antibody. 
 
As a result of having no capable antibodies, a functional assay was performed in an attempt to 
detect ZNS5-BirA protein expression. All three ZNS5-BirA cell clones were cultured with and 
without doxycycline for 4d alongside 293-Flp cells. Biotin was added on the third day and 18h after 
biotin addition, the cells were lysed. The protein concentrations in the cell lysates were quantified 
by BCA assay and then equal quantities of protein were used for a fluorescent western blot. As 
biotin was the target, green-fluorescent-conjugated Streptavidin was used and as skim milk-
powder can contain biotin, the samples were blocked using 5% BSA (in PBS containing 0.02% 
SDS and 0.1% Tween). After 4d of doxycycline (1μg/ml) exposure and 18h of biotin (2μg/ml) 
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exposure, all three ZNS5-BirA cell clones have high levels of biotinylated proteins which was not 
observed in any samples that lacked biotin, doxycycline, or both treatments (Figure 24). 
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In addition, only a single protein was detected in lysates from the parental cell line which was 
also present in lysates derived from the ZNS5-BirA cells. RT-PCR was also performed on RNA 
extracted from C3, C4, and C5 cells that had been cultured with/without doxycycline (1μg/ml) for 
4d using primers specific for ZNS5-BirA RNA (shown in table 2 in 2.2.4) to confirm the transcription 
of the ZNS5-BirA gene. The process was performed using primers that would amplify two 
overlapping ~1.9kb fragments. The results (Figure 25) show the amplification, and therefore 
presence, of ZNS5-BirA RNA in all samples induced with doxycycline. There was also some level 
of ZNS5-BirA RNA in samples not induced with doxycycline and therefore amplification of the 
created cDNA, suggesting some low-level transcription occurred even without doxycycline. 
 
The products were sent to Eurofins sequencing and the results confirmed the expression of 
ZNS5-BirA without mutations (Appendix B). The results suggested that all three cell lines stably 
expressed ZNS5-BirA in a relatively inducible fashion. 
3.5: Pulldowns 
3.5.1: NS5-FLAG pulldown 
 Using the previously produced stable ZNS5-FLAG cell line, 293-Flp cells, and previously 
constructed D2NS5-FLAG and D4NS5-FLAG-expressing cells, 3x T225 flasks of cells were grown 
and incubated with doxycycline (1μg/ml) for 4d and then lysed in mild, non-denaturing lysis buffer 
to create large pool of proteins without interfering with protein-protein interactions. Using anti-FLAG 
antibody-coated magnetic beads, it was possible to extract the FLAG tagged NS5 proteins by 
affinity purification as well as any proteins that bound to them (protocol described in further detail in 
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2.3.8). In this way, the cellular interactome of the respective NS5 proteins could be isolated for 
further analysis. A sample taken from each lysate at the start of the procedure was compared with 
a small sample of the proteins bound to the anti-FLAG magnetic beads at the end of the procedure 
using a western blot to determine if there had been an increase in concentration of the NS5-FLAG 
proteins as would be expected of this procedure. Figure 26 shows an increase in concentration of 
protein detected by anti-FLAG antibody at ~105kDa, the expected size of the NS5-FLAG proteins. 
A band of a similar size was not observed in the 293-Flp control cells and so it was decided that 
the pulldown was a success. 
 
The remainder of the FLAG magnetic beads that retained the captured NS5-FLAG proteins and 
their cellular interaction partners were then sent to the University of Bristol Proteomics facility for 
tryptic digestion of the proteins bound to the beads, differential 10-plex TMT labelling and LC-
MS/MS analysis. 
3.5.2: Streptavidin pulldown 
Whole cell lysate pulldowns using Streptavidin coated beads had not been done previously in 
the laboratory, therefore a protocol was developed based on the whole cell lysate/ FLAG tag 
affinity purification protocol and a previously reported protocol for the isolation of biotin-labelled 
proteins using Streptavidin coated beads (204). C3, C4, and C5 and three replicates of 293 Flp-
In™ cells were grown in 3x T225 flasks and incubated with doxycycline (1μg/ml) for 4d and biotin 
(2μg/ml) for 18h to promote proximity labelling from the BirA tag. The cells were lysed in the same 
mild, non-denaturing lysis buffer as the FLAG pulldown and the lysate was then processed 
according to the pulldown procedure outlined in 2.3.10 using the Streptavidin-coated beads. 
Proteins not labelled with biotin were removed using strong detergent and high salt conditions to 
give a final sample that contains only labelled proteins. A sample taken from the initial lysate of 
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each sample was compared to the same sample post-pulldown on a fluorescent western blot 
(protocol in 2.3.6) using fluorescent Streptavidin as a biotin probe. The results, shown in Figure 27, 
showed that C4 in particular pulled down numerous biotinylated proteins and best reflected the 
biotinylation show in figure 24. C3 had enriched some biotinylated proteins though was clearly less 
successful than C4 and C5 showed no clear signs of having been successful.  
 
It was decided to send all of the samples to be analysed by TMT-MS/MS and remove C5 from 
the subsequent bioinformatic analysis if the results showed the pulldown to have failed to enrich 
biotinylated proteins compared with C3 and C4.  
3.6: FLAG TMT-MS/MS and bioinformatic programme comparison 
3.6.1: TMT-MS/MS 
TMT labelling allows for up to 11 samples to be analysed in a single LC-MS/MS run. Each 
peptide population derived from a protein lysate by proteolytic digestion is labelled with a specific 
mass tag that uses different isotopes of oxygen, carbon and nitrogen in different positions within 
the tag molecule so that while the overall mass of the tag remains the same, a cleavable portion of 
76 
 
the tag (known as the mass reporter) allows identification of each tag when analysed by LC-
MS/MS.  
The process of sample set-up and TMT-LC-MS/MS is shown in Figure 28. The proteins bound 
to the FLAG beads are eluted from the beads and then digested. The peptide fragments are then 
labelled with a TMT tag, each sample receiving a different tag. All the peptides from every sample 
are then pooled and re-separated using column liquid chromatography before being analysed by 
MS/MS to detect the fragment identities. As the tags only add ~130 Da onto the peptide fragments, 
the chromatography is not greatly affected by their addition. The TMT tags also contain a ‘cleavage 
linker’ that breaks during a specific stage of the MS/MS analysis of the peptide fragment, allowing 
for the release of the mass reporter. The mixed mass reporters are detected at the same time as 
the peptide fragments they were linked to and due to the altered locations of the isotopes within 
each tag’s structure, each tag has a distinct mass which can be detected by MS/MS. The quantity 
of each tag can therefore be quantified and compared to each other sample for each individual 
peptide fragment. The raw data that is returned can be analysed using a number of different 
proteomic analysis programmes which use protein search databases based on the species of the 
host cell used or a custom list, to match the peptide fragment data to prospective proteins, giving a 
final readout of the proteins that are predicted to have been detected and the relative quantities at 




3.6.2: FLAG pulldown bioinformatics and proteomics programme 
comparison 
The NS5-FLAG pulldown data was analysed using the proteomics bioinformatics software 
MaxQuant (207) using two false discovery rates (FDR) of 0.01 and 0.05, as well as PDv1.4 (at its 
default settings) to identify and quantify the proteins that bound to the FLAG beads. The datasets 
were then filtered to identify the protein hits that were most reliable and common to all three data 
sets. The processed data was then analysed statistically using an SPSS based programme, 
Perseus v1.5.0.15 (208), developed specifically for proteomic data analysis. Using Perseus, 
protein hits that were considered to be contaminants, reverse/mirror proteins, or those that were 
identified only by a single site were removed from the datasets. A log2 transformation was 
performed on the raw values which were then normalised by subtraction of the median value from 
the dataset for each condition, to ensure a normal distribution around the median value as shown 







Using Perseus, Pearson’s Correlation analysis was performed on the replicate samples within 
the same category (293-Flp/ZNS5/D2NS5/D4NS5) to determine how closely the replicates of each 
set correlated with each other with a scatterplot generated as a visual representation of this 
similarity. As shown in Figures 32-34, the replicates were highly comparable for every dataset, 
suggesting the results in each were reproducible and reliable however PD showed a lower level of 








The output from the MaxQuant analysis provided raw quantitation values for each protein 
identified and so the data from both the 0.01 and 0.05 FDR analyses could be grouped into 
categories for two sample t-tests so that each category (ZNS5/D2NS5/D4NS5) could be compared 
against the control category of 293-Flp. Perseus automatically averaged the samples within the 
group and performed a two sample t-test so that a single t-test difference value was given as well 
as a log2 value for that t-test. 
PDv1.4 analysis produced ratios comparing each sample to a single chosen control sample, 
therefore the data of all the expression values of the 293-Flp samples had to be averaged first so 
that a single ratio was given per replicate of ZNS5/D2NS5/D4NS5. The data used for the Perseus 
analysis were the ZNS5, D2NS5, and D4NS5 replicates, each with a ratio (to the averaged control 
values) rather than a raw detection value. Relative quantitation values for the 293-Flp control 
samples were not produced using PD for analysis as it would always have a ratio of 1 compared to 
itself for every protein identified. Therefore one sample t-tests were used to analyse the ratios 
comparing against a log2 values of ‘0’ (ie no change compared to control), whereas the MaxQuant 
analysis produced abundance values for all conditions which could be used for 2 sided t-test 
analysis (ie condition vs control). 
The resulting datasets were then exported into Microsoft Office Excel to be analysed. The 
processed data is supplied on the CD in Appendix C. Table 5 summarises the differences between 
the PD and MaxQuant outputs as well as the difference using different FDRs for both MaxQuant 
datasets. 
A log2 t-test difference of >0.58 was chosen as the lower boundary of our classification of 
increased protein binding as it equates to roughly a 1.5 fold increase between our sample 
pulldowns and the 293-Flp control pulldowns. However, proteins with a log2 t-test difference 
between 0.5-0.58 were also examined in the final data in case of mitigating factors that may have 
affected t-test values. The p values were given as –log10 p values and so >1.3 represented a p 
value of <0.05. The ideal protein targets therefore had a log2 t-test difference >0.58 and a –log10 p 




Table 5: Comparison of raw datasets from the FLAG pulldown analysis using Proteome 
Discoverer and MaxQuant with 0.01 and 0.05 FDRs. 
















































544 316 117 140 104 176 135 292 
MaxQuant - 
0.05 FDR 
669 329 113 162 111 203 173 343 
PD 856 856 114 135 78 155 180 371 
 
High confidence protein hits within each dataset were separated for each NS5 interactors list 
by isolating protein hits that had a >0.58 log2 t-test difference. Proteins down to 0.5 were also 
considered if there were reasons to include it such as a single poor replicate or a failed occurrence 
in a replicate. Proteins were then determined to be reliable or not based on a –log10 p value >1.3. 
Due to the nature of variability within proteomic data and in the interest of generating the largest 
pool of potential interactors, proteins with a –log10 p value <1.3 were manually reviewed regarding 
their counts, unique peptides, coverage scores, and their individual replicate values to determine 
the cause of the lower p value. In numerous cases, it was found to be the result of the identification 
of a protein using a single replicate in either the control or pulldown sample and in these cases, 
and where a protein was confidently identified by high coverage, unique peptide number, and 
count value, it was also included into the dataset. Inclusion of these proteins did not affect the 
enrichment of particular pathways shown in STRING and DAVID analysis (data not shown). This 
final protein list was considered to be the ‘high confidence proteins’ for the general interactomic 




Table 6: Comparison of the quantity of high confidence proteins of NS5-FLAG from Proteome 
Discoverer and MaxQuant at 0.01 and 0.05FDR 
Dataset No. of high confidence 
proteins for ZNS5 
No. of high confidence 
proteins for D2NS5 
No. of high confidence 
proteins for  
D4NS5 
MaxQuant - 0.01 FDR 123 116 138 
MaxQuant - 0.05 FDR 112 105 175 
PD 123 95 153 
 
The analysis therefore produced lists of high confidence protein hits that could then be 
compared between the datasets and between the different flaviviral NS5 proteins. A summary of 
the common high confidence proteins between the different samples in each dataset is shown 
below in table 7. 
Table 7: Comparison of the quantity of common high confidence protein interactors of NS5-
FLAG identified by the Proteome Discoverer and MaxQuant at 0.01 and 0.05 FDR analyses. 
Datasets No. common high 
confidence proteins  
for ZNS5 
No. common high 
confidence proteins 
for D2NS5 
No. common high 
confidence proteins 
for D4NS5 
0.01 and 0.05 83 85 120 
0.01 and PD 46 46 60 
0.05 and PD 40 47 70 
0.01, 0.05, and PD 39 40 55 
 
It was also possible to compare the same samples from different datasets to see which hits 
were consistently being discovered using different programmes and different FDRs. These proteins 
were considered to be the most reliable hits. There were 76 proteins identified to be present in all 
three datasets that had a >0.58 log2 fold change in at least one of the NS5 sample sets 
(ZNS5/D2NS5/D4NS5) compared to the control. It was these proteins that were most suited for 
validation as they were present in all datasets and identified as binding at increased levels to at 
least one of the NS5 proteins. These proteins are shown in Table 8 with the log2 t-test difference 




Table 8: Common high confidence proteins from the NS5-FLAG pulldowns 










Q9P021 2.51 0.13 2.44 




P46783 1.91 2.38 2.63 
Reticulocalbin-2 H0YL43 1.79 0.78 1.84 
28 kDa heat- and acid-
stable phosphoprotein 
Q13442 1.66 2.78 1.45 
40S ribosomal protein 
S20 
P60866 1.65 2.49 2.55 
40S ribosomal protein 
S25 
P62851 1.56 2.47 2.40 
40S ribosomal protein 
S29 
P62273 1.55 2.53 2.26 
Slit homolog 2 protein A0A087WYV5 2.44 2.09 1.94 
Cleft lip and palate 
transmembrane protein 
1 
K7ERL5 1.45 0.67 0.67 
ATP synthase subunit 
gamma (fragment) 
Q8TAS0 1.77 1.20 1.47 
Peptidyl-prolyl cis-trans 
isomerase FKBP3 
Q00688 1.37 1.56 0.98 
Cyclin-dependent 
kinase 1 
P06493 1.29 0.52 0.31 
ATP synthase subunit 
alpha, mitochondrial 
K7ENP3 1.29 0.84 0.50 
E3 ubiquitin-protein 
ligase listerin 
H7BYG8 1.24 -0.02 -0.14 
Eukaryotic translation 
initiation factor 3 
subunit B 
C9JZG1 1.22 0.90 0.86 




initiation factor 5B 
O60841 1.11 0.47 1.34 
40S ribosomal protein 
S19 
P39019 1.19 2.35 2.65 
ATP synthase subunit 
O, mitochondrial 
P48047 1.08 0.76 2.00 
40S ribosomal protein 
S18 
P62269 1.08 1.18 1.86 
40S ribosomal protein 
S28 




H7C4H2 1.03 0.05 0.36 
40S ribosomal protein 
S17-like;40S ribosomal 
protein S17 
H0YN88 0.97 1.23 2.10 
ATPase inhibitor, 
mitochondrial 
Q9UII2-3 0.94 0.93 0.85 
40S ribosomal protein 
S30 
E9PR30 0.83 1.18 1.59 
Protein FRG1 Q14331 0.84 0.94 1.33 
Transcription initiation 
factor TFIID subunit 2 
Q6P1X5 0.72 1.84 1.50 
Lamin B receptor, 
isoform CRA_a 
A0A024R3R5 0.76 0.65 -1.73 
Vimentin Q5JVS8 0.68 0.40 -0.14 
MICOS complex 
subunit MIC60 
Q16891-2 0.68 0.15 -0.70 
Histone H2A type 2-C Q16777 0.79 0.15 0.77 
60S ribosomal protein 
L12 
P30050-2 0.65 0.97 2.18 
40S ribosomal protein 
S16 
P62249 0.65 0.37 0.43 
60S ribosomal protein 
L9 
H0Y9V9 0.63 1.13 2.36 
Arginine and 
glutamate-rich protein 1 
Q9NWB6-2 0.62 -0.02 2.039 
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40S ribosomal protein 
S7 
B5MCP9 0.62 0.61 1.55 
PHD finger protein 6 Q5JRC6 0.61 0.57 1.18 
High mobility group 
protein HMGI-C 
P52926 0.60 0.51 1.34 
Elongation factor Tu, 
mitochondrial 
P49411 0.59 0.95 -0.34 
RNA-binding protein 25 P49756 0.57 0.48 0.99 
Pre-mRNA 3-end-
processing factor FIP1 
Q6UN15-3 0.54 0.88 1.36 
Pre-mRNA-processing 
factor 40 homolog A 
O75400 0.69 0.59 0.91 
Protein BUD31 
homolog 
C9JNV2 0.51 0.44 0.85 
GTP-binding nuclear 
protein Ran 
B5MDF5 0.50 0.66 1.93 
Histone H1.2;Histone 
H1.3 
P16403 0.49 0.76 1.18 
Emerin Q5HY57 1.21 0.36 0.98 
Plasminogen activator 
inhibitor 1 RNA-binding 
protein 




A6NL93 0.43 0.03 1.51 
40S ribosomal protein 
S23 
P62266 0.57 1.26 -0.02 
Protein SREK1IP1 Q8N9Q2 0.40 0.97 -0.04 
Histone H1.4 P10412 0.36 0.85 1.00 
60S ribosomal protein 
L37a 
P61513 0.47 0.54 1.28 
60S ribosomal protein 
L23a 
P62750 0.45 0.34 1.40 
Calnexin D6RAQ8 0.34 0.84 -0.18 
60S ribosomal protein 
L22 
K7ERI7 0.32 0.37 1.26 
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High mobility group 
protein HMG-I/HMG-Y 
P17096 0.14 0.50 1.18 
40S ribosomal protein 
S15 
K7EJ78 0.55 0.53 1.18 
60S ribosomal protein 
L32 
D3YTB1 0.28 1.55 0.42 
40S ribosomal protein 
S14 
P62263 0.25 0.05 1.35 
Cytochrome b-c1 
complex subunit 2, 
mitochondrial 




O60869-2 0.24 1.37 0.55 
Histone H4 P62805 0.20 0.13 0.96 
Leucine-rich repeat-
containing protein 59 
Q96AG4 0.18 0.60 0.87 
Poly(U)-binding-splicing 
factor PUF60 
Q9UHX1-4 0.13 0.02 0.83 
Serine/arginine-rich 
splicing factor 11 
Q05519-2 0.11 -0.11 0.88 
Protein DEK P35659 0.18 0.09 1.19 
Cold-inducible RNA-
binding protein 
Q14011 0.07 0.89 1.46 
High mobility group 
protein B1 
P09429 1.16 0.63 0.93 
High mobility group 
protein B2 
P26583 0.03 0.57 1.08 




O00479 -0.01 0.16 1.57 
Uncharacterized 
protein C19orf47 
Q8N9M1-3 -0.06 -0.06 1.35 
Serine/threonine-
protein kinase RIO1 
Q9BRS2 -0.07 1.02 -0.22 
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High mobility group 
protein B3 




Q8N5F7 -0.45 -1.24 0.93 
Kinesin-like protein 
KIF11 
P52732 -1.02 1.01 -0.45 
TBC1 domain family 
member 10B 
Q4KMP7 -1.05 0.21 2.07 
 
Although the validation targets would be most likely selected from the list of 76 common 
proteins, the entire list of high confidence protein interaction partners for each NS5 protein was 
used for STRING and DAVID analysis to identify potential proteins and cellular pathways that were 
enriched in the respective FLAG pulldowns for the different NS5-FLAG proteins (Figures 35-43; 
Tables 9-17)). The identification of cellular pathways that were potentially influenced by the 
flaviviral NS5 proteins could also be used to guide the choice of validation targets towards 
biologically important NS5 binders by selecting proteins in pathways clearly heavily targeted by the 





Figure 35 shows the STRING results for high confidence ZNS5 interactors in the 0.01FDR 
MaxQuant dataset with main functional annotation clusters from DAVID analysis of the same data 
highlighted. The top DAVID results and details from the STRING analysis are also presented in 





Table 9: DAVID/STRING functional annotation clustering for high confidence interactors of 
ZNS5 in the MaxQuant 0.01FDR dataset  
Functional annotation cluster EASE score STRING false discovery rate 
Ribosome/translation 17.16 8.99e-14 
Histone/chromatin 13.1 4.25e-16 




Actin 2.96 0.018 
Figures 36 and 37 show the STRING analysis on the high-confidence proteins from MaxQuant 
0.05FDR and PD for comparison. 
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The proteins discovered in 0.05FDR MaxQuant show a lot of similarity in the STRING analysis 
(Figure 36) to the 0.01FDR with most of the same main clusters appearing. DAVID analysis (Table 
10) also showed similar enrichment groups as the 0.01FDR MaxQuant data which are displayed in 
Figure 35 and Table 9. 
Table 10: DAVID/STRING functional annotation clustering for high confidence interactors of 
ZNS5 in the MaxQuant 0.05FDR dataset 
Functional annotation cluster EASE score STRING false discovery rate 
Ribosome/translation 13.32 1.68e-11 
Histone/nucleosome 12.94 4.1e-13 
Actin 2.88 8.76e-07 
Mitochondrial inner membrane/ATP 
synthesis 
2.81 1.2e-06 




Figure 37 shows PD’s ZNS5 high-confidence protein STRING analysis. The results are far less 
clustered than that of the MaxQuant analyses and DAVID analysis only returned one high level 
enrichment which was the translation/ribosome proteins highlighted in Figure 37. The two following 
groups of ATP synthesis/mitochondria and mRNA splicing/processing are also displayed in Figure 
37 as well as table 11 where the enrichment scores and false discovery rates show the large 
difference. Fewer high-confidence proteins identified by PD hits were found to form enriched 
clusters by STRING and DAVID analysis as many were proteins of unknown origin and were not 
identifiable by STRING or DAVID. They therefore did not appear on the STRING/DAVID analysis. 
Those that did map were far less clustered causing STRING to fail to present ATP 
synthesis/mitochondria as an enriched category to highlight and determine the false discovery rate 
of. Alternatively, it may have detected this enrichment but considered the false discovery rate to be 
>0.05.  
Table 11: DAVID/STRING functional annotation clustering for high confidence interactors of 
ZNS5 in the PD dataset 
Functional annotation cluster EASE score STRING false discovery rate 
Ribosome/translation 9.73 1.78e-09 
ATP synthesis/mitochondria 2.1 - 
mRNA splicing/processing 1.29 9.98e-07 
 
The D2NS5 STRING analysis is shown in Figures 38, 39, and 40 for 0.01FDR MaxQuant, 
0.05FDR MaxQuant, and PD respectively. Once again, the differences between MaxQuant 
(Figures 38, 39) and PD (Figure 40) are clear. MaxQuant produces very clear defined clusters with 
greater enrichment and p values while PD analysis produced far fewer enrichment clusters. Tables 




D2NS5 enriched ubiquitin-related proteins in the FLAG pulldown (table 12); a large pool of 
proteins that involves ubiquitin E3 ligases, regulators of ubiquitination, and proteins involved in 
ubiquitin-dependent pathways such as DNA repair or protein degradation. It also shows 
enrichment for ribosome/translation which is expected in viral, and particularly flaviviral, proteins. 





Table 12: DAVID/STRING functional annotation clustering for high confidence interactors of 
D2NS5 in the MaxQuant 0.01FDR dataset 
Functional annotation cluster EASE score STRING false discovery rate 
Ribosome/translation 20.88 4.9e-24 
Unfolded protein binding/chaperone 10.77 4.34e-06 
Actin 2.81 1.05e-06 
Ubiquitin-related proteins 2.7 2.47e-06 
mRNA processing 2.65 0.00226 
Mitochondria inner membrane/ATP synthesis 2.33 0.000648 
The DAVID analysis of 0.05FDR MaxQuant showed the same enrichments as 0.01FDR 
MaxQuant though with the added enrichments of microtubule-related proteins (Figure 39) 
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Table 13: DAVID/STRING functional annotation clustering for high confidence interactors of 
D2NS5 in the MaxQuant 0.05FDR dataset 
Functional annotation cluster EASE score STRING false discovery rate 
Ribosome/translation 17.54 1.14e-19 
Microtubule 4.96 0.0162 
Actin 3.22 4.83e-07 




PD, as with ZNS5, provided a much less defined set of proteins for D2NS5 and only 
showed three functional annotation clusters within DAVID (Figure 40). 
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Table 14: DAVID/STRING functional annotation clustering for high confidence interactors of 
D2NS5 in the PD dataset 
Functional annotation cluster EASE score STRING false discovery rate 
Ribosome/translation 12.89 3.13e-06 
Histone/nucleosome 2.32 0.00045 
Helicase/ATP binding 1.46 0.0028 
D4NS5 provided very clear protein clusters in all three datasets during STRING analysis. 
Figure 41 shows D4NS5 high-confidence protein interactors from the 0.01FDR analysis MaxQuant. 
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The top DAVID defined enrichment clusters are highlighted in Figure 41 and bears a high level 
of similarity to D2NS5 and ZNS5. ‘Ribosome/translation’ is the most highly enriched term and has 
the lowest false discovery rate (Table 15) though ‘chromosome/DNA binding’ and 
‘nucleosome/histone’ are enriched for D4NS5 and not for D2NS5 which is the more nuclear-
localised of the two. 
Table 15: DAVID/STRING functional annotation clustering for high confidence interactors of 
D4NS5 in the MaxQuant 0.01FDR dataset 
Functional annotation cluster EASE score STRING false discovery rate 




Spliceosome/mRNA export 5.56 1.49e-07 
Chromosome/DNA binding 3.47 0.0236 
Nucleosome/histone 3.45 2.94e-06 
 
Figure 42 shows the STRING analysis for 0.05 MaxQuant D4NS5 protein interactors where the 
five main clusters from the 0.01FDR MaxQuant STRING analysis can still be easily seen. 
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Table 16: DAVID/STRING functional annotation clustering for high confidence interactors of 
D4NS5 in the MaxQuant 0.05FDR dataset 
Functional annotation cluster EASE score STRING false discovery rate 





Chromatin 4.53 4.34e-06 
Nucleosome/chromosome 4.12 1.63e-05 
Spliceosome 3.53 2.13e-05 
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Finally, PD’s D4NS5 protein interactor list was processed through STRING and DAVID and, 
although less defined compared to the MaxQuant datasets, still showed a clear clustering of 
ribosomal/translation initiation proteins (Figure 43). The remaining categories identified as highly 
enriched by DAVID are less clearly defined in STRING but were; mRNA processing, cell-cell 




Table 17: DAVID/STRING functional annotation clustering for high confidence interactors of 
D4NS5 in the PD dataset 
Functional annotation cluster EASE score STRING false discovery rate 
Ribosome/translation 15.08 3.66e-10 
mRNA splicing/processing 5.74 2.8e-08 
Cell-cell adhesion 5.4 3.19e-07 
Chromatin 3.73 3.84e-06 
RNA transport 2.61 0.000111 
 
Beyond the highest enriched categories, there were also a number of borderline enriched 
categories within DAVID that did not appear clearly within STRING and so an exhaustive list of 
DAVID functional annotation clusters for each NS5 protein’s high confidence interactor list from 
MaxQuant 0.01FDR has been provided in table 18. The categories are organised from highest 
enrichment to the lowest for each dataset from top to bottom. 
Table 18: Full list of DAVID functional annotation clusters for the high confidence interactors of 
each NS5 protein 

















Actin 2.81 Spliceosome/ 
mRNA export 








































1.79 DNA binding/ 
DNA bending 
1.81 Spliceosome 1.3 





1.28 DNA damage/ 
DNA repair/base 
excision repair 
1.37 DNA damage/ 
DNA repair 
1.3 
  Cell-cell 
adhesion 
1.31   
 
DNA damage is one of the most notable hallmarks of ZIKV infection with the development of 
pyknotic nuclei a recognised feature of ZIKV-infected cells (54) so the appearance of ‘DNA 
damage/DNA repair’ as a functional annotation cluster was unsurprising. However, ‘DNA 
damage/DNA repair’ was also seen in D4NS5 at a slightly higher level of enrichment than in ZNS5 
high confidence interactors. So far there have been no reports of DENV-NS5 causing DNA 
damage like ZNS5. Closer analysis of the proteins involved in the ZNS5/D4NS5 ‘DNA 
damage/DNA repair’ cluster has been shown in tables 19, 20, and 21 which revealed numerous of 




Table 19: DNA damage/DNA repair cluster proteins in both ZNS5 and D4NS5 
Protein name UniProt 
accession 
Function 
Histone H2AX P16104 Histone protein - involved in regulation of numerous DNA 
processes like repair, transcription, and replication 
Flap 
endonuclease 1 
P39749 Cuts 5’ RNA flap from okazaki fragments as well as 
performing endonuclease and exonuclease activities within 
base excision repair and in the cases of nicked DNA or ds 
breaks as part of the repair process 
High mobility 
group protein B1 
P09429 Nucleosomal member of a group of proteins that regulate 
numerous DNA functions including replication, repair, 
apoptosis, nucleosome rearrangement, and transcription as 
well as a large number of intracellular processes. It can also 
function as a DAMP, mediating the response to inflammation, 
infection, and damage when secreted extracellularly 
 
Table 20: DNA damage/DNA repair cluster proteins in ZNS5 only 





P11440 Cell cycle regulation protein (G1→ S phase) with large 
number of intracellular targets for phosphorylation including 




P33993 DNA helicase responsible for cell cycle progression through S 
phase - detects UV-related DNA damage 
40S ribosomal 
protein S3 
P23396 Contains endonuclease activity used in DNA repair - has a 






O95071 Ubiquitin ligase - activates CDK9 in DNA maturation, 
regulates TopBP1 and RNF168 (both involved in DNA repair), 
and also theorised to have a role in cell cycle progression 
 
Table 21: DNA damage/DNA repair cluster proteins in D4NS5 only 





O15527 DNA incision protein with a high affinity for ROS-
damage guanine within DNA 
E3 ubiquitin-protein 
ligase RBBP6 
Q7Z6E9 Ubiquitin ligase - encourages the degradation of YBX1 
as well as promoting cell growth and apoptosis via the 
degradation of p53 
Circadian locomoter 
output cycles protein 
kaput 
O15516 TF involved in the regulation of the circadian rhythm - 
repressed by p53 and NONO 
High mobility group 
protein HMG-I/Y 
P17096 Regulates expression in dsDNA regions with high AT 
concentrations - could be involved in nucleosome 
placement 
High mobility group 
protein HMGI-C 
P52926 Regulator of transcription and plays a role in cell cycle 
progression via interactions with Cyclin-A2 
High mobility group 
protein B2 
P26583 Involved in histone remodelling and transcription 
regulation within the nucleus and is reported to be 




Q15233 Repressor of CLOCK and a target of CDK1 
phosphorylation. Interacts with U5 snRNA and could 






P09874 Utilised in base excision repair of damaged DNA and 
acts as a transcription regulator for specific genes 
E3 ubiquitin-protein 
ligase RNF168 
Q8IYW5 Ubiquitin ligase - encourages recruitment of DNA 
repair proteins to sites of DNA damage particularly are 
sites of ds breaks 
 
The differences between 0.01FDR and 0.05FDR MaxQuant are as expected with the 0.05FDR 
dataset having a greater number of proteins detected and slightly fewer high confidence proteins 
as well as higher p values in STRING analysis and lower enrichment values in DAVID analysis but 
still retaining a high degree of similarity in the functional annotation clusters. The differences 
between PD and MaxQuant however are much more noticeable. Table 7 shows how few common 
proteins were found between the two programmes when compared to the comparison of the two 
FDRs within the same programme. PD also provided fewer DAVID categories in general and less 
clear STRING clusters as shown in Figures 37, 40, and 43, partly due to a tendency to assign 
detected peptides to poorly reported proteins that were not on the STRING/DAVID database. It 
was decided because of this that the Streptavidin pulldown proteomic data would initially be 
analysed with MaxQuant set at an FDR of 0.01 with the possibility to reanalyse the data afterwards 




3.6.3: Streptavidin pulldown bioinformatics 
The streptavidin pulldown samples described in Section 3.5.2 were processed using TMT-
MS/MS and the resulting data files analysed by MaxQuant at an FDR of 0.01 using the same 
protein search list as the FLAG pulldown samples with the addition of the ZNS5-BirA sequence. 
The resulting data was analysed first in Perseus (as in 3.6.2) where proteins detected by only a 
single site were removed from the sample set. A log2 transformation was performed on the raw 
values which were then normalised with a median subtraction to provide a normal distribution 
around the value of log2 value of ‘0’. Histograms were generated using Perseus to show the 
normal distributions and are shown in Figure 44. 
 
Scatterplots were produced with Pearson’s Correlation values to show the correlation of the 
replicates with each other. As shown in Figure 45, the replicates for the 293-Flp cells were highly 
reproducible and reliable as were the datasets using the three independently produced ZNS5-BirA 




The pull down data produced using the C5 cell line (Figure 44 and 45 as well as raw values) 
suggested that the C5 pulldown was comparable to C3 and C4 and it was therefore included in the 
final analysis. As with the MaxQuant data in Section 3.6.2, the dataset for the streptavidin pulldown 
was analysed using a two sample t-test to generate a t-test difference value and a –log10 p value 
for each protein detected. This data was then exported to Microsoft Office Excel to for further 
analysis and is provided on the supplementary CD in the appendix (filename; ‘BirA’). 
The dataset was analysed using the same criteria as the FLAG pulldown data; a log2 t-test 
difference of >0.58 and a –log10 p value of >1.3 being the lower boundary for selection. No 
proteins with a log2 t-test difference between 0.50-0.58 were added to this dataset and all proteins 
detected within the dataset had >1 peptide detected and a –log10 p value >1.3. Table 22 shows a 




Table 22: Quantity of streptavidin pulldown raw hits and high confidence proteins 
No. of proteins 
detected 
No. of proteins log2 t-
test>0.58 
No. of proteins –log10 
p value >1.3 
No. of final high 
confidence proteins 
812 275 553 247 
 
As shown in Table 22, there was a larger number of proteins detected compared to the FLAG 
pulldown and a higher number of high confidence proteins. The full list is shown in Table 23. 
Table 23: High confidence protein list from streptavidin pulldown on ZNS5-BirA cell lines 




-log10 p value 
Small acidic protein O00193 4.629092 2.530277 
TOX high mobility group box family 
member 4 O94842 4.228101 1.784686 
General transcription factor IIE subunit 1  P29083 4.091256 1.762518 
cDNA, FLJ94590, highly similar to Homo 
sapiens craniofacial development protein 1 
(CFDP1), mRNA B2R9W9 3.968232 2.058638 
Zinc finger CCCH domain-containing 
protein 18 E7ERS3 3.651489 5.517842 
Treacle protein  E7ETY2 3.520173 2.741643 
ELL-associated factor 1  Q96JC9 3.496523 1.979384 
PEST proteolytic signal-containing nuclear 
protein  Q8WW12 3.379783 2.494137 
RNA polymerase II elongation factor ELL2 O00472 3.310556 1.974359 
Transcriptional regulator Kaiso Q86T24 3.297905 2.358113 
DDB1- and CUL4-associated factor 5 Q96JK2 3.292729 2.43229 
YEATS domain-containing protein 2  Q9ULM3 3.199635 2.608447 
UPF0428 protein CXorf56 Q9H5V9 3.163606 2.099316 
WW domain-binding protein 11  Q9Y2W2 3.101506 2.95131 
Treacle protein  Q13428 3.046453 2.12005 
Tuftelin-interacting protein 11  Q8N523 3.039954 2.190444 
ZNF507 protein  B9EGE7 3.029881 1.889423 
Spliceosome-associated protein CWC15 
homolog  Q9P013 2.979059 1.634118 
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Zinc finger CCCH domain-containing 
protein 4 Q9UPT8 2.972613 4.282398 
RNA cytidine acetyltransferase  Q9H0A0 2.959367 2.374478 
Targeting protein for Xklp2  Q9ULW0 2.825635 2.213261 
Nucleoporin 153kDa, isoform CRA_a  A0A024QZW7 2.825548 2.372861 
Phosphorylated adapter RNA export 
protein Q9H814 2.811495 2.860488 
Transcription initiation factor IIE subunit 
beta  P29084 2.793195 2.159655 
Transcription initiation factor TFIID subunit 
9  Q16594 2.758743 2.242561 
Histone-lysine N-methyltransferase SETD2 Q9BYW2 2.731504 2.103004 
cDNA FLJ76716, highly similar to Homo 
sapiens WD repeat domain 70 (WDR70), 
mRNA A8K564 2.638719 3.070081 
cDNA FLJ30322 fis, clone 
BRACE2006703, highly similar to Surfeit 
locus protein 6 B3KNS8 2.633578 3.093013 
Negative elongation factor E H9ZYJ1 2.632782 3.620597 
Bcl-2-associated transcription factor 1 E9PK91 2.615508 3.448974 
NMDA receptor regulated 2, isoform 
CRA_b A0A024R5V9 2.60136 2.110984 
HIV Tat-specific factor 1 O43719 2.591445 2.664477 
Coilin P38432 2.537444 2.336884 
Calcium homeostasis endoplasmic 
reticulum protein J3QK89 2.50319 1.950664 
SAP30-binding protein (Fragment) J3QQJ0 2.478776 3.572543 
RAD21 homolog (S. pombe), isoform 
CRA_a A0A024R9J0 2.42804 3.958031 
SURP and G-patch domain-containing 
protein 2 M0R2Z9 2.426897 2.66168 
Zinc finger protein 447, isoform CRA_a A0A024R4T0 2.414669 2.678586 
cDNA FLJ58676, highly similar to Protein 
AF-9 B7Z4N5 2.408514 1.684084 
Little elongation complex subunit 1 Q9Y2F5 2.395516 2.288308 
Nucleoprotein TPR P12270 2.319734 2.367651 
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cDNA FLJ76043, highly similar to Homo 
sapiens cyclin T1 (CCNT1), mRNA A8K4M5 2.228825 3.311964 
Paired amphipathic helix protein Sin3b O75182 2.223139 2.922717 
Nuclear pore complex protein Nup88 Q99567 2.217167 2.411873 
Pre-mRNA-processing factor 17 O60508 2.210404 2.307844 
Zinc finger MYM-type protein 1 Q5SVZ6 2.2075 2.111967 
Ubiquitin carboxyl-terminal hydrolase 28 Q96RU2 2.198953 4.250165 
Thyroid hormone receptor-associated 
protein 3 Q9Y2W1 2.17513 2.474572 
Uncharacterized protein C19orf43 Q9BQ61 2.167783 2.599537 
Cyclin K, isoform CRA_c A0A024R6K1 2.166432 2.083365 
Ran-binding protein 3 Q9H6Z4 2.156872 2.990789 
E3 SUMO-protein ligase RanBP2 P49792 2.156651 2.263373 
Kinesin-like protein KIF23 Q02241 2.153106 3.438644 
Segment polarity protein dishevelled 
homolog DVL-3 Q92997 2.15095 1.981496 
Filamin-A P21333 2.138541 2.039296 
Bromodomain-containing protein 4 O60885 2.137367 2.94827 
Thymopoietin, isoform CRA_c A0A024RBE7 2.110509 2.054822 
Bcl-2-associated transcription factor 1 Q9NYF8 2.030242 2.201267 
Mediator of RNA polymerase II 
transcription subunit 1 Q15648 2.014831 2.969941 
U4/U6.U5 tri-snRNP-associated protein 1 O43290 2.004564 3.821661 
Serine/threonine-protein phosphatase 4 
regulatory subunit 3A Q6IN85 1.992283 2.549191 
RNA-binding protein 27 Q9P2N5 1.973138 2.773509 
Chromodomain-helicase-DNA-binding 
protein 4 A0A0C4DGG9 1.965321 2.581496 
PERQ amino acid-rich with GYF domain-
containing protein 2 I1E4Y6 1.958627 2.471605 
General transcription factor 3C polypeptide 
4 Q9UKN8 1.939162 2.246829 
Myb/SANT-like DNA-binding domain-
containing protein 2 Q6P1R3 1.930214 1.623364 
cDNA, FLJ95596, highly similar to Homo 
sapiens activity-dependent neuroprotector 
(ADNP), mRNA B2RBM8 1.920433 1.30159 
110 
 
Nuclear factor 1 B1AKN8 1.904528 3.309829 
UPF0690 protein C1orf52 Q8N6N3 1.896129 4.137287 
Nucleolar and coiled-body phosphoprotein 
1 (Fragment) A0A0A0MRM9 1.892745 4.360396 
Probable ATP-dependent RNA helicase 
DDX46 A0A0C4DG89 1.885934 2.529869 
Splicing factor 3B subunit 1 O75533 1.880557 2.512787 
RNA-binding protein 33 Q96EV2 1.872197 2.445714 
Zinc finger DBF-type containing 2 vesion 1 N0DVB2 1.86688 2.158866 
RNA-binding protein 25 P49756 1.864361 3.9205 
BCL6 corepressor-cyclin B3 fusion protein H9A532 1.861885 3.10134 
cDNA FLJ77796, highly similar to Homo 
sapiens evolutionarily conserved G-patch 
domain containing protein mRNA A8K8Y8 1.858805 2.206902 
RNA-binding protein 26 A0A087X0H9 1.846651 3.267271 
cDNA FLJ75279, highly similar to Homo 
sapiens elongation factor RNA polymerase 
II (ELL), mRNA A8KAP0 1.831473 2.02775 
Nuclear autoantigenic sperm protein P49321 1.830069 3.631122 
Negative elongation factor A A0A0C4DFX9 1.827671 1.986882 
PCM1 protein B9EIS5 1.821753 2.070436 
Cleavage and polyadenylation specificity 
factor subunit 6 Q16630 1.814633 4.639645 
RNA binding motif protein 17, isoform 
CRA_a Q5W009 1.778106 2.027115 
Nuclear mitotic apparatus protein 1, 
isoform CRA_a A0A024R5M9 1.758977 2.556108 
Antigen KI-67 P46013 1.755822 2.061346 
Splicing factor 4 A5PLN4 1.753743 2.736034 
CASP8-associated protein 2 Q9UKL3 1.74339 1.733813 
Protein PML P29590 1.729818 3.597707 
Chromodomain-helicase-DNA-binding 
protein 8 Q9HCK8 1.708258 2.722994 
Zinc finger protein 318 Q5VUA4 1.705546 2.419869 
Nibrin  A6H8Y5 1.697521 1.824391 
Wings apart-like protein homolog Q7Z5K2 1.67554 2.817996 
Nuclear pore complex protein Nup50 Q9UKX7 1.669251 2.456212 
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RNA polymerase-associated protein LEO1 Q8WVC0 1.665639 2.610585 
Zinc finger protein 609 O15014 1.661363 1.789352 
Chromodomain helicase DNA binding 
protein 7, isoform CRA_a  A0A024R7V7 1.658542 2.562533 
Serine/arginine-rich splicing factor 11  Q05519 1.650664 1.585411 
Segment polarity protein dishevelled 
homolog DVL-2 O14641 1.648903 1.8389 
Adapter molecule crk P46108 1.648269 4.016389 
Adenosine deaminase, RNA-specific 
isoform ADAR-a variant (Fragment) Q59EC0 1.63492 2.715724 
Nuclear cap-binding protein subunit 3 Q53F19 1.624838 1.631089 
WD repeat-containing protein 36 Q8NI36 1.623085 1.507234 
U2 small nuclear ribonucleoprotein A' P09661 1.622078 3.638087 
Nucleoporin 214kDa, isoform CRA_b A0A024R8B6 1.608553 2.837137 
RNA binding motif protein 10 isoform 1 
(Fragment) A0A0S2Z4X1 1.594113 5.35855 
ATPase WRNIP1 Q96S55 1.593846 2.036543 
Ankyrin repeat domain-containing protein 
11 Q6UB99 1.579614 2.611768 
Apoptotic chromatin condensation inducer 
in the nucleus Q9UKV3 1.576627 2.706251 
cDNA FLJ76962, highly similar to Homo 
sapiens nucleolar protein 5A (56kDa with 
KKE/D repeat) (NOL5A), mRNA A8K9K6 1.571525 2.323066 
SWI/SNF-related matrix-associated actin-
dependent regulator of chromatin subfamily 
A containing DEAD/H box 1 Q9H4L7 1.564526 2.151807 
cDNA FLJ54492, highly similar to 
Eukaryotic translation initiation factor 4B B4DRM3 1.563131 3.615853 
cDNA, FLJ92684, highly similar to Homo 
sapiens IK cytokine, down-regulator of HLA 
II (IK), mRNA B2R5Y4 1.56238 2.272685 
60S ribosomal protein L10 F8W7C6 1.554221 2.394062 
Paired amphipathic helix protein Sin3a Q96ST3 1.544627 1.636043 
EF-hand domain-containing protein D2 Q96C19 1.543405 1.754067 
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cDNA, FLJ93335, highly similar to Homo 
sapiens PRP3 pre-mRNA processing factor 
3 homolog (yeast) (PRPF3), mRNA B2R791 1.540373 2.276223 
Importin subunit alpha-3 O00629 1.531234 1.98502 
Neuroblast differentiation-associated 
protein AHNAK Q09666 1.527779 2.161916 
cDNA, FLJ95010, highly similar to Homo 
sapiens Bloom syndrome (BLM), mRNA B2RAN0 1.509638 2.962984 
Nuclear ubiquitous casein and cyclin-
dependent kinase substrate 1 Q9H1E3 1.506829 2.264606 
E3 ubiquitin-protein ligase RBBP6 Q7Z6E9 1.501486 2.533098 
Interferon regulatory factor 2-binding 
protein 2 Q7Z5L9 1.499756 3.926243 
Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase 48 kDa subunit A0A024RAD5 1.499171 2.458352 
Host cell factor 1 A6NEM2 1.496914 2.672996 
Zinc finger Ran-binding domain-containing 
protein 2 A0A0C4DGV5 1.476376 2.494644 
Mediator of DNA damage checkpoint 
protein 1 Q14676 1.473804 2.688164 
HCG19665, isoform CRA_a A0A024QZF1 1.461629 2.130096 
NF-kappaB repressing factor A3F768 1.457391 2.227948 
Protein PRRC2A P48634 1.452344 1.740385 
AF4/FMR2 family member 4 Q9UHB7 1.417857 3.253733 
Leukocyte receptor cluster member 8 A0A087WUE4 1.416961 2.95401 
Splicing factor, arginine/serine-rich 15 O95104 1.390012 2.213113 
cDNA, FLJ96580, highly similar to Homo 
sapiens hepatoma-derived growth factor 
(high-mobility group protein 1-like) (HDGF), 
mRNA B2RDE8 1.362928 2.720004 
CD2-associated protein Q9Y5K6 1.357271 2.172356 
Lysine-rich nucleolar protein 1 Q1ED39 1.324569 1.586402 
cDNA FLJ37346 fis, clone 
BRAMY2021310, highly similar to 
Transcriptional repressor p66 beta B3KSZ4 1.319931 2.803249 
U2 snRNP-associated SURP motif-
containing protein O15042 1.316139 2.360484 
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Msx2-interacting protein Q96T58 1.312439 2.899443 
Ribosomal protein S19 (Fragment) Q8WVX7 1.309227 2.162313 
Cyclin-dependent kinase 12 Q9NYV4 1.306797 1.441003 
Myb-binding protein 1A Q9BQG0 1.305222 2.680913 
Regulation of nuclear pre-mRNA domain-
containing protein 2 Q5VT52 1.296972 3.497621 
cDNA FLJ75211, highly similar to Homo 
sapiens ubiquitin specific peptidase like 1, 
mRNA A8K1B1 1.290854 1.756735 
Probable JmjC domain-containing histone 
demethylation protein 2C Q15652 1.28818 3.662465 
TNPO2 variant protein (Fragment) Q4LE60 1.283974 2.568543 
Double-strand break repair protein 
MRE11A P49959 1.283543 3.781323 
Origin recognition complex, subunit 2-like 
(Yeast), isoform CRA_a A0A024R411 1.27295 2.53586 
Splicing factor 3B subunit 2 Q13435 1.272198 2.776691 
ESF1 homolog Q9H501 1.255969 3.863564 
Tumor suppressor p53-binding protein 1 Q12888 1.252024 2.029592 
Cactin Q8WUQ7 1.251818 2.613322 
Eukaryotic translation initiation factor 5 P55010 1.235951 1.625504 
Lysozyme C P61626 1.22756 1.359255 
Serine/threonine kinase 38, isoform CRA_a A0A024RD18 1.218952 2.672397 
cDNA, FLJ93224 B2R713 1.21609 1.304024 
Nuclear fragile X mental retardation protein 
interacting protein 2 A1L3A7 1.2153 1.331827 
Shugoshin-like 2 Q562F6 1.192524 1.977134 
Poly(U)-binding-splicing factor PUF60 Q9UHX1 1.190017 2.329497 
cDNA FLJ53206 B4DUT2 1.188667 2.401761 
cDNA, FLJ95650, highly similar to Homo 
sapiens karyopherin (importin) beta 1 
(KPNB1), mRNA B2RBR9 1.181074 1.901562 
FB19 protein Q2L6I0 1.174618 4.155342 
Sex comb on midleg-like protein 2 Q9UQR0 1.169147 2.542609 
RNA polymerase-associated protein RTF1 
homolog Q92541 1.158275 3.185639 
Coatomer subunit gamma-2 Q9UBF2 1.155413 2.637598 
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La-related protein 1 Q6PKG0 1.149616 3.053881 
Transcription initiation factor TFIID subunit 
1 P21675 1.149306 3.599869 
Ubiquitin-specific protease 7 isoform 
(Fragment) Q6U8A4 1.146947 2.863499 
Lysine-specific demethylase 3A F5H070 1.146464 2.782132 
Serine/arginine repetitive matrix 1 isoform 2 
(Fragment) A0A0S2Z4Z6 1.123029 1.772964 
Pre-mRNA-processing factor 40 homolog A P19338 1.111365 2.79678 
MKL/myocardin-like protein 2 O75400 1.098342 1.642213 
cDNA FLJ16777 fis, clone BRHIP2029567, 
highly similar to Cell division cycle 5-like 
protein Q9ULH7 1.081925 1.449427 
Nuclear pore complex protein Nup98-
Nup96 B3KY60 1.081469 2.377513 
WD repeat-containing protein 43 P52948 1.073947 3.756649 
Peptidyl-prolyl cis-trans isomerase-like 4 Q15061 1.068626 2.265753 
Zinc finger CCCH domain-containing 
protein 11A Q8WUA2 1.062828 2.930983 
Transcription elongation regulator 1 O75152 1.061671 1.561305 
Translocase of inner mitochondrial 
membrane 50 homolog O14776 1.059651 2.340964 
CCAAT/enhancer-binding protein zeta A0A024R0M6 1.05109 2.715821 
Microfibrillar-associated protein 1 Q03701 1.043362 2.429041 
ATP-dependent RNA helicase DDX42 P55081 1.034498 1.637678 
Trinucleotide repeat-containing gene 18 
protein Q86XP3 1.033659 2.35692 
Uncharacterized protein C17orf47 H9KVB4 1.031234 1.784598 
Death-inducer obliterator 1 Q8NEP4 1.025556 1.88081 
cDNA FLJ76656, highly similar to Homo 
sapiens scaffold attachment factor B 
(SAFB), mRNA Q9BTC0 1.019607 2.955056 
Probable ATP-dependent RNA helicase 
DDX10 A8K329 1.012194 2.627393 
Importin subunit alpha Q13206 1.010095 2.010998 
Pinin A0A024RDV7 0.99676 1.577388 
Ataxin-2-like protein Q9H307 0.993746 3.264844 
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Coiled-coil domain-containing protein 94 Q8WWM7 0.981437 2.436901 
Zinc finger protein 638 Q9BW85 0.96992 4.663891 
PHD finger protein 6 Q14966 0.96139 2.10817 
Microtubule-associated protein 1B, isoform 
CRA_b A0A0D9SGE8 0.961353 2.945796 
Sentrin-specific protease 6 A0A024RAM4 0.934588 2.872377 
cDNA, FLJ94609 Q9GZR1 0.917343 2.605648 
28 kDa heat- and acid-stable 
phosphoprotein B2R9Y2 0.911135 3.786661 
Putative uncharacterized protein 
DKFZp686I05169 Q13442 0.899499 2.295289 
cDNA FLJ78753, highly similar to Homo 
sapiens zinc fingers and homeoboxes 3 
(ZHX3), mRNA Q6MZP3 0.893272 1.368506 
Thyroid receptor-interacting protein 6 A8K8Q0 0.892876 2.026548 
Serine arginine-rich pre-mRNA splicing 
factor SR-A1, isoform CRA_a Q15654 0.890137 1.910481 
Protein capicua homolog A0A024QZH6 0.881083 3.234565 
Histone deacetylase I3L2J0 0.875791 2.250333 
RNA polymerase II-associated factor 1 
homolog Q6IT96 0.872574 1.315722 
ZNF521 protein (Fragment) Q8N7H5 0.864935 2.153751 
cDNA FLJ59238, highly similar to SNW 
domain-containing protein 1 Q8IYZ2 0.862354 1.414091 
Pleiotropic regulator 1 B4DEG7 0.861419 3.771498 
Protein FAM192A O43660 0.861415 2.34135 
Protein PRRC2C Q9GZU8 0.855652 1.546051 
Replication protein A 70 kDa DNA-binding 
subunit Q9Y520 0.832744 1.656849 
Insulin receptor substrate 4 P27694 0.799467 2.128269 
Squamous cell carcinoma antigen 
recognized by T-cells 3 O14654 0.797072 1.653278 
Protein kinase C-binding protein 1 Q15020 0.791573 2.749668 
Ubiquitin-associated protein 2-like  Q9ULU4 0.786746 2.724188 
Cytoplasmic FMR1-interacting protein 2 Q14157 0.786108 1.853979 
Pachytene checkpoint protein 2 homolog  Q96F07 0.784148 1.855357 
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Fragile X mental retardation autosomal 
homolog variant p2K Q15645 0.782367 2.88105 
Midasin A0A0F7KYT8 0.780846 2.101795 
Tubulin alpha-1A chain Q9NU22 0.759815 2.588918 
Serine/arginine repetitive matrix protein 2 Q71U36 0.755911 3.08486 
Zinc finger protein 687 Q9UQ35 0.753527 2.968319 
Peroxisome proliferator activated receptor 
interacting complex protein Q8N1G0 0.752799 1.655331 
cDNA, FLJ95388, highly similar to Homo 
sapiens step II splicing factor SLU7 
(SLU7), mRNA E1NZA1 0.744879 1.951224 
DNA polymerase eta B2RBA0 0.724464 1.823501 
Tubulin alpha-1C chain Q9Y253 0.722088 1.434936 
ATP-dependent RNA helicase A F5H5D3 0.717359 2.492 
Nucleophosmin isoform 2 Q08211 0.704302 3.308272 
THO complex subunit 2 A0A0S2Z491 0.692535 3.00997 
Heterogeneous nuclear ribonucleoprotein L Q8NI27 0.68892 2.391013 
14-3-3 protein theta P14866 0.685394 1.990324 
Histone acetyltransferase type B catalytic 
subunit P27348 0.670576 3.368625 
TIP41-like protein O14929 0.666057 1.452336 
PRP4 pre-mRNA processing factor 4 
homolog B O75663 0.665711 2.327751 
Parafibromin A0A024QZY5 0.647306 2.93022 
Histone-binding protein RBBP7 Q6P1J9 0.646723 2.033434 
cDNA FLJ75831, highly similar to Homo 
sapiens exportin, tRNA (nuclear export 
receptor for tRNAs) (XPOT), mRNA Q16576 0.644728 1.65272 
Survival motor neuron protein A8KA19 0.644333 2.395685 
General transcription factor 3C polypeptide 
5 E7EQZ4 0.639785 2.350308 
Biorientation of chromosomes in cell 
division protein 1-like 1 Q9Y5Q8 0.634204 2.959526 
cDNA FLJ56176, highly similar to Poly(A) 
polymerase alpha Q8NFC6 0.632562 1.844291 
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cDNA FLJ33964 fis, clone 
CTONG2019029, highly similar to 
Pseudouridylate synthase 7 homolog B4DYF4 0.627714 2.093342 
Beta 5-tubulin B3KRB2 0.605685 1.904993 
Signal transducer and activator of 
transcription 1-alpha/beta Q5SU16 0.603546 2.306446 
Protein CASC5 P42224 0.595479 1.852176 
cDNA, FLJ94025, highly similar to Homo 
sapiens tripartite motif-containing 28 
(TRIM28), mRNA Q8NG31 0.594615 1.993436 
Small acidic protein B2R8R5 0.587359 1.675933 
 
To determine whether there were similarities between the proteins detected in the ZNS5-FLAG 
pulldown and those detected in the ZNS5-BirA Streptavidin pulldown, a list of all ZNS5-FLAG 
interactors from the MaxQuant and PD datasets was constructed within Microsoft Office Excel and 
compared to the high confidence proteins detected in the streptavidin pulldown (available on the 
CD provided in Appendix C; filename ‘masterlists’). This analysis showed that there were only 8 
proteins that were common between the streptavidin pulldowns and the ZNS5-FLAG pulldowns. 
These are shown in Table 24 and 25 with a comparison between their ratios in the FLAG and 
streptavidin pulldowns and their function/description according to Uniprot. 
Table 24: Common proteins between all ZNS5 pulldown high confidence proteins 










O75400 Suppressor of cytoplasmic action 
of WASL/N-WASP by preventing 





P49756 Regulator of pre-mRNA splicing 








Q13442 Enhances the level of fibroblast 
growth in response to PDGFA 









Table 25: Common proteins between ZNS5-BirA high confidence interactors and those not 
found in all three ZNS5-FLAG high confidence interactor datasets 









A0A024RBE7 Plays a structural role within the 
nucleus and predicted to be 





A8K8Y8 Has no known role but has 
mRNA highly similar to 
evolutionarily conserved G-


















Q9Y2F5 Component in the little 
elongation complex which is 







To investigate why there was such a lack of correlation between the two experiments at the 
individual protein level, the streptavidin pulldown dataset was analysed by STRING and DAVID to 
determine whether proteins participating in similar pathways were enriched in the pulldown 
samples. Figure 46 shows the STRING pathway analysis with DAVID functional annotation 







Table 26: DAVID/STRING functional annotation clustering for high confidence interactors of 
ZNS5-BirA 








Cell-cell adhesion 4.48 - 




Cell-cell adhesion was not identified within STRING as it was below the 0.05 false discovery 
rate cut-off. ‘Ribosome/translation’, the functional cluster which had been the highest enriched in all 
previous samples was not present at all in the DAVID or STRING analysis of the streptavidin 
pulldown. An exhaustive list of functional annotation clusters for both the streptavidin pulldown and 
the FLAG pulldown have been presented in table 27. 
Table 27: Functional annotation clusters for ZNS5-FLAG and ZNS5-BirA high confidence 
interactors 
ZNS5-FLAG EASE score ZNS5-BirA EASE score 
Ribosome/ translation 17.16 mRNA processing/ splicing/ 
spliceosome 
12.07 
Histone/ chromatin 13.1 RNA-binding 8.33 
Unfolded protein binding/ 
microtubule 
3.95 Transcription/ transcription 
regulation 
7.2 
Mitochondrial protein/ inner 
membrane 
3.36 Cell-cell adhesion 4.48 





Protein biosynthesis/ RNA 
transport 
2.78 G-patch domain 4.10 
Nucleotide binding/ ATP 
binding 
2.32 Cell cycle/ cell division  4.07 
Unfolded protein binding/ 
DnaJ 
2.03 CID domain 3.21 
Spliceosome 1.3 Zinc finger 2.82 
Cell cycle/ division 1.3 DNA damage/ DNA repair 2.82 
DNA damage/ DNA repair 1.3 Histone modification 2.8 
  Centromere 2.68 
  Histone deacetylation 2.6 
 




 RAN GTPase binding 1.93 
 
 Helicase 1.87 
 
 Transcription factor TFIID 
complex 
1.82 
  Homologous recombination/ 
ds break repair 
1.57 
  SAP domain 1.54 
 
The streptavidin pulldown instead showed an enrichment of highly nuclear functional 
annotation clusters (table 24) and lacked the enrichment of almost all of the individual proteins that 
were shown in the FLAG pulldown. The lack of correlation between the two pulldowns and the 
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novelty of the ZNS5-BirA cell lines and streptavidin pulldown protocol influenced the decision on 
validation targets. 
3.7: Validation 
3.7.1: Validation targets 
The ZNS5 interaction partners chosen for validation were cyclin-dependent kinase 1 (Cdk1) 
and E3 ubiquitin-protein ligase UBR5 (UBR5). Both were found within the FLAG pulldown datasets 
with UBR5 being identified within the high confidence interactors list by the MaxQuant 0.05FDR 
and PD analyses and Cdk1 being detected in the outputs from all three analyses. Both were also 
ZNS5-specific interactors which afforded the chance to show differences in the interactomes of 
both ZIKV and DENV. The log2 t-test difference and –log10 p values are presented in table 28. 
Table 28: Cdk1 and UBR5 log2 t-test differences and –log10 p values for ZNS5, D2NS5, and 
D4NS5 FLAG pulldowns 












Cdk1 1.128808041 1.241630291 0.329683378 1.473690918 0.104311436 0.200287243 
UBR5 1.138352076 1.706456547 -0.10303892 0.817535146 -1.14451909 1.223404439 
 
Cdk1 was a target of interest because control of cell cycle regulation and cell cycle arrest had 
already been shown to be a characteristic of ZIKV infection (209). Cdk1 is involved with progress 
through the G2 and M phases of the cell cycle by interacting with cyclin A and B. The targeting of 
cell cycle regulation is known to occur in other viral infections and whilst in many cases viral 
infection acts to encourage cell cycle progression, viral infection is also known to prevent cell cycle 
progression such as the case of SARS-CoV (210). Cdk1 has also been shown to be linked to 
apoptosis, another key characteristic of ZIKV infection (211). Cdk1 was identified using 10 
peptides, 6 of which were unique peptides, giving additional confidence about its identification. 
UBR5 was of interest because STAT2 is known to be degraded by ZNS5 in a fashion similar to 
DENV-NS5 which involves the use of UBR4 to ubiquitin-label STAT2 and target it for proteasomal 
degradation. UBR4 however was shown previously to not be responsible for this function in ZIKV 
infection. Proving whether UBR5 interacted with ZNS5 was therefore enticing as the close relation 
of ZIKV and DENV as well as their similar methods of STAT2 degradation may well have resulted 
in the use of two E3 ubiquitin-protein ligases from the same family. Within the dataset, it was 
identified using 10 peptides, 2 of which were unique peptides.  
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3.7.2: Validation experiments 
To validate the differential binding of Cdk1 and UBR5 to ZNS5 and DENV-NS5, reverse 
pulldowns were performed using antibodies against UBR5 and Cdk1 (details in Table 4 in 2.3.12) 
with lysates generated from 293-Flp, D2/4NS5-FLAG, and ZNS5-FLAG cells which had been 
exposed to doxycycline (1μg/ml) for 4d. The pulldowns were then done on the lysates using the 
specific antibodies and Protein G beads as described in 2.3.11. After the final wash step, proteins 
were eluted from the beads by heating to 95 ⁰C for 10 min. The eluate was recovered and kept 
while the beads were discarded. Western blots were then performed using these samples probing 
with the anti-FLAG antibody to detect whether ZNS5 or D2/4NS5 were present within the final 
samples. 
 
As Figure 47 shows, the Cdk1 pulldown was deemed successful with Cdk1 being detected in 
both pre- and post-pulldown samples. The anti-FLAG antibody detected a band at the size 
expected for NS5-FLAG, not only for ZNS5 but also to a lesser extent for D2NS5 and an even 
lesser extent for D4NS5. The result confirmed the proteomic analysis as ZNS5-FLAG had the 
highest enrichment of Cdk1 with D2NS5 also showing a smaller enrichment although that was not 
statistically significant in MaxQuant 0.01FDR and PD datasets (table 28). 
124 
 
Due to the size of UBR5 (~309 kDa), wet transfer was used for the Western blot procedure in 
an attempt to detect UBR5 in the pulldown samples, however it was not possible to obtain a 
successful western blot for UBR5 before the project ended. Despite this, the samples were probed 
with the anti-FLAG antibody to investigate whether there was any indication of ZNS5-FLAG 
present in the post-pulldown samples. Figure 48 shows the anti-FLAG probes of the UBR5 
pulldown samples. 
 
Figure 48 shows that ZNS5-FLAG was detectable within the UBR5 post-pulldown samples 
whereas D4NS5-FLAG was not. D2NS5-FLAG was present at a very faint level in the post-
pulldown sample. However there was a clear loading difference within, at least, the pre-pulldown 
samples. The proteomic analysis showed UBR5 was enriched significantly within ZNS5-FLAG 






4.1: The importance of a direct comparison of NS5 interactors 
Currently there is only one study that reports a large scale interactomic analysis of multiple 
NS5 proteins. Using Y2H analysis, Le Breton et al (143), investigated the cellular interaction 
partners of NS3 and NS5 for multiple flaviviruses, however an extensive comparison between the 
different flavivirus proteins (for either NS3 or NS5) was not done, instead pooling all flavivirus NS5 
interactors from the tested species. Multiple individual NS5 interactomic studies have been 
performed using; computational prediction (212, 213), Y2H (143, 170, 214), and tagged co-IP (171, 
215) however none of these studies been done in tandem with two flavivirus species or serotypes 
of a single flavivirus. Past studies have been used collectively to discover common interactors for a 
specific NS5, but each study can have profound experimental differences to another that affect the 
reliability of being able to compare two individual studies, even when using the same technique. 
The direct study reported here, using the same methods and side-by-side processing of samples 
grants a much more robust comparison than previously possible across different studies. It also 
used the approach of quantitative proteomics rather than using approaches that provide purely 
qualitative data. Alongside this, the direct comparison of the same samples using different 
proteomics programmes at different settings and for the same NS5 protein using two different 
methods of pulldown-proteomics granted insight into the reliability of comparing different studies. 
The use of stably transformed 293-Flp cells and co-IP LC-MS/MS meant that the NS5 proteins 
could be expressed at more physiologically relevant levels and naturally localised, unlike in 
previous Y2H studies.  
4.2: ZNS5 damages cell health 
Analysis of the stably transfected cell lines produced in this study by western blotting (Figure 
17) and IFA analyses (Figures 16 and 18), suggested that the cells expressed ZNS5 as intended. 
However it was observed that there was a drop in cell viability on day 6 and 8 after doxycycline 
induction of ZNS5 (as evidenced by the phase contrast images of the cells used in the IFA in 
Figure 16) that was not seen for the DENV-NS5 cell lines (data not shown). The cells became 
rounded and grew very slowly, as a population, beyond 4 days of doxycycline exposure, along with 
a number of them becoming detached, a sign of 293-Flp cell death. At first, it was assumed that 
perhaps high expression levels of ZNS5 caused cellular toxicity, but the recent literature has 
repeatedly reported that apoptosis and cell cycle cessation at a sub-G1 phase is a hallmark of 
ZIKV infection, suggesting that NS5 may play an important role in this process (54). The later 
discovery that ZNS5 interacted with proteins involved in cell cycle regulation/apoptosis, as well as 
DNA damage/repair pathways (another hallmark of ZIKV infection due to the formation of pyknotic 
nuclei) suggested that at least some of the damage to cell health that occurs in ZIKV infection 
appears to be due to the action of the NS5 protein. A recent study on the interactomics and 
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transcriptional effects of individual ZIKV proteins, to investigate their apoptotic effect, did not 
include NS5. This was due to the lack of apoptotic phenotype seen in one of the study’s early 
experiments, however this is in direct opposition to what was seen for the ZNS5-FLAG cell line 
developed in this study (216). The previous study, however, used fission yeast cells instead of 
human cells, which are far less biologically relevant and may have lacked key interactors and it 
also reported that NS5 had no distinct localisation within the yeast cells as seen in IFA analysis 
which goes against both previous literature (217, 218) and what was seen in Figures 16 and 18. 
4.3: The validity of the ZNS5-BirA cell line 
The lack of an effective antibody recognising the ZNS5-BirA protein (as shown by Figures 21, 
22, and 23) meant that direct detection of ZNS5-BirA in 293-Flp cells to validate ZNS5-BirA protein 
production was not possible. A functional biotinylation assay (Figure 24) and RT-PCR (Figure 25 
and Appendix B) were used to prove that the whole gene was being transcribed and that the 
ZNS5-BirA protein was produced. As Figure 24 shows, biotin labelling only occurred when ZNS5-
BirA cells were incubated with both doxycycline and biotin, which suggested that the BirA tag was 
being expressed and functioning as expected. However the lack of an effective antibody 
recognising ZNS5-BirA precluded protein localisation studies. The D2NS5-FLAG and D4NS5-
FLAG cell lines have previously been used for NS5 localisation studies (159). As such the ZNS5-
FLAG cell line was analysed by IFA (Figure 18) which not only tested the control of the 
doxycycline-induced expression, but also confirmed that the ZNS5-FLAG protein localised as 
previously reported for ZNS5 expressed in Vero and HEK-293 cells (217, 218). As epitope tags 
and modifications can alter protein localisation, it was important to check that the localisation of 
ZNS5-BirA was unaffected in the new cell lines. Due to the lack of functional antibody, this was not 
possible to do before the end of the project. Therefore, this was one of the factors taken into 
account when targets identified by proteomic analysis were selected for validation. As the cellular 
localisation of ZNS5-FLAG could be confirmed, the interaction partners identified from pulldown 
using ZNS5-FLAG were given precedence for validation. The ZNS5 protein was recently 
expressed as a BirA fusion in HEK-293 cells by Coyaud et al (218). However the FLAG tag epitope 
was also fused to the protein, allowing IFA confirmation of ZNS5 protein localisation to the nucleus 
and cytoplasm. Whilst the BirA tag can clearly be added to the protein without affecting 
localisation, it was not possible to conclusively state this for the ZNS5-BirA produced in this study. 
4.4: Reliability of FLAG and streptavidin pulldowns based on 
bioinformatic analysis 
The proteomic datasets produced using the anti-FLAG antibody and streptavidin pulldown 
samples showed a high correlation, in terms of the relative amounts of identified proteins between 
replicate sample groups, as shown by the scatterplot graphs and accompanying Pearson’s 
Correlation values (Figures 32-34, 45) with less correlation seen between the data produced using 
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samples derived from cells expressing different NS5 proteins (data not shown), as would be 
expected. The protein search list provided to MaxQuant and PD for protein identification included 
the Uniprot human proteome and the sequences of the ZNS5, D2NS5, and D4NS5 proteins used 
in this study. The respective viral NS5 proteins were amongst the top hits in each corresponding 
dataset, confirming the presence of the proteins in each pull-down sample and their identification 
by LC-MS/MS and MaxQuant/PD analysis. The identification of the NS5 proteins added confidence 
to the results, as western blotting (Figure 26) had already shown the success of the pulldowns in 
enriching the NS5-FLAG proteins in the samples. Proteomic analysis of the streptavidin pulldown 
samples also showed an enrichment of the ZNS5-BirA protein. As BirA acts as a proximity-labelling 
tag, it could have biotinylated the ZNS5 protein it was fused to or other molecules of ZNS5-BirA 
that had localised to the same area intracellularly. 
The identification of known NS5 interactors in the datasets is one means to provide validity to 
the results. STAT2 is the most well characterised interaction partner of the DENV-NS5 and ZNS5 
proteins (88, 168) and was previously found to interact with high-confidence with DENV-2 and -4 
NS5, using the same cell lines used in this study in a SILAC based proteomic analysis (Dr A. 
Davidson, personal communication). However, puzzlingly, STAT2 was not identified as an 
interaction partner for any of the NS5 proteins examined in this analysis. It may have been that 
STAT2 was targeted for degradation by NS5 within the cells before the pulldown experiments took 
place. Alternatively, differences in the TMT labelling and SILAC based proteomic approaches may 
result in different interaction datasets. Another known interactor of DENV-2 NS5 is ELKS/ERC1, 
which has been identified in numerous NS5 interaction studies (143) including the previous SILAC 
based study in the laboratory, albeit not as reproducibly as for STAT2. However, once again, this 
interaction partner was not identified in the pull-down samples for DENV-2 or the other NS5 
proteins. It is unclear whether ELKS/ERC1 was not present in sufficient amount in the samples or 
the MaxQuant/PD bioinformatic analysis failed to identify the protein from the peptide spectral data. 
Nevertheless, a number of specific interactors of DENV-NS5 were identified within the FLAG 
pulldown samples by proteomic analysis including the; DnaJ proteins, MCM7, YBOX proteins, DDX 
proteins (171), PPIases (172), Hsp90 (219, 220), and eukaryotic initiation factors (221) which 
added confidence and reliability to the datasets generated in this study. The questions raised in 4.3 
to do with whether the ZNS5-BirA was functioning/localising properly could also explain why that 
dataset saw none of the key interactors that we might expect to see like endosomal proteins, 
ER/ER-stress related proteins, and translation/ribosome proteins (218). Cell cycle proteins and 
RNA/DNA processing proteins were however enriched within the streptavidin pulldowns but due to 
the nature of proximity labelling, the 18h biotin incubation, and the unconfirmed localisation 
discussed in 4.3, the specificity of this labelling is questionable. 
In addition to the identification of specific proteins, the identification of groups of proteins 
belonging to specific cellular pathways by gene ontology enrichment and network analysis is 
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another way to provide confidence in the interactomic results. Individual proteins can be 
misidentified in MS/MS proteomic analysis but in a holistic view, it is expected that the majority of 
proteins would be correctly identified. Analysis of the full set of data together, rather than based on 
individual interactors would therefore give insight into whether proteins involved in the pathways 
and cellular processes reported to be affected by NS5 were present in the pulldown-proteomics 
results. The DAVID (in 3.6.2; Tables 9-18) and STRING analyses (presented in Figures 35-43), 
revealed the proteins associated with functional annotation terms that were enriched in the 
pulldown samples. Proteins interacting with D2NS5 were enriched for ribosomal proteins as well as 
proteins participating in the UPR. Proteins in both of these processes have previously been 
reported as being enriched in DENV-NS5 interaction studies. Proteins interacting with D4NS5 also 
showed an enrichment of ribosomal proteins as well as RNA processing/splicing proteins which 
has also been previously identified as a process targeted by DENV-NS5 (171). DENV-NS5 has 
also been previously shown to interact with proteins participating in pathways involved in the 
cytoskeleton and in chromatin/histones (212, 215) which was also the case in this study. ZNS5 has 
been previously linked to cell cycle arrest, DNA damage, and chromatin/histones (213) and so the 
enrichment of cell cycle regulation proteins, DNA damage/repair proteins, and histones/chromatin-
related proteins as determined by DAVID also added confidence to the results of the proteomic 
analysis (Table 18).  
4.5: Differences and similarities between the ZNS5 and DENV-NS5 
interactors 
Using the full functional annotation clustering provided by the DAVID analysis, it was possible 
to already identify similarities and differences between the high confidence interactor lists that were 
generated from the different NS5 pulldown and subsequent TMT-MS/MS experiments. As shown in 
Table 18, there is a great deal of similarity in the functional annotation clustering analysis of the 
high confidence interactors of each NS5 protein. For example; ‘ribosome/translation initiation’ is a 
common and highly enriched functional annotation cluster defined for all three NS5 proteins. 
However there are also differences. Proteins interacting with D2NS5 included those associated 
with the functional annotation cluster of ‘rotamase/isomerase’ that was not observed for D4NS5 
and ZNS5. Rotamases/isomerases include PPIases (previously mentioned in 4.4) like cyclophilins 
and other prolyl isomerases which have previously been reported to interaction with D2NS5 (172). 
Closer analysis of the proteomic data showed that, although D4NS5 and ZNS5 both had 
rotamases/isomerases within their high confidence interactors list, D2NS5 had a greater number 
that were significantly enriched. Another clear difference between the interactomic data was the 
presence of proteins associated with the functional annotation cluster ‘cell-cell adhesion’ in the 
DENV-NS5 but not ZNS5 interactome. Although not particularly highly enriched, the D2/4NS5 
interactomes did include more high confidence interactors that were classed within this cluster; 
plasminogen activator inhibitor 1 RNA-binding protein and GTP-binding nuclear protein Ran. Not 
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much is known about the function of the former besides its interaction with cadherin and a potential 
role in stabilising mRNA but Ran is a GTP switch which has been shown to be a host interactor 
with other human viruses (222). It has roles in numerous pathways within the cell, most notably the 
import and export of RNA and proteins from/to the nucleus. Although identified within the ‘cell-cell 
adhesion’ cluster, the interaction of the D2/4NS5 proteins with Ran would much more likely be for 
the manipulation of this host pathway, rather than of cell-cell adhesion.  
Non-POU domain-containing octamer-binding protein (NONO), which was identified as an 
interactor of D4NS5 and not ZNS5 (Table 21), is an upstream regulator of cGAS-STING; a protein 
which is already known to interact with DENV (223). It was also shown to interact with DENV-2 
RNA during another proteomic study (224). Both D4NS5 and ZNS5 have interaction partners that 
are involved in DNA damage/DNA repair processes that link to ROS damage which is not 
unexpected, as DENV and other flaviviruses are known to cause oxidative stress in the cells they 
infect (225). A number of DNA damage/DNA repair proteins that interacted exclusively with D4NS5 
were not specifically DNA repair proteins but were instead linked to the process of cell cycle 
progression. DNA damage does play a role in suppressing cell cycle progression, however cell 
cycle regulation interference is a common attribute of numerous viral infections and so the higher 
enrichment of DNA repair/DNA damage proteins as D4NS5 interaction partners may have resulted 
from an increased level of cell cycle regulation proteins being detected. The D4NS5 interactors did 
however include ds break-related proteins; the reason for which is unknown. 
Unlike D2NS5 and ZNS5, the D4NS5 interaction partners were not enriched in mitochondrial 
proteins. Multiple DENV serotypes, including DENV-2, are already known to have an effect on 
mitochondria (223) and so the enrichment of mitochondrial proteins as D2NS5 and ZNS5 
interaction partners, albeit weakly, was not unexpected. Proteins interacting with D4NS5 however, 
failed to show any signs of enrichment for mitochondrial proteins. The enrichment of ATPases and 
ribosomal proteins as interaction partners for all three NS5 proteins may have been the result of 
the weak detergent conditions used for the pulldown assays, which failed to break the interactions 
between multimer constructs such that an interaction with a single protein within the complex 
would result in the pulldown of numerous attached proteins.  
Beyond differences in functional clustering analysis, there were individual protein differences 
and similarities of interest due to the evidence in the literature associating them with NS5, although 
the significance of the interaction, as well as the confirmation of the interactions, needs further 
study. For example, RNA helicases in the DDX protein family are known to interact with D2NS5 
(214) and in this study D2NS5 interacted with DDX39 with high confidence which has not been 
previously described, whereas D4NS5 interacted with DDX55 which is known to restrict the 
replication of other viruses (226). DDX17; an RNA helicase that is also well-documented for being 
a target for viruses such as the reported interaction with influenza virus polymerases (227) was 
enriched in one replicate of the ZNS5 FLAG-pulldown although it did not make the high confidence 
130 
 
interactor list. Its interaction with DDX5 is particularly important within viral infection (228). 
Therefore, taking the proteomic data at face value would suggest that all three NS5 proteins 
potentially interact with RNA helicases and seem to predominantly interact with different members 
of that family. 
In addition, both ZIKV and DENV cause oxidative stress as previously mentioned and both 
D2NS5 and D4NS5 interacted with AOX1 with high confidence; a mitochondrial protein which 
functions to reduce oxidative stress by removing ROS. Once again, more investigation would be 
needed to confirm this interaction and the significance and outcome of the interaction if any as 
higher levels of AOX1 within the pulldown samples could be from a higher level of AOX1 
expression in response to oxidative stress caused by DENV-NS5. ZNS5 however, interacted with a 
greatly reduced level of AOX1 when compared with the two DENV NS5 proteins, although it did 
still show a slight but not statistically significant enrichment compared to control cells. 
Other examples of differences between the two species include ZNS5’s apparent higher affinity 
for COA5; an important mitochondrial assembly factor for cytochrome c oxidase, and the 
interaction of ZNS5 with SAMHD1 which has previously been implicated in viral disease and yet 
was not shown to be enriched within either the D2NS5 or D4NS5 pulldown data. 
Therefore, despite the differences in individual proteins identified to interact with the NS5 
proteins (as shown by tables 6 and 7), a holistic view of the data reveals a high overall level of 
similarity in the pathways and host cell processes that both the DENV and ZIKV NS5 proteins 
interact. Even with the inaccuracies that are known to occur with proteomic analysis, the results fit 
with what may be expected for two closely related species; the same pathways are targeted but 
with some differences at the individual protein level. Although the ZNS5 interactome may be less 
reliable, the clear similarities between it and DENV-NS5’s high confidence interactome, as well as 
the presence of proteins previously identified to be viral targets, allowed a level of confidence in the 
results. 
4.6: Streptavidin pulldown compared to FLAG pulldown 
As discussed in 4.3 and 4.4, there are limitations to proteomic analysis and there were some 
questions regarding the reliability of the BioID labelling that was attempted using the ZNS5-BirA 
cell lines. As previously mentioned, three independently-raised cell lines were used as triplicate 
replicates to provide more confidence in the analysis. Western blot analysis (figures 24 and 27) 
showed that the BioID labelling functioned only under the control of doxycycline and when biotin 
was available. The streptavidin pulldown technique was not previously developed in the laboratory 
and had to be adapted from previous examples of streptavidin pulldowns used in studies that 
focused on fractionated samples, rather than whole cell lysates, however the presence of 
biotinylated proteins within the pulldown samples (as shown in figure 27) gave reason to believe 
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that the process had worked. However, for optimal results, a cell line expressing ZNS5-BirA with 
confirmed correct localisation would need to be used.  
The data shown in table 10 along with the comparison in table 24 revealed differences between 
the datasets generated using the ZNS5-FLAG and ZNS5-BirA pulldowns. Proteins identified to 
interact with ZNS5-FLAG were deemed to have a more widespread localisation within the cell 
according to the functional annotation clusters that were shown in Table 27, which is consistent 
with previous literature. By contrast, the proteins interacting with ZNS5-BirA were almost 
exclusively classified as belonging to nuclear-based functional annotation clusters. The G-patch 
domain, CID domain, zinc finger domain, FHA domain, and SAP domain (shown in Table 27) are 
all domains commonly found within RNA/DNA binding proteins and so are generally found in 
nuclear-localised proteins. A recent study by Coyaud et al (218) utilised BioID labelling to identify 
proteins interacting with ZNS5 within HEK293 cells and found functional annotation cluster 
enrichment within translation/RNA processing, splicing machinery, and chromatin 
binding/regulation which is highly comparable to the level of RNA/DNA-processing proteins shown 
in tables 26 and 27. The same study reported an interaction with the Cajal body within the nucleus 
as defined by the labelling of coilin; a high confidence interactor in the streptavidin pulldown as 
shown in table 23. 
The streptavidin pulldown would have been expected to show a large overlap with the 
interactors identified by the FLAG pulldown, with additional protein identifications signifying non-
specific, close proximity proteins and transient interactors. However, as tables 24 and 25 report, 
there were only eight common proteins between the two interaction datasets. Tables 24 and 25 
also show that the common proteins were almost exclusively nuclear in their cellular distribution, 
with the exception of the 28kDa heat- and acid-stable phosphoprotein. As BioID-labelling 
covalently links biotin to the targeted protein, the lack of purely cytoplasmic interactors suggested 
that the ZNS5-BirA protein was not functioning/localising comparably to the ZNS5-FLAG protein. 
The study from Coyaud et al also reported an enrichment of endosomal proteins and ER proteins 
and, although they reported a greater enrichment of nuclear proteins compared with their co-IP 
pulldown, endosomal and ER proteins were not seen within the proteomic data generated here. It 
was therefore not possible to confidently compare transient and stable interactors within the scope 
of this project using the ZNS5-BirA cell line, due to questions regarding the reliability of the 
localisation/function of the protein. 
4.7: Cdk1 and UBR5 
The functional annotation cluster analysis performed using DAVID was, in part, used for 
validation target selection as well as the comparative studies described in 3.7.1. Both Cdk1 and 
UBR5 are relatively well studied proteins which meant they had well-defined mechanisms of action 
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and, as antibodies that recognised them were commercially available, they were deemed suitable 
targets for validation experiments within the timeframe of this project. 
The reverse pulldowns using the anti-Cdk1 and anti-UBR5 antibodies were partially successful. 
Cdk1 was successfully pulled down as shown by western blot (Figure 47), however the large size 
of UBR5 required a change in the protein transfer protocol which delayed a successful blot beyond 
the timespan of this project. The pulldown protocol used for UBR5 was the same as that 
successfully used for Cdk1, however the procedure ultimately required correct recognition of UBR5 
by the anti-UBR5 antibody, which could not be confirmed.  The commercially available antibody 
used had, however, been validated for use in the immunoprecipitation protocol used in this study.   
The results of the anti-FLAG western blot analysis on the Cdk1 pulldown showed the presence 
of NS5-FLAG in all three NS5-FLAG samples, implying an interaction with both DENV-NS5 and 
ZNS5. In contrast, the proteomic data did not identify Cdk1 as a high-confidence interaction partner 
for either DENV-NS5 protein. As the two procedures were done with different antibodies (ie anti-
FLAG vs anti-Cdk1) the results raises questions about the specificity of the interaction of the Cdk1 
antibody for the NS5 proteins. DENV infection, unlike ZIKV, does not show signs of cell-cycle 
cessation although, as described in table 20, Cdk1 does have numerous roles within the cell 
including interactions with HSP70 family members, which are known to interact with DENV NS5 
(229). However, identification of NS5-FLAG within the Cdk1 pulldown western blots for all viruses 
(Figure 47) did go against the quantitative results seen in the MS/MS proteomics. 
If it is taken that the UBR5 pulldown was successful, then the results shown in figure 48 are 
promising. However, there is a clear loading issue with the NS5-FLAG quantities, at least in the 
pre-pulldown samples, and this places the result into contention such that it needs to be repeated. 
ImageJ analysis suggested that ZNS5 does pulldown more UBR5 than D2NS5 with the ZNS5-
FLAG band in Figure 48 having a relative density of 1.152 compared with the D2NS5-FLAG band 
when adjusting for the variation in pre-pulldown levels of NS5-FLAG. This is a far smaller 
difference than suggested by the quantitative proteomic analysis within the FLAG pulldowns. The 
wide variation in quantitative data in the proteomic analysis for UBR5 in the two replicates of 
D2NS5 (-2.95 and -4.13) means it was not possible to draw a reliable conclusion regarding the 
level of interaction based on proteomic analysis alone, however the western blot and subsequent 
ImageJ analysis suggested a weaker (but detectable) interaction than for ZNS5. For D4NS5, UBR5 
was only identified in one of the pulldown replicates, so it was not possible to determine the level of 
interaction from the proteomic analysis, although the result of the western blot shown in Figure 48 




4.8: The limitations of proteomic data 
4.8.1: The general concept of pulldowns/TMT-MS/MS 
There are numerous limitations to TMT-MS/MS proteomics. As mentioned in 3.6.1, MS/MS 
proteomics is based on prediction. Raw MS/MS data is generated and then proteomic programmes 
assign the peptide fragments to a specific protein or protein group (if a number of protein isoforms 
are all matched by the peptide) based upon a match between the peptide spectrum and a 
theoretical spectrum generated in silico using a protein search list. The predictive nature of MS/MS 
proteomics gives rise to the possibility of both false positives and false negatives. Therefore, even 
with the validations done on the dataset such as those performed in 3.7.2, all proteins of interest 
would ideally be experimentally validated as interaction partners by complimentary approaches 
before they can be confidently considered more than just predicted interactors. With the use of a 
protein search list from a well annotated organism and rigorous MS/MS analysis, it would be 
expected that a significant portion of the predicted proteins are correctly assigned and pathways 
analysis using bioinformatic resources such as STRING or DAVID would be a potential next step in 
analysing cell processes targeted by viral proteins. However, the analysis can still be skewed by 
the limitation that the pulldown technique, except for the case of the streptavidin/biotin pulldown, 
doesn’t use strong detergents to disrupt non-specific binding or protein complexes as the detergent 
will disrupt antibody-protein binding. This means that interactomic datasets produced using 
techniques which employ mild detergents, such as the anti-FLAG pulldowns, contain protein 
complexes and non-specific binders that can affect the pathways analysis. D2NS5 is known for 
interacting with ribosomal complexes in tagged pulldowns (215), leading to enrichment of those 
proteins in STRING and DAVID, as shown in Figures 35-43 and Tables 9-18. However, DENV-
NS5 likely only interacts with one or two of those proteins, with the rest being pulled down because 
of strong protein-protein interactions within the ribosomal complex. The biotin/streptavidin pulldown 
approach was adopted in this study as a means to identify proteins that bind directly or indirectly 
but are in close proximity to the BirA tagged protein. The very high binding affinity of biotin for 
streptavidin allows for the use of detergents strong enough to dissociate protein complexes and 
any non-specific binders from the captured proteins. The use of the BirA tag as a proximity 
labelling tag can still lead to the identification of false positives as the biotinylation reaction does 
not distinguish between the close proximity generated by protein-protein binding and close 
proximity caused by naturally protein-dense areas. In addition, the use of an 18h incubation period 
for protein biotinylation means the BirA tag has the potential to come into close proximity with 
numerous non-interactors. The streptavidin pulldown samples were therefore expected to contain 
more specific interactors from the ZNS5-FLAG pulldown list as well as extra proteins that would be 
either proteins that came into proximity through close localisation but no interaction or those that 
transiently/weakly interacted with ZNS5 and so would have dissociated from ZNS5 in the weak 




Part of this study looked at the differences between a FLAG pulldown processed through both 
MaxQuant and Proteome Discoverer as well as looking at the differences between 0.01FDR and 
0.05FDR within MaxQuant. All of the datasets used the same protein search list to ensure the only 
difference would be how each programme assigns the peptide fragments it detects. A direct 
comparison between the differences between the initial data from all three datasets was shown in 
Table 5 with a comparison of high-confidence interactors obtained after further processing shown 
in table 6. The differences using the 0.01FDR and 0.05FDR values were as expected, processing 
with a 0.05FDR yielded a higher number of identifications compared with a 0.01FDR. However, the 
differences between MaxQuant and Proteome Discoverer were far greater, with the initial protein 
identifications made with Proteome Discoverer (shown in table 5) containing considerably more 
proteins than when the data was processed with MaxQuant at both FDRs. The differences were 
less extreme once the data was further filtered to produce high confidence protein lists (as shown 
in table 6) however, when the high confidence proteins were compared it was clear that Proteome 
Discoverer and MaxQuant were detecting largely different groups of proteins as high confidence 
interactors. Comparisons between the datasets produced using MaxQuant at the two FDRs 
showed roughly twice as many common high confidence proteins as the comparison between 
Proteome Discoverer and MaxQuant at either FDR, with only roughly a third of each high 
confidence list being common across all three datasets. While this increased the confidence in the 
common proteins identified in all analyses, the results also highlighted how the use of different 
proteomic software packages influenced the resultant datasets. As discussed in 4.8.1, the concept 
of TMT-MS/MS proteomics relies on prediction and there will always be some false positives and 
false negatives identified, but the large extent of the differences occurring due to differences in the 
bioinformatic analysis is highlighted in the comparison performed in this study with only a small 
fraction of interactors being picked up reliably between different programmes. 
The comparison of proteomic bioinformatic programmes performed in this study does have the 
limitation that it was not possible to conclusively determine which programme and FDR performed 
the best. What can be concluded however, is that a stricter FDR can exclude relevant interactors if 
they are weakly identified and that there definitely is a large difference in the proteomic results 
depending on which programme is used to process the raw MS/MS data; a difference that is large 
enough to have an effect even at the level of full data analysis as evidenced by the STRING 
(Figures 35-43) and DAVID analysis (Tables 9-18). Given the differences in the results of the 
proteomic analyses the most reliable identifications are undoubtedly those common to all analyses, 




4.9: Future directions 
There are a number of potential future directions this project could progress in. The most 
important future step would be the confirmation of the UBR5 pulldown to determine if there is a 
specific interaction with ZNS5. Next would be to perform FLAG pulldowns once again on the NS5-
FLAG cell lines to then determine via western blot whether Cdk1 was present in all pulldowns or 
whether the FLAG proteomic data showed a much more representative reflection of which NS5 
proteins interacted with Cdk1. The specificity of that interaction would be important for determining 
the accuracy of the quantitative aspects of the proteomic analyses. This project has already 
revealed a notable difference in protein identification between different proteomic programmes and 
even different FDRs within one single programme and whether there is also an issue with reliable 
quantitative information would be important to know. Using the same pulldown sample for both 
western blots and proteomics side-by-side would allow for a better controlled test of the quality of 
protein identification from MS/MS proteomics. 
Another further step, upon confirming the ZNS5/UBR5 pulldown, would be to analyse whether 
UBR5, ZNS5, and STAT2 all co-localise using IFA imaging as well as performing a UBR5 knock-
down in ZNS5 cells to see whether STAT2 levels were affected. In this way it would be possible to 
determine whether ZNS5 utilises UBR5 to degrade STAT2. 
The ZNS5-BirA cell lines showed promise in that the proximity-labelling proved to be successful 
however without a functioning antibody that can be used to test the localisation of the ZNS5-BirA 
protein, further work on that cell line raises questions about the validity of the interactions detected. 
Potentially, the cell line could be remade with the inclusion of a FLAG tag in the ZNS5-BirA fusion, 
or a more specific antibody could be generated.  
Further validations could also be made using reverse pulldowns (as in 3.7.2), siRNA knock-
downs, or fluorescent imaging co-localisation analysis to confirm the interaction of other 
representative proteins within the MS/MS proteomic datasets. 
The use of robust controls within experiments is vital for the validity of the findings. However, 
within this project, numerous experiments did not have the appropriate controls and so repeating 
those experiments with the proper positive and negative controls would be required. These are as 
follows: 
 Figure 16 and 17 – The introduction of a ‘day 0’ sample showing the expression of 
ZNS5-FLAG in the absence of doxycycline as well as including a 293-Flp cell line which 
contains no ZNS5-FLAG gene and a known expresser of the FLAG; either a 293-Flp 
cell line with solely the FLAG tag introduced into the Flp site or the previously-
documented DENV-NS5-FLAG cell lines which have already been shown to express 
selectively under doxycycline control to ensure the specificity of the FLAG antibody. 
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Both of these controls would be treated to the same conditions as the samples in terms 
of doxycycline exposure. 
 Figure 21 and 22 – The inclusion of a positive control would greatly strengthen these 
results but the lack of proven antibody to both ZNS5 and BirA meant that it was not 
possible. Recreating the cell line using a ZNS5-BirA-FLAG construction would allow for 
the use of the already-tested FLAG antibody to function as our positive control for both 
the BirA and ZNS5 antibodies to determine their functionality against. 
 Figure 23 – The ZNS5-FLAG ‘4 days’ and ‘6 days’ samples acted as positive controls 
for this experiment however the failure to include a negative control in the form of lysate 
from 293-Flp cells treated to 4 days doxycycline as per the test samples C3, C4, and C5 
needs to be rectified. 
 Pulldowns – In all performed pulldown experiments in this study, the 293-Flp cell line 
was used as a negative control however it was not the most appropriate nor effective 
control. A far better control would have been to run simultaneous pulldowns from lysed 
NS5-FLAG cell lines using antibodies against proteins known to not interact with NS5, 
like GAPDH, to determine whether the presence of the NS5-FLAG proteins in the 
pulldowns in Figures 47 and 48 was due to NS5/Cdk1 and NS5/UBR5 interactions as 
had been originally assumed or non-specific interactions between NS5-FLAG and the 
antibody-bead constructs. Ideally the antibodies used would be similar to those using in 
the pulldowns; IgG mouse antibodies for the Cdk1 pulldown and IgG goat for the UBR5 
pulldown, to create as close to the same environment as the pulldowns as possible 
except for the target of the antibody and so the bound protein for NS5 to interact with. In 
that way, the specificity of the protein-protein binding can be confirmed. 
These changes would significantly improve the validity of the findings of this study and 
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6.1: Appendix A – Recipes 
 6.1.1: Cell culture 
Growth media (GM): 
- Dulbecco’s modified eagle’s medium (DMEM) + Glutamax 
- 10% FBS 
- 0.1mM non-essential amino acids 
 
Luria broth (LB): 
- 10g bacteriological peptone 
- 5g yeast extract 
- 5g NaCl 
- Up to 1L ddH2O and autoclave 
 
LB agar: 
- 10g bacteriological peptone 
- 5g yeast extract 
- 5g NaCl 
- 1g agar powder 
- Up to 1L ddH2O and autoclave 
 
 6.1.2: DNA/RNA techniques 
10x TBE buffer: 
- 108g Tris base 
- 55g boric acid 
- 40ml 0.5M EDTA 





1% agarose gel: 
- 1g agarose powder 
- 100ml 1xTBE 
 
 6.1.3: Protein techniques 
6x sample buffer: 
- 1.2g SDS 
- 7ml 0.5M Tris-HCl pH6.8 
- 3ml glycerol 
 
0.5M Tris-HCl pH6.8: 
- 6g Tris base 
- 100ml ddH2O 
- Adjust to pH6.8 with conc. HCl 
 
1.5M Tris-HCl pH 8.8: 
- 36.3g Tris base 
- 200ml ddH2O 
- Adjust to pH8.8 with conc. HCl 
 
4% paraformaldehyde: 
- 40g paraformaldehyde powder 
- 1L PBS 
- Dissolve using conc. NaOH and heat 
- Adjust to pH6.9 with conc. HCl 
 
Coomassie Brilliant Blue dye: 
- 0.575g Coomassie Brilliant Blue R-250 powder 
- 200ml methanol 
149 
 
- 50ml acetic acid 
- 250ml ddH2O 
 
Coomassie destain solution: 
- 50ml glacial acetic acid 
- 350ml ddH2O 
- 100ml methanol 
 
10% resolving SDS PAGE gel: 
- 2.3ml ddH2O 
- 1.3ml 40% polyacrylamide 
- 1.3ml 1.5M Tris-HCl pH8.8 
- 50μl 10% SDS 
- 50μl 10% APS 
- 3μl TEMED 
 
5% stacking SDS PAGE gel: 
- 2.4ml ddH2O 
- 0.5 ml 40% polyacrylamide 
- 1ml 0.5M Tris-HCl pH6.8 
- 40μl 10% SDS 
- 40μl 10% APS 
- 4μl TEMED 
 
10x SDS PAGE running buffer: 
- 30.275g Tris base 
- 144g glycine 
- 50ml 20% SDS 
- Up to 1L with ddH2O 
 
1x transfer buffer: 
- 100ml methanol 
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- 12.5g Tris base 
- 5.63g glycine 
- Up to 500ml with ddH2O 
- Adjust to pH8.3 with acetic acid 
 
Western blot blocking solution: 
- 2g skim milk powder 
- 40ml 0.1% tween (PBS) 
 
Streptavidin western blot blocking solution: 
- 5% BSA in 0.1% tween (PBS) 
 
10x TBS: 
- 12.125g Trizma HCl 
- 40.0g NaCl 
- Up to 500ml ddH2O 
- Adjust to pH7.6 with conc. HCl 
 
Pulldown lysis buffer: 
- 1ml 10xTBS 
- 10μl 500mM EDTA 
- 1ml 10% triton X-100 (PBS) 
- 6.6ml ddH2O 
- 7x protease inhibitor tablets (in 1.4ml ddH2O) 
 
Pulldown equilibration buffer: 
- 1ml 10xTBS 




Pulldown wash buffer: 
- 1ml 10x TBS 
- 10μl 500mM EDTA 
- 0.25ml 10% Triton X-100 (PBS) 
- 8.72ml ddH2O 
 
Streptavidin pulldown Wash buffer 1: 
- 2% SDS (ddH2O) 
 
Streptavidin pulldown Wash buffer 2: 
- 0.2% Sodium deoxycholate 
- 1% Triton X-100 
- 500mM NaCl 
- 1mM EDTA 
- 50mM HEPES pH7.5 
 
Streptavidin pulldown Wash buffer 3: 
- 10mM Tris pH8.1 
- 250mM LiCl 
- 0.5% Sodium deoxycholate 
- 1% Triton X-100 
- 500mM NaCl 
- 1mM EDTA 
- 0.5% NP-40 
 
Streptavidin pulldown Wash buffer 4: 
- 50mM Tris pH7.4 




LC Buffer A: 
- 20mM ammonium hydroxide pH10 
 
LC Buffer B: 





6.2: Appendix B – Sequences 


















































Red = FLAG tag 






































































Orange = RE site 
Green = primer sites 
Blue = BirA tag  
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Orange = RE sites 
Green = Forward primer sites 
Red = Reverse primer sites 
Blue = BirA tag   
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6.2.4: ZNS5-BirA RT-PCR sequencing results 
C3: 






















































































































































































































































































































6.3: Appendix C – CD 
